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1. Introduction  
1.1. G-protein coupled receptors  
 
G-protein coupled receptors, also known as seven-transmembrane receptors, are the 
largest class of membrane proteins in the human genome1 and one of the most ubiquitous 
and versatile receptor family2. For mankind, about 800 GPCRs have been identified, and 
these receptors regulate a lot of physiological processes.3 
 
1.1.1. Classification 
About 50 % of the GPCRs have sensory functions or mediate olfaction, taste, light 
perception and pheromone signaling.4 The remaining non-sensory GPCRs which mediate 
inter-signaling by ligands from small molecules to large proteins, are targets for the majority 
of clinical drugs.5, 6 Based on sequence homology, GPCRs can be divided into: rhodopsin-like, 
secretin receptor family, metabotropic glutamate, fungal mating pheromone receptors, cyclic 
AMP receptors and frizzled/smoothened.7 As fungal mating pheromone receptors and cyclic 
AMP receptors are not discovered in vertebrates, the classification “GRAFS” (Glutamate, 
Rhodopsin, Adhesion, Frizzled/Taste2 and Secretin) was suggested based on evolutionary 
aspects.8   
 
1.1.2. Structure 
  The characteristic features of GPCRs (Fig. 1.1) are an extracellular amino terminus, an 
intracellular carboxyl terminus and seven hydrophobic transmembrane (TM) domains 
connected by three extracellular loops (ECL1-3) and three intracellular loops (ICL1-3).9 
Extracellular and intracellular regions are involved in ligand binding and signal transduction 
respectively, which show the least conservation between different GPCRs.10-12 The first 
high-resolution 3D structure of a GPCR, the x-ray crystallography of bovine rhodopsin, was 
reported by Palczewski et al. in 2000.9 In 2007 the structure of the 2 adrenergic receptor 
(β2AR) was solved by Rasmussen et al.13 and Cherezov et al.14. Another milestone in 
crystallography of GPCR was published 2011, when Rasmussen et al. reported on the 
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structure of the β2AR active state.15 Meanwhile, the structures of more than 30 different 
GPCRs are described in the literature.   
 
Figure. 1.1 Schematic representation of a prototypical class A GPCR (ICL = intracellular loop; ECL = 
extracellular loop; 1-7 = transmembrane domains) 
 
1.1.3. Function 
GPCRs may be considered to act as molecular switches which transmit extracellular 
signals to intracellular responses through conformational change. In a simplified model, a 
GPCR exists in an “on mode” (active, Ra), stabilized by an agonist, and an “off mode” 
(inactive, Ri), stabilized by an inverse agonist (Fig. 1.2). Agonists eliciting the maximal 
biological response are named full agonists, while ligands, which are less effective in 
stabilizing the active state are referred to as partial agonists, and their intrinsic activity ranges 
from 0 to < 100 %.16 When the intrinsic activity of a ligand is 0 %, it does not alter the basal 
equilibrium between both, the active Ra and the inactive Ri state. Such ligands are referred as 
neutral antagonists. GPCRs can change their conformation from the inactive to the active 
state in the absence of an agonist, resulting in constitutive activity. Ligands capable of 
decreasing the basal activity of a receptor by stabilizing the inactive conformation are referred 
to as partial or full inverse agonists.17       
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Figure. 1.2 Two state model of a GPCR. The receptor toggles between the inactive state Ri and the 
active state Ra. (modified according to Seifert and Wenzel-Seifert17) 
 
1.1.4. Signaling 
1.1.4.1. G-protein cycle 
According to the classical model (Fig. 1.3), the GPCR active state, for example, stabilized 
by an agonist, is capable of interacting with the inactive form of a heterotrimeric G-protein 
(consisting of a Gα subunit with bound GDP and a Gβγ complex) resulting in the activation of 
the G-protein by evoking the exchange of GDP by GTP.18, 19 Subsequently, the Gα subunit is 
detached from the Gβγ subunit and both of them interact with effector proteins, resulting in 
changes of second messenger concentrations and various cellular responses. The G-protein 
returns to the inactive state upon cleavage of GTP to GDP by the intrinsic GTPase activity of 
the Gα subunit and re-associates with Gβγ marking the completion of the cycle.11 Regulators of 
G-protein signalling (RGS proteins; GTPase activating proteins, GAPs) can enhance the 
activity of the GTPase.20-22  
 
Figure. 1.3 Generalized diagram of the G-protein cycle. (modified according to Bridges et al.23) 
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1.1.4.2. G-Proteins and their pathways 
Till now, 16 different Gα-, 5 Gβ- and 12 Gγ-subunits are known: The Gα subunits are 
grouped into four main families: Gαs, Gαi/o, Gαq/11 and Gα12/13 based on the differences in 
structure and signaling pathway.24, 25 The Gαs family can activate the adenylyl cyclases (AC 
1-9), resulting in an increase in concentration of the second messenger cAMP (3’,5’-cyclic 
adenosine monophosphate). The opposite effect on cAMP levels is caused by the Gαi/o family 
as a consequence of the inhibition of adenylyl cyclase activity (AC 5 and AC 6).26, 27 The 
second messenger cAMP activates the protein kinase A (PKA) or the mitogen-activated 
protein kinase (MAPK) pathway.28 The Gαq/11 family regulates the activity of phospholipase C 
(PLCβ), leading to the hydrolysis of phosphatidylinositol-4,5-bisphosphate (PIP2) into 
inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). Both are second messengers, 
being responsible for various intracellular effects including the release of Ca2+ ions from 
intracellular stores29 and the stimulation of protein kinase C (PKC) which further modulates 
the function of cellular proteins by phosphorylation.30 The Gα12/13 family interferes with the 
cytoskeletal assembly by interaction with Rho-GEFs (Ras homology guanine nucleotide 
exchange factors).11, 24, 31 Besides the Gα-subunits, the Gβγ-heterodimer is also involved in 
effector regulation, e.g., PLCβ and K+, Ca2+ ion channels.24 
 
1.1.5. Oligomerization 
An oligomer refers to a macromolecular complex formed by non-covalent bonding of a few 
macromolecules. A homo-oligomer would be formed by few identical molecules and by 
contrast, a hetero-oligomer would be made of different macromolecules.  
Over a long period of time, GPCRs were thought to exist and function exclusively as 
monomeric units. However, there was evidence from native cells and heterologous 
expression systems that GPCRs are able to form dimers or even higher-order oligomers.32-35 
Trafficking, signaling and internalization have been demonstrated for GPCR monomers as 
well as for dimers/oligomers.33, 34, 36 Compared to GPCR monomers, GPCR dimers may 
provide distinct properties with respect to ligand binding37, signaling38-40, receptor trafficking,41 
and it may be speculated about the clinical relevance of such differences.42, 43  
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1.1.6. Allosteric modulation 
The term allosterism is used to describe a phenomenon which enables proteins to sense 
changes in their environment and to respond to them.44, 45 Regarding GPCRs, an allosteric 
site is physically distinct from the orthosteric binding site, that is, the binding pocket of the 
endogenous ligand.23, 46-48 Allosteric modulators cooperatively effect the binding of a ligand to 
the orthosteric ligand binding in a positive or a negative manner. A positive allosteric 
modulator (PAM) induces a receptor conformational change enhancing the binding affinity or 
the functional efficacy of an orthosteric agonist,49 whereas a negative allosteric modulator 
(NAM) has the opposite effect. Besides PAM and NAM, there are silent allosteric modulator 
(SAM) and allosteric agonists (ago-PAM). A SAM doesn’t effect orthosteric binding, and an 
ago-PAM can activate the receptor in the absence of an orthosteric ligand.50 Allosteric 
modulation may offer a possibility to increase the receptor subtype selectivity of ligands due 
to lower conservation of allosteric compared to orthosteric sites.44, 51, 52  
 
1.1.7. Dimeric/bivalent ligands for GPCRs 
The term “dimeric/bivalent ligand” refers to molecules composed of two pharmacophoric 
moieties covalently linked through a spacer.53-55 The pharmacophores can be identical 
(homo-bivalent) or different (hetero-bivalent ligands). Such dimeric or bivalent ligands may be 
useful as pharmacological tools to investigate receptor dimers (Fig. 1.4 B).56-58 With a spacer 
of appropriate length attached in the right position, bivalent ligands might achieve higher 
affinity and selectivity compared to their monomeric counterparts.42, 43, 53, 54, 59 In principle, a 
bivalent or dimeric ligand with a relatively short spacer might address interactions sites on the 
same protomer (Fig. 1.4 A) and allow for the detection of accessory binding sites such as 
allosteric binding pockets.60, 61     
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Figure 1.4 Bivalent ligand binding to (A) a GPCR with an accessory binding site or to (B) a GPCR 
dimer (modified according to Portoghese et al.53 and Birnkammer et al.61). 
 
1.2. Histamine and its receptors 
1.2.1. Histamine 
Histamine, (2-(1H-imidazol-4-yl)ethanamine), discovered more than a century ago,62 acts 
as an endogenous mediator, immunomodulator and neurotransmitter targeting histaminergic 
receptors. Histamine is a biogenic amine, synthesized from the amino acid L-histidine by 
decarboxylation.63  
 
1.2.2. Histamine receptors 
1.2.2.1. The histamine H1R 
The histamine H1 receptor (H1R) is expressed mainly in mammalian brain, smooth muscle, 
endothelium cells and lymphocytes and is involved in pathophysiological processes such as 
allergic and inflammatory reactions.64 H1R-mediated biological effects include, for instance, 
vasodilatation, bronchoconstriction, increased vascular permeability, pain and itching upon 
insect stings.65 The H1R preferentially couples to the Gαq protein, resulting in an increase in 
intracellular Ca2+.64, 66 Betahistine (e.g. Aequamen®) is the only marketed H1R agonist (Fig. 
1.5), approved for the treatment of Menière’s disease. H1R antagonists, also known as 
antihistamines, have been used to treat allergic disorders (allergic rhinitis, chronic urticarial 
and atopic dermatitis), nausea and vomiting, as well as to cause sedation.67, 68 The first 
generation antagonists like pyrilamine or diphenhydramine (Fig. 1.5) have been replaced by 
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the second generation antagonists, e.g., cetirizine (Fig. 1.5), in order to reduce sedation, 
which is a side effect of the classical antihistamines, which are capable of penetrating across 
the blood-brain barrier.63, 69, 70 Regardless of that, pyrilamine is still the most commonly used 
reference H1R antagonist and radioligand ([3H]pyrilamine) for pharmacological studies.71 
X-ray crystallography of the H1R in complex with doxepine gave insights in ligand binding on 
the molecular level.72 Recently, Na+ was identified as a negative allosteric regulator bound to 
Asp2.50 of H1R.73 
 
Figure 1.5 Structures of selected H1R agonist and antagonists.  
1.2.2.2. The histamine H2R 
The histamine H2 receptor (H2R) is expressed in a variety of tissues including brain, gastric 
parietal cells, heart, airways and uterus.69 The H2R couples to the Gαs protein, which leads to 
an increase in cAMP followed by activation of PKA.74 The H2R was pharmacologically 
characterized in 1972 using the first H2R antagonist burimamide (Fig. 1.6), which was able to 
inhibit the histamine-stimulated gastric acid secretion and the positive chronotropic effect on 
the heart.75 Cimetidine (Tagamet®) was the first clinically available H2R antagonist, followed 
by non-imidazoles such as ranitidine and famotidine (Fig. 1.6), with reduced pharmacokinetic 
interactions with CYP450 enzymes.63 The H2R antagonists had been very important antiulcer 
drugs over decades, but were replaced by the more effective proton pump inhibitors. 
Impromidine (Fig. 1.6) was the first highly potent H2R agonist demonstrated to be clinically 
effective in the treatment of severe catecholamine-refractory congestive heart failure.76, 77 In a 
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bivalent ligand approach, H2R agonists such as UR-AK381 (Fig. 1.6) were developed, which 
are among the most potent and selective H2R agonists known so far.61 A potential application 
for highly selective H2R agonists might be the treatment of acute myeloid leukemia (AML).78, 
79 
 
Figure 1.6 Structures of selected H2R agonists and antagonists.  
 
1.2.2.3. The histamine H3R 
The histamine H3 receptor (H3R) was first discovered in 198380 and cloned in 1999.81 It is 
predominantly located in the CNS, acts as a presynaptic auto- and heteroreceptor and 
controls the release of histamine and various other neurotransmitters, including dopamine, 
serotonin, noradrenalin and acetylcholine.82-86 The H3R couples to Gαi/o proteins and has 
been shown to interfere with various transduction pathways apart from the modulation of the 
AC activity, for example activation of PLA2 and inhibition of K+-induced Ca2+ mobilization.87 
Consequently, H3R influences the regulation of a broad variety of physiological functions like 
food intake, sleep-wake cycle, body temperature and blood pressure. The first approved 
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H3 receptor inverse agonist, pitolisant (Fig. 1.7), used in the therapy of narcolepsy, is also 
considered to have potential value in the treatment of Parkinson’s disease and obstructive 
sleep apnoea.88, 89 Numerous H3R ligands, e.g. thioperamide, clobenpropit, immethridine and 
methimepip (Fig. 1.7) are derived from histamine. Due to the imidazole moiety, these 
compounds are not H3R selective but show also H4R affinity, and they are potential CYP450 
binders, which may cause drug-drug interactions. 
 
Figure 1.7 Structures of selected H3R agonists and antagonists.  
 
1.2.2.4. The histamine H4R 
The histamine H4 receptor (H4R) is the latest member of histamine receptor family. An 
“eosinophil” histamine receptor was already postulated more than 40 years ago.90, 91 In 2000 
and 2001, the H4R was independently identified and cloned by six research groups,92-98 and 
the H4R was reported to be expressed in bone marrow and immunocytes.99 Like the H3R, the 
H4R interacts with the Gαi/o protein, leading to an inhibition of the AC and an activation of the 
phospholipase C-β (PLCβ) via Gβγ complexes.99-101 As a major player in immunological and 
inflammatory reactions, the H4R was suggested to be a potential drug target for the treatment 
of asthma, pruritus, and rheumatoid arthritis.100, 102-109 The indole derivative JNJ-7777120 (Fig. 
1.8) was the first selective high-affinity non-imidazole H4R antagonist and has been widely 
used as a reference compound in vitro and in vivo.110 However, the pharmacological action of 
JNJ-7777120 is species-dependent, for example, to a rather low sequence identity 
comparing human and rodent H4Rs and to a different extent of constitutive activity of the H4R 
orthologues.111-113 Furthermore, JNJ-7777120 was reported to be a biased agonist, 
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stimulating H4R mediated β-arrestin recruitment.114 Several H4R antagonists, e.g. 
PF-3893787, JNJ-39758979 and Toreforant (Fig. 1.8), entered clinical trials for the treatment 
of allergic rhinitis, allergic asthma, atopic dermatitis and rheumatoid arthritis.115, 116 Compared 
with antagonists, H4R agonists (Fig. 1.8) are important as pharmacological tools rather than 
as drugs. 
 
Figure 1.8 Structures of selected H4R agonists and antagonists.  
 
1.2.3. Dual ligands of histamine receptors 
Ligands with moderate to high affinity for two histamine receptor subtypes are referred as 
dual histamine receptor ligands. Theoretically, a single ligand which can address multiple 
desired receptor targets may enhance affinity, potency, efficacy and safety,56, 117 e.g. lower the 
risk of drug-drug interactions compared to drug cocktails.118 In the histamine receptor field, a 
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synergistic effect of H1R and H4R antagonism was observed in various models of 
inflammation.119-121 Some ligands exhibiting affinity to both, H1R and H4R, were discovered 
(Fig. 1.9). These results suggest that despite the low sequence homology between both 
receptors it should be feasible to obtain H1R/H4R ligands with balanced receptor subtype 
affinity.122-125 Another combination is H1R and H3R antagonists: series of H1R/H3R antagonists 
were developed by GSK. GSK835726 and GSK1004723 (Fig. 1.9) entered clinical trials to 
treat allergic rhinitis, but both compounds did not show a differentiation from H1R antagonist 
treatment.126, 127 Considering the high sequence similarity between the transmembrane 
domains (TMs) of the human H3R and H4R, it is not surprising that many H4R ligands 
containing imidazole moieties show also H3R affinity.128 Dual H3R/H4R antagonists (Fig. 1.9) 
may have a potential in the treatment of pain and cancer since it is likely these two targets 
contribute to the development of pain sensation and itching as well as 
cell-proliferation-associated effects129.  
 
Figure 1.9 Structures of selected dual HxR ligand structures.  
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2. Scope and objectives 
 
To reach multiple molecular targets simultaneously, a prevailing way is to use cocktails of 
drugs. But this approach is sometimes hampered due to poor patient compliance.1 A single 
ligand addressing multiple desired receptor targets (multitarget ligands) might be of 
advantage to enhance affinity, potency,2 efficacy3 and safety, e.g., due to a lower risk of 
drug-drug interactions, compared to drug cocktails.4 Besides their potential clinical value, 
such hybrid compounds may also be useful pharmacological tools for in vitro investigations. 
Among the four histamine receptor subtypes (H1R, H2R, H3R, and H4R) both, the H1R and 
H4R, were suggested to be involved in type-I allergic reactions.5 A synergistic effect of 
co-administered H1R and H4R antagonists was observed, e. g., regarding inhibition of pruritus 
and skin inflammation from chronic dermatitis6, acute hapten-induced scratching7, and 
peanut-induced intestinal allergy.8 All these results suggest that dual H1R/H4R antagonists 
may have a potential clinical value. 
The aim of this work is to synthesize and characterize potential dual H1R/H4R antagonists. 
Homo- and hetero-dimeric (or bivalent) compounds will be constructed from crucial structural 
features of various H1R and H4R ligands (Fig. 2.1), which will be combined in different ways, 
e.g., by merging pharmacophoric moieties or separating the respective substructures by 
spacers of different chemical nature and appropriate length. The resulting compounds should 
be useful to explore the interactions with the H1R and the H4R on the molecular level and, 
possibly, to search for additional binding sites on H1R and H4R, respectively.  
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Fig. 2.1 Structures and affinities of selected H1R and/or H4R ligands as pharmacophores. 
Pharmacological data were taken from a) Strasser et al.9 b) Igel et al.10 c) Smits et al.11 d) Wagner et 
al.12 e) Wittmann et al.13 f) Deml et al.14 g) Baumeister 15 h) Geyer et al.16 
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3. Homo-dimeric ligands as human histamine H1 
receptor ligands or dual H1/H4 receptor ligands 
3.1. Introduction 
 
Over the past decades, our knowledge of GPCR has been changed revolutionarily with the 
discovery of receptor oligomerization1-4 and allosteric modulation5, 6. The existence of 
oligomers in class A GPCRs including opioid receptors7-9, adrenergic receptors10, 
somatostatin receptors11, 12, dopamine receptors13-15, muscarinic receptors16, 17 and all 
histamine receptor subtypes18-21 has been demonstrated. It is supposed that potentially all 
GPCRs possess drugable allosteric sites.22 Consequently, suitable pharmacological tools for 
investigating GPCR dimers or high order oligomers and putative allosteric binding sites are 
required. One possible tool are dimeric ligands, which refer to molecules composed of two 
pharmacophoric moieties covalently linked through a spacer.23-25 Homo- and hetero-dimeric 
ligands have emerged in the GPCR field in recent years, e.g., histamine26, 27, dopamine28-30, 
and adenosine31, 32 and NPY33, 34 receptors. 
On one hand, dimeric ligands with a long spacer, e.g., a molecular modeling study 
suggests that the distance between two recognition sites of a contact opioid receptor dimer 
with a TM5/TM6 interface is about 22−27 Å23, can be designed to probe dimerized receptors. 
On the other hand, a relatively short spacer allows that the duplication of pharmacophores 
addresses to two neighboring interaction sites on the same protein.26, 35 Theoretically, bivalent 
ligands were postulated to increase the affinity compared to their constituent mono-valent 
ligands because the binding of one of the constituent pharmacophore proceeds through a 
univalent bound state and therefore allows the unbound partner to be in closer proximity to 
neighboring binding sites36. 
 The present study was aiming at high affinity dimeric/bivalent H1R and/or H4R ligands as 
pharmacological tools. Small series of homo-dimeric/homo-bivalent ligands were 
synthesized using building blocks derived from the well-known H1R antagonists37 
diphenhydramine (3.1) and pyrilamine (3.2) and from a dual H1R/H4R antagonist, the 
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quinazoline derivative (3.3).38 Alkyl chains with/without amide groups, and various lengths 
(6-18 atoms) were employed as spacers (Figure. 1). Such compounds should be helpful in 
searching for putative accessory binding sites on the receptors of interest. 
 
Figure 1 Selected H1R and H1R/H4R dual ligands, and general structures of synthesized homo-dimeric 
ligands. Pharmacological data were taken from a) Wittmann et al.39 b) Deml et al.40 c) Smits et al.38 d) 
Wagner et al.41 
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3.2. Results and discussion 
3.2.1. Chemistry 
The bivalent ligands 3.6a-d, 3.7a-d, 3.9a-d, 3.13a, 3.13b, 3.15a-d, 3.16a-d were according 
to the synthetic pathway shown in Schemes 1 and 2.  
 
Scheme 1 Synthesis of compounds 3.6a-d, 3.7a-d and 3.9a-d.  
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Scheme 2 Synthesis of compounds 3.13a, 3.13b, 3.15a-d and 3.16a-d.  
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3.2.2. Results and discussion  
3.2.2.1. Competition binding studies 
Twenty-two novel homo-dimeric ligands were synthesized and routinely analyzed by 
radioligand competition binding assays. All assays were performed using membrane 
preparations of Sf9 insect cells expressing the hH1R + RGS4 (regulator of G-protein signaling 
4)42 in presence of 5 nM [3H]pyrilamine, or the hH4R + Gαi2 + Gβ1γ243 in presence of 10 nM 
[3H]histamine. The resulting affinity data are summarized in Tables 1-3. 
 
Table 1 hH1R affinities of compound 3.6a-d and 3.9a-d  
 
Values represent the mean ± SEM of at least three independent experiments each performed in 
triplicate. 
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Table 2 hH1R affinities of compound 3.7a-d 
 
Values represent the mean ± SEM of at least three independent experiments each performed in 
triplicate. 
 
Two types of spacers, alkyl chains with/without amide groups, with different length were 
used to bridge two identical pharmacophores. However, both spacer types failed to improve 
affinities of all homo-dimeric ligand series at hH1R and hH4R in an obvious way. Thus, 
introducing amide bearing alkyl spacers by analogy with a report by McRobb et al30 on 
diphenhydramine (3.1), pyrilamine (3.2) and quinazoline derivative (3.3) proved unsuccessful. 
The spacer length from this given study was 9-20Å, shorter than a suggested receptor dimer 
interface (22−27 Å),23 were more suitable for probing potential accessory binding sites on the 
receptors of interest rather than receptor dimers. At hH1R, all homo-dimeric ligands with 
spacers containing amide groups (3.9a-d, 3.15a-d and 3.16a-d) showed similar affinities 
compared to corresponding monomeric parent leads (Tables 1-3) and no significant influence 
of spacer length variation on binding affinities was observed. The homo-dimeric ligands with 
amide-free-spacers present much lower affinities at hH1R compared to the amide-containing 
ones. A reason for that may be the introducing of the pure alkyl spacers raised up the 
lipophilicity of the compound resulted a solubility problem and high non-specific binding in 
assays. At hH4R, it may propose the introducing of spacers to the piperazine moiety of 
quinazoline derivative hindered the pharmacophore from optimally bound to orthosteric 
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binding site, leading to a considerable affinity drop for all quinazoline type homo-dimeric 
ligands. 
Table 3 hH1R and hH4R affinities of compound 3.13a, 3.13b, 3.15a-d and 3.16a-d 
Values represent the mean ± SEM of at least three independent experiments each performed in 
triplicate. a(pKi) hH1R = 7.70, hH4R = 8.12 (Smits et al.38) 
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3.2.2.2. Conclusion 
Aiming at H1R and/or H4R pharmacological tools with high affinities, H1R antagonists or 
dual H1R/H4R antagonists were employed as building blocks to generate series of 
homo-dimeric ligands. Based on the competition binding study results, it was speculated 
while one of the pharmacophore (diphenhydramine, pyrilamine or quinazoline moiety) of 
homo-dimeric ligand bound to receptor’s orthosteric binding site, the other pharmacophore 
did not contribute to the binding of receptor. Later, a computational MD simulation of 
compound 3.15d together with hH1R (crystal structure 3RZE44) confirmed this proposed 
binding mode (Figure 2). This suggested either there were no accessory binding sites, or 
diphenhydramine, pyrilamine and quinazoline derivative have no enough affinities to bind to 
the putative accessory binding sites.  
 
Figure 2 An overlay of two snapshots of 3.15d bound to hH1R. (MD simulation, performed by PD Dr. 
Andrea Strasser) 
   
To sum up, no concrete proof of an additional binding site at the extracellular surface of 
hH1R or hH4R can be found from given competition binding results. In order to prove or 
disprove the existence of accessory binding sites on hH1R and hH4R, different linkage point 
for spacer or a hetero-dimeric ligand approach should be considered in future studies. 
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3.3. Experimental section 
3.3.1. Chemistry  
3.3.1.1. General conditions 
  Commercially available reagents were from the following suppliers: Merck (Darmstadt, 
Germany), Acros Organics (Geel, Belgium), Sigma Aldrich (Munich, Germany) and TCI 
Europe (Eschborn, Germany). All solvents were of analytical grade or distilled prior to use 
and stored under protective gas. Deuterated solvents for NMR spectroscopy were from 
Deutero (Kastellaun, Germany). Millipore water was used throughout for the preparation of 
buffers and HPLC eluents. If moisture-free conditions were required, reactions were 
performed in dried glassware under argon. Column chromatography was carried out using 
Merck silica gel Geduran 60 (0.063-0.200 mm) and Merck silica gel 60 (0.040-0.063 mm) for 
flash-column chromatography. In certain cases, flash-chromatography was performed on an 
Intelli Flash-310 Flash-Chromatography Workstation from Varian Deutschland GmbH 
(Darmstadt, Germany). Reactions were monitored by thin layer chromatography (TLC) on 
Merck silica gel 60 F254 aluminium sheets and spots were visualized with UV light at 254 nm 
and/or iodine vapor, ninhydrine spray. Nuclear Magnetic Resonance (1H NMR and 13C NMR) 
spectra were recorded on an Avance-300 (1H: 300 MHz, 13C: 75 MHz), Avance-400 (1H: 400 
MHz, 13C: 101 MHz), or Avance-600 (1H: 600 MHz, 13C: 151 MHz) NMR spectrometer from 
Bruker BioSpin (Karlsruhe, Germany). Multiplicities are specified with the following 
abbreviations: s (singlet), d (doublet), t (triplet), q (quartet), quint (quintet), m (multiplet), bs 
(for broad singulet), as well as combinations thereof. The multiplicity of carbon atoms 
(13C-NMR) was determined by DEPT 135 (distortionless enhancement by polarization 
transfer): “+” primary and tertiary carbon atom (positive DEPT 135 signal), “-” secondary 
carbon atom (negative DEPT 135 signal), “quat” quaternary carbon atom. In certain cases, 
2D-NMR techniques were used to assign 1H and 13C chemical shifts. All spectra were 
analyzed using the program MestReNova (Mestrelab Research, Santiago de Compostela, 
Spain). High-resolution mass spectrometry (HRMS) was performed on an Agilent 6540 UHD 
Accurate-Mass Q-TOF LC/MS system (Agilent Technologies, Santa Clara, CA) using an ESI 
source. Melting points (mp) were measured on a Büchi 530 (Büchi GmbH, Essen, Germany) 
    Chapter 3                                             17 
and are uncorrected. Lyophilisation of the products was done with a Christ alpha 2-4 LD, 
equipped with a Vacuubrand RZ 6 rotary vane vacuum pump. Preparative HPLC was 
performed with a pump model K-1800 (Knauer, Berlin, Germany), the column was a 
Eurospher-100 (250 x 32 mm) (Knauer, Berlin, Germany) or a Nucleodur 100-5 C18 ec (250 
× 21 mm, 5 μm (Macherey-Nagel, Düren, Germany), which was attached to the UV-detector 
model K-2000 (Knauer, Berlin, Germany). UV-detection was done at 220 nm. The 
temperature was between rt and 30 °C and the flow rate was 15 mL/min. All compounds were 
filtered through PTFE-filters (25 mm, 0.2 μm, Phenomenex, Aschaffenburg, Germany) prior to 
preparative HPLC. Analytical HPLC analysis was performed on a system from Merck, 
composed of an L-5000 controller, a 655A-12 pump, a 655A-40 auto sampler, a L-4250 
UV-VIS detector, and a RP column Kinetex-XB C18, 5 μm, 250 mm × 4.6 mm (Phenomenex, 
Aschaffenburg, Germany) at a flow rate of 0.8 mL/min. Mixtures of acetonitrile (A) and 0.1% 
aqueous TFA solution (B) were used as mobile phase. Detection was performed at 220 nm, 
the oven temperature was 30 °C. Helium degassing prior to HPLC analysis was performed. 
Compound purities were calculated as percentage peak area of the analyzed compound by 
UV detection at 220 nm. HPLC conditions, retention times (tR), the capacity (retention) factors 
were calculated according to k = (tR-t0)/t0, and purities of the synthesized compounds are 
listed in the appendix. Purity of tested compounds was >95% as determined by 
high-performance liquid chromatography. For all compounds, which were obtained as TFA 
salts, the number of respective hydrotrifluoroacetate were calculated by ACD/I-lab 
(ACD/Labs, Toronto, Ontario, Canada). 
 
3.3.1.2. Synthesis 
Benzyl (2-bromoethyl)carbamate.45  
Benzyl (2-bromoethyl)carbamate was synthesized according to Aissaoui et al.45 
 
tert-Butyl(3-bromopropyl)carbamate. 46  
tert-butyl(3-bromopropyl)carbamate were synthesized according to Jörg et al.46 
 
tert-Butyl piperazine-1-carboxylate.47  
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A solution of piperazine (8.6 g, 100 mmol) in DCM (100 mL) was cooled to 0 °C. 
Di-tert-butyl dicarbonate (10.9 g, 50 mmol) dissolved in DCM (100 mL) was added dropwise. 
The resulting mixture was stirred at rt overnight and concentrated under reduced pressure. 
The crude product was dissolved in brine (100 mL) and extracted with diethyl ether (3 x 50 
mL). The organic layer was dried over Na2SO4, and organic solvent was evaporated, then 
subjected to silica gel column chromatography (EtOAc/MeOH, 9/1) to yield a white solid (6.67 
g, 35.9 mmol, 71.8%). 1H-NMR (300 MHz, CDCl3) δ [ppm]: 3.40-3.36 (m, 4H), 2.83-2.78 (m, 
4H), 1.77 (s, 1H), 1.45 (s, 9H). 
 
2-(Benzhydryloxy)-N-methylethanamine (3.4).48  
Diphenhydramine hydrochloride (15 g, 51.4 mmol) was dissolved in a solution of K2CO3 
(10.5 g, 76 mmol) in 100 mL water. The mixture was extracted three times with 150 mL (50 x 
3) DCM. After removal of the solvent, the remaining crystal oil was dissolved in a solution of 
150 mL of 1,2-dichloroethane, Na2CO3 (6 g, 56.61 mmol) was added. The mixture was cooled 
to -10 °C, and 1-chloroethyl chloroformate (11.13 mL, 104 mmol) was added dropwise. After 
stirring for 10 min at -10 °C, the solution was heated under reflux for 2 h (94 °C). The solvent 
was removed, the remaining oily residue was dissolved in 150 mL methanol and heated at 
50 °C for 2 h. The solvent was removed and the resulting pale brown crystalline residue was 
dissolved in a solution of Na2CO3 (8 g, 75.48 mmol) in 150 mL of water in order to get the free 
base of the product, which was extracted with DCM and purified by column chromatography 
(EtOAc/MeOH containing 1% NH3, 4/1). Yellow oil (4.51 g, 18.69 mmol, 35.9%). 1H-NMR 
(300 MHz, DMSO-d6) δ [ppm]: 7.43-7.18 (m, 10H), 5.43 (s, 1H), 3.45 (t, J = 5.6 Hz, 2H), 2.69 
(t, J = 5.6 Hz, 2H), 2.28 (s, 3H). 13C-NMR (75 MHz, DMSO-d6) δ [ppm]: 142.59 (Cquat), 128.18 
(+, Ar-CH), 127.08 (+, Ar-CH), 126.42 (+, Ar-CH), 82.46 (+, CH), 67.64 (-, CH2), 50.77 (-, CH2), 
35.92 (+, CH3). HRMS (EI-MS) calcd for C16H19NO [MH+] 242.1539, found 242.1549. 
 
N1-(4-Methoxybenzyl)-N2-methyl-N1-(pyridin-2-yl)ethane-1,2-diamine (3.5). 
Compound 3.5 was prepared from pyrilamine maleate (20 g, 49 mmol) by analogy with the 
procedure for the preparation of compound 3.4. Yellow oil was obtained. (910 mg, 3.35 mmol, 
6.7%). 1H-NMR (300 MHz, CDCl3) δ [ppm]: 8.16-8.12 (m, 1H), 7.41-7.34 (m, 1H), 7.16-7.09 
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(m, 2H), 6.85-6.81 (m, 2H), 6.57-6.52 (m, 1H), 6.52-6.48 (m, 1H), 4.69 (s, 2H), 3.77 (s, 3H), 
3.70 (t, J = 6.3 Hz, 2H), 2.85 (t, J = 6.4 Hz, 3H), 2.45 (s, 3H). 13C-NMR (75 MHz, CDCl3) δ 
[ppm]: 158.66 (Cquat), 158.43 (Cquat), 147.88 (+, Ar-CH), 137.41 (+, Ar-CH), 130.37 
(Cquat),128.01 (+, 2Ar-CH), 114.00 (+, 2Ar-CH), 112.08 (+, Ar-CH), 106.16 (+, Ar-CH), 55.28 
(+, CH3), 51.61 (-, CH2), 49.90 (-, CH2), 48.11 (-, CH2), 36.32 (+, CH3).  
 
N1,N6-Bis[2-(benzhydryloxy)ethyl]-N1,N6-dimethylhexane-1,6-diamine (3.6a).  
To a solution of compound 3.4 (241 mg, 1 mmol) in 5 mL acetone, Cs2CO3 (325 mg, 1 
mmol) was added, and 1,6-diiodohexane (169 mg, 0.5 mmol) was added dropwise. The 
mixture was stirred at room temperature for 8 h (control by TLC). The solvent was removed 
under reduced pressure and the remaining mixture was subjected to preparative TLC over 
silica gel (EtOAc/MeOH containing 1% NH3, 50/1). Yellow oil (62.8 mg, 0.11 mmol, 22.2%). 
1H-NMR (300 MHz, CDCl3) δ [ppm]:7.36-7.22 (m, 20H), 5.37 (s, 2H), 3.61 (t, J = 5.9 Hz, 4H), 
2.74 (t, J = 5.9 Hz, 4H), 2.44 (t, J = 5.9 Hz, 4H), 2.32 (s, 6H), 1.55-1.42 (m, 4H), 1.32-1.21 (m, 
4H). 13C-NMR (75 MHz, CDCl3) δ [ppm]: 142.14 (4Cquat), 128.39 (+, 8Ar-CH), 127.47 (+, 
4Ar-CH), 126.96 (+, 8Ar-CH), 84.06 (+, 2CH), 66.86 (-, 2CH2), 57.89 (-, 2CH2), 56.63 (-, 
2CH2), 42.65 (+, 2CH3), 27.28 (-, 2CH2), 26.77 (-, 2CH2). HRMS (EI-MS) calcd for C38H48N2O2 
[MH+] 565.3789, found 565.3790.  
 
N1,N8-Bis[2-(benzhydryloxy)ethyl]-N1,N8-dimethyloctane-1,8-diamine (3.6b). 
 Compound 3.6b was prepared from compound 3.4 (241 mg, 1 mmol) and 1,8-diiodooctane 
(183 mg, 0.5 mmol) by analogy with the procedure for the preparation of compound 3.6a. 
Yellow oil (37.7 mg, 0.06 mmol, 12.8%). 1H-NMR (300 MHz, CDCl3) δ [ppm]: 7.37-7.20 (m, 
20H), 5.37 (s, 2H), 3.58 (t, J = 6.1 Hz, 4H), 2.70 (t, J = 6.1 Hz, 4H), 2.40 (t, J = 6.1 Hz, 4H), 
2.29 (s, 6H), 1.55-1.39 (m, 4H), 1.28-1.24 (m, 8H). 13C-NMR (75 MHz, CDCl3) δ [ppm]: 
142.27 (4Cquat), 128.36 (+, 8Ar-CH), 127.42 (+, 4Ar-CH), 126.98 (+, 8Ar-CH), 84.02 (+, 2CH), 
67.20 (-, 2CH2), 58.15 (-, 2CH2), 56.77 (-, 2CH2), 42.84 (+, 2CH3), 29.57 (-, 2CH2), 27.46 (-, 
2CH2), 27.08 (-, 2CH2). HRMS (EI-MS) calcd for C40H52N2O2 [MH+] 593.4102, found 
593.4101. 
N1,N10-Bis[2-(benzhydryloxy)ethyl]-N1,N10-dimethyldecane-1,10-diamine (3.6c).  
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Compound 3.6c was prepared from compound 3.4 (241 mg, 1 mmol) and 
1,10-diiododecane (197 mg, 0.5 mmol) by analogy with the procedure for the preparation of 
compound 3.6a. Yellow oil (136.8 mg, 0.22 mmol, 44.0%). 1H-NMR (300 MHz, CDCl3) δ [ppm]: 
7.37-7.20 (m, 20H), 5.37 (s, 2H), 3.59 (t, J = 6.1 Hz, 4H), 2.71 (t, J = 6.1 Hz, 4H), 2.41 (t, J = 
6.1 Hz, 4H), 2.29 (s, 6H), 1.54-1.39 (d, J = 6.6 Hz, 4H), 1.29-1.21 (m, 12H). 13C-NMR (75 
MHz, CDCl3) δ [ppm]: 142.30 (4Cquat), 128.36 (+, 8Ar-CH), 127.41 (+, 4Ar-CH), 126.98 (+, 
8Ar-CH), 84.01 (+, 2CH), 67.26 (-, 2CH2), 58.19 (-, 2CH2), 56.81 (-, 2CH2), 42.89 (+, 2CH3), 
29.61 (-, 4CH2), 27.51 (-, 2CH2), 27.17 (-, 2CH2). HRMS (EI-MS) calcd for C42H56N2O2 [MH+] 
621.4415, found 621.4419. 
 
N1,N12-Bis[2-(benzhydryloxy)ethyl]-N1,N12-dimethyldodecane-1,12-diamine (3.6d). 
Compound 3.6d was prepared from compound 3.4 (241 mg, 1 mmol) and 
1,12-dibromododecane (164 mg, 0.5 mmol) by analogy with the procedure for the preparation 
of compound 3.6a. Yellow oil (270 mg, 0.42 mmol, 84.0%). 1H-NMR (300 MHz, CH3OD) δ 
[ppm]:7.39-7.12 (m, 20H), 5.36 (s, 2H), 3.53 (t, J = 5.7 Hz, 4H), 2.64 (t, J = 5.7 Hz, 4H), 
2.44-2.30 (m, 4H), 2.22 (s, 6H), 1.52-1.38 (m, 4H), 1.31-1.19 (m, 16H). 13C-NMR (75 MHz, 
CH3OD) δ [ppm]: 143.88 (4Cquat), 129.43 (+, 8Ar-CH), 128.54 (+, 4Ar-CH), 128.15 (+, 
8Ar-CH), 85.36 (+, 2CH), 67.94 (-, 2CH2), 59.01 (-, 2CH2), 57.68 (-, 2CH2), 43.30 (+, 2CH3), 
30.85 (-, 2CH2), 30.82 (-, 2CH2), 30.78 (-, 2CH2), 28.75 (-, 2CH2), 27.81 (-, 2CH2). HRMS 
(EI-MS) calcd for C44H60N2O2 [MH+] 649.4728, found 649.4728.  
 
N1,N1'-(Hexane-1,6-diyl)bis[N2-(4-methoxybenzyl)-N1-methyl-N2-(pyridin-2-yl)ethane-1,2-
diamine] (3.7a).  
To a solution of compound 3.5 (350 mg, 1.29 mmol) in 5 mL MeCN, K2CO3 (178 mg, 1.29 
mmol) was added, and 1,6-diiodohexane (216 mg, 0.64 mmol) was added dropwise. The 
mixtures were stirred at room temperature for 8 h (control by TLC). The solvent was removed 
under reduced pressure, and the remaining mixtures were subjected to column 
chromatography over silica gel (EtOAc/MeOH containing 1% NH3, 20/1). Yellow oil (58 mg, 
0.09 mmol, 14.5%). 1H-NMR (300 MHz, CDCl3) δ [ppm]: 8.16-8.13 (m, 2H), 7.40-7.37 (m, 2H), 
7.18-7.11 (m, 4H), 6.86-6.79 (m, 4H), 6.56-6.44 (m, 4H), 4.69 (s, 4H), 3.77 (s, 6H), 3.74-3.64 
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(m, 4H), 2.72-2.56 (m, 4H), 2.51-2.38 (m, 4H), 2.34 (s, 6H), 1.55-1.43 (m, 4H), 1.33-1.22 (m, 
6H). 13C-NMR (75 MHz, CDCl3) δ [ppm]: 158.66 (2Cquat), 158.06 (2Cquat), 148.02 (+, 2Ar-CH), 
137.28 (+, 2Ar-CH), 130.59 (2Cquat), 128.16 (+, 4Ar-CH), 113.97 (+, 4Ar-CH), 111.88 (+, 
2Ar-CH), 105.90 (+, 2Ar-CH), 57.75 (-, 2CH2), 55.28 (+, 2CH3), 54.34 (-, 2CH2), 51.49 (-, 
2CH2), 45.92 (-, 2CH2), 42.27 (+, 2CH3), 27.23 (-, 4CH2). HRMS (EI-MS) calcd for C38H52N6O2 
[MH+] 625.4225, found 625.4227.  
 
N1,N1'-(Octane-1,8-diyl)bis[N2-(4-methoxybenzyl)-N1-methyl-N2-(pyridin-2-yl)ethane-1,2-
diamine] (3.7b).  
Compound 3.7b was prepared from compound 3.5 (271 mg, 1 mmol) and 1,8-diiodooctane 
(183 mg, 0.5 mmol) by analogy with the procedure for the preparation of compound 3.7a. 
Yellow oil (121 mg, 0.19 mmol, 37.1%). 1H-NMR (300 MHz, CDCl3) δ [ppm]: 8.16-8.13 (m, 
2H), 7.40-7.34 (m, 2H), 7.15 (d, J = 8.7 Hz, 4H), 6.86-6.79 (m, 2H), 6.55-6.49 (m, 2H), 6.46 (d, 
J = 8.6 Hz, 2H), 4.70 (s, 4H), 3.77 (s, 6H), 3.68-3.62 (m, 4H), 2.61-2.56 (m, 4H), 2.43-2.33 (m, 
4H), 2.28 (s, 6H), 1.53-1.37 (m, 4H), 1.27-1.24 (m, 8H). 13C-NMR (75 MHz, CDCl3) δ [ppm]: 
158.62 (2Cquat), 158.12 (2Cquat), 148.04 (+, 2Ar-CH), 137.20 (+, 2Ar-CH), 130.77 (2 Cquat), 
128.19 (+, 4Ar-CH), 113.92 (+, 4Ar-CH), 111.71 (+, 2Ar-CH), 105.78 (+, 2Ar-CH), 58.05 (-, 
2CH2), 55.26 (+, 2CH3), 54.48 (-, 2CH2), 51.35 (-, 2CH2), 46.20 (-, 2CH2), 42.52 (+, 2CH3), 
29.55 (-, 2CH2), 27.41 (-, 2CH2), 27.09 (-, 2CH2). HRMS (EI-MS) calcd for C40H56N6O2 [MH+] 
653.4538, found 653.4535.  
 
N1,N1'-(Decane-1,10-diyl)bis[N2-(4-methoxybenzyl)-N1-methyl-N2-(pyridin-2-yl)ethane-1,
2-diamine] (3.7c).  
Compound 3.7c was prepared from compound 3.5 (200 mg, 0.74 mmol) and 1, 
10-diiododecane (146 mg, 0.37 mmol) by analogy with the procedure for the preparation of 
compound 3.7a. Yellow oil (110 mg, 0.16 mmol, 43.0%). 1H-NMR (300 MHz, CDCl3) δ [ppm]: 
8.17-8.12 (m, 2H), 7.40-7.34 (m, 2H), 7.19-7.12 (m, 4H), 6.86-6.79 (m, 4H), 6.55-6.41 (m, 4H), 
4.71 (s, 4H), 3.78 (s, 6H), 3.66-3.58 (m, 4H), 2.58-2.50 (m, 4H), 2.39-2.30 (m, 4H), 2.26 (s, 
6H), 1.49-1.35 (m, 4H), 1.29-1.21 (m, 12H). 13C-NMR (75 MHz, CDCl3) δ [ppm]: 158.60 
(2Cquat), 158.17 (2Cquat), 148.07 (+, 2Ar-CH), 137.17 (+, 2Ar-CH), 130.89 (2Cquat),128.22 (+, 
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4Ar-CH), 113.91 (+, 4Ar-CH), 111.64 (+, 2Ar-CH), 105.71 (+, 2Ar-CH), 58.21 (-, 2CH2), 55.27 
(+, 2CH3), 54.60 (-, 2CH2), 51.27 (-, 2CH2), 46.37 (-, 2CH2), 42.69 (+, 2CH3), 29.64 (-, 4CH2), 
27.52 (-, 2CH2), 27.35 (-, 2CH2). HRMS (EI-MS) calcd for C42H60N6O2 [MH+] 681.4851, found 
681.4850.  
 
N1,N1'- (Dodecane- 1, 12- diyl)bis[N2- (4- methoxybenzyl)- N1- methyl- N2- (pyridin- 2- 
yl)ethane- 1, 2- diamine] (3.7d).  
Compound 3.7d was prepared from compound 3.5 (542 mg, 2 mmol) and 
1,12-dibromododecane (328 mg, 1 mmol) by analogy with the procedure for the preparation 
of compound 3.7a. Yellow oil (410 mg, 0.58 mmol, 57.9%). 1H-NMR (300 MHz, CDCl3) δ 
[ppm]: 8.17-8.13 (m, 2H), 7.40-7.34 (m, 2H), 7.19-7.12 (m, 4H), 6.86-6.80 (m, 2H), 6.55-6.49 
(m, 2H), 6.48-6.43 (m, 2H), 4.70 (s, 4H), 3.77 (s, 6H), 3.67-3.62 (m, 4H), 2.61-2.55 (m, 4H), 
2.42-2.33 (m, 4H), 2.28 (s, 6H), 1.50-1.37 (m, 4H), 1.30-1.20 (m, 16H). 13C-NMR (75 MHz, 
CDCl3) δ [ppm]: 158.61 (2Cquat), 158.12 (2Cquat), 148.08 (+, 2Ar-CH), 137.21 (+, 2Ar-CH), 
130.78 (2Cquat),128.20 (+, 4Ar-CH), 113.92 (+, 4Ar-CH), 111.71 (+, 2Ar-CH), 105.77 (+, 
2Ar-CH), 58.09 (-, 2CH2), 55.27 (+, 2CH3), 54.47 (-, 2CH2), 51.33 (-, 2CH2), 46.22 (-, 2CH2), 
42.55 (+, 2CH3), 29.65 (-, 6CH2), 27.48 (-, 2CH2), 27.14 (-, 2CH2). HRMS (EI-MS) calcd for 
C44H64N6O2 [MH+] 709.5164, found 709.5167. 
 
N1-[2-(Benzhydryloxy)ethyl]-N1-methylethane-1,2-diamine (3.8).  
To a mixture of compound 3.4 (3.31 g, 13.73 mmol) and K2CO3 (5.68 g, 41.19 mmol) in 50 
mL of MeCN benzyl (2-bromoethyl)carbamate (4.24 g, 16.48 mmol) was added. The reaction 
mixture was stirred at 100 °C for 2 h. The reaction mixture was cooled to rt, concentrated, and 
the residue dissolved in 15 mL MeOH. After addition of 5% palladium-on-charcoal catalyst 
(450 mg) a slow stream of hydrogen was passed via a glass tube into the vigorously stirred 
suspension at 1 atm H2 for 17 h. After depletion of the starting material (control by TLC) the 
catalyst was removed by filtration through Celite. The filtrate was concentrated in vacuo to 
give the product as a white solid (2.0 g, 7.04 mmol, 98%). 1H-NMR (300 MHz, CDCl3) δ [ppm]: 
7.38-7.19 (m, 10H), 5.37 (s, 1H), 3.56 (t, J = 5.9 Hz, 2H), 2.77-2.65 (m, 4H), 2.47 (t, J = 6.0 
Hz, 2H), 2.27 (s, 3H). 
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N1,N4-Bis(2-{[2-(benzhydryloxy)ethyl](methyl)amino}ethyl)succindiamide (3.9a).  
To a solution of compound 3.8 (284 mg, 1 mmol) and TEA (303 mg, 3 mmol) in 3 mL of 
anhydrous THF, succinyl dichloride (101 mg, 0.65 mmol) were added dropwise at 0 °C. The 
reaction mixture was stirred at 0 °C for 30 min. The mixture was allowed to warm to room 
temperature with stirring for 2 h (control by TLC). The solvent was evaporated, and the 
remaining mixture was poured into water. The aqueous layer was extracted with DCM, and 
the combined organic layers were dried over Na2SO4. After removal of the solvent under 
reduced pressure the product was purified by column chromatography (silica gel, 
DCM/MeOH/25% aqueous ammonia, 100/2.5/1). Colorless oil (170 mg, 0.26 mmol, 52.3%). 
1H-NMR (300 MHz, CDCl3) δ [ppm]: 7.38-7.18 (m, 20H), 5.36 (s, 2H), 3.54 (t, J = 5.6 Hz, 4H), 
3.32-3.25 (m, 4H), 2.70-2.64 (m, 4H), 2.52 (t, J = 6.0 Hz, 4H), 2.26 (s, 6H), 2.24-2.22 (m, 4H). 
13C-NMR (75 MHz, CDCl3) δ [ppm]: 172.05 (2Cquat), 142.19 (4Cquat), 128.45 (+, 8Ar-CH), 
127.52 (+, 4Ar-CH), 126.96 (+, 8Ar-CH), 83.99 (+, 2CH), 67.11 (-, 2CH2),56.59 (-, 2CH2), 
56.02 (-, 2CH2), 42.48 (+, 2CH3), 36.85 (-, 2CH2), 31.43 (-, 2CH2). HRMS (EI-MS) calcd for 
C40H50N4O4 [MH+] 651.3905, found 651.3910.  
 
N1,N6-Bis(2-{[2-(benzhydryloxy)ethyl](methyl)amino}ethyl)adipdiamide (3.9b). 
Compound 3.9b was prepared from compound 3.8 (542 mg, 2 mmol) and adipoyl 
dichloride (357 mg, 1.95 mmol) by analogy with the procedure for the preparation of 
compound 3.9a. Yellow oil (63 mg, 0.09 mmol, 12.4%). 1H-NMR (300 MHz, CDCl3) δ [ppm]: 
7.37-7.20 (m, 20H), 5.37 (s, 2H), 3.56 (t, J = 5.4 Hz, 4H), 3.37-3.27 (m, 4H), 2.71 (t, J = 5.4 
Hz, 4H), 2.58 (t, J = 5.8 Hz, 4H), 2.31 (s, 6H), 1.98 -1.88 (m, 4H), 1.53-1.44 (m, 4H). 13C-NMR 
(75 MHz, CDCl3) δ [ppm]: 171.85 (2Cquat), 141.00 (4Cquat), 127.42 (+, 8Ar-CH), 126.53 (+, 
4Ar-CH), 125.86 (+, 8Ar-CH), 82.95 (+, 2CH), 65.65 (-, 2CH2), 56.42 (-, 2CH2), 56.00 (-, 
2CH2), 42.42 (+, 2CH3), 36.52 (-, 2CH2), 35.97 (-, 2CH2), 25.08 (-, 2CH2). HRMS (EI-MS) 
calcd for C42H54N4O4 [MH+] 679.4218, found 679.4221.  
 
N1,N8-Bis(2-{[2-(benzhydryloxy)ethyl](methyl)amino}ethyl)octanediamide (3.9c).  
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Compound 3.9c was prepared from compound 3.8 (284 mg, 1 mmol) and octanedioyl 
dichloride (116 mg, 0.55 mmol) by analogy with the procedure for the preparation of 
compound 3.9a. Yellow oil (205 mg, 0.29 mmol, 58.1%). 1H-NMR (300 MHz, CDCl3) δ [ppm]: 
7.34-7.20 (m, 20H), 5.37 (s, 2H), 3.56 (t, J = 5.4 Hz, 4H), 3.36-3.28 (m, 4H), 2.70 (t, J = 5.4 
Hz, 4H), 2.57 (t, J = 5.8 Hz, 4H), 2.30 (s, 6H), 1.98-1.91 (m, 4H), 1.56-1.45 (m, 4H), 1.24-1.16 
(m, 4H). 13C-NMR (75 MHz, CDCl3) δ [ppm]: 173.20 (2Cquat), 142.08 (4Cquat), 128.47 (+, 
8Ar-CH), 127.58 (+, 4Ar-CH), 126.92 (+, 8Ar-CH), 84.00 (+, 2CH), 66.76 (-, 2CH2), 56.45 (-, 
2CH2), 56.01 (-, 2CH2), 42.42 (+, 2CH3), 36.50 (-, 2CH2), 36.39 (-, 2CH2), 28.93 (-, 2CH2), 
25.53 (-, 2CH2). HRMS (EI-MS) calcd for C44H58N4O4 [MH+] 707.4531, found 707.4532.  
 
N1,N10-Bis(2-{[2-(benzhydryloxy)ethyl](methyl)amino}ethyl)decanediamide (3.9d).  
Compound 3.9d was prepared from compound 3.8 (284 mg, 1 mmol) and octanedioyl 
dichloride (116 mg, 0.55 mmol) by analogy with the procedure for the preparation of 
compound 3.9a. Yellow oil (264 mg, 0.36 mmol, 71.9%). 1H-NMR (300 MHz, CDCl3) δ [ppm]: 
7.37-7.20 (m, 20H), 5.37 (s, 2H), 3.56 (t, J = 5.4 Hz, 4H), 3.37-3.28 (m, 4H), 2.70 (t, J = 5.4 
Hz, 4H), 2.57 (t, J = 5.7 Hz, 4H), 2.30 (s, 6H), 2.01-1.90 (m, 4H), 1.58-1.44 (m, 4H), 1.24-1.16 
(m, 8H). 13C-NMR (75 MHz, CDCl3) δ [ppm]: 173.30 (2Cquat), 142.09 (4Cquat), 128.47 (+, 
8Ar-CH), 127.58 (+, 4Ar-CH), 126.92 (+, 8Ar-CH), 84.00 (+, 2CH), 66.75 (-, 2CH2), 56.40 (-, 
2CH2), 55.96 (-, 2CH2), 42.39 (+, 2CH3), 36.53 (-, 2CH2), 36.48 (-, 2CH2), 29.23 (-, 4CH2), 
25.69 (-, 2CH2). HRMS (EI-MS) calcd for C46H62N4O4 [MH+] 735.4844, found 735.4846. 
 
2,4,6-Trichloroquinazoline (3.10) 
2,4,6-Trichloroquinazoline was prepared according to Smits et al.38 
 
tert- Butyl 4- {6- chloro- 4- [(thiophen- 2- ylmethyl)amino]quinazolin- 2- yl}piperazine- 1- 
carboxylate (3.11).  
A mixture of compound 3.10 (2.33 g, 9.7 mmol), EtOAc (15 mL), DIPEA (2.47 g, 19.14 
mmol), 2-thienylmethylamine (1.08 g, 9.55 mmol) in a 20-mL microwave tube was stirred at rt 
for 30 min. tert-Butyl piperazine-1-carboxylate (4.5 g, 23.9 mmol) was added, the microwave 
tube was sealed, and the mixture was subjected to microwave irradiation (120 °C) for 10 min. 
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Solid material was filtered off and washed with EtOAc. The filtrate was washed with brine, 
dried over Na2SO4 and evaporated. Purification by column chromatography (EE/PE, 1/5) 
yielded a white solid (3.69 g, 8.02 mmol, 83.8%); mp 184 °C. 1H-NMR (300 MHz, CDCl3) δ 
[ppm]: 7.42-7.35 (m, 3H), 7.20-7.14 (m, 1H), 7.01 (d, J = 2.7 Hz, 1H), 6.94-6.90 (m, 1H), 4.89 
(d, J = 5.5 Hz, 2H), 3.89-3.85 (m, 4H), 3.48-3.44 (m, 4H), 1.44 (s, 9H). 
 
6-Chloro-2-(piperazin-1-yl)-N-(thiophen-2-ylmethyl)quinazolin-4-amine (3.12).  
TFA (15 mL) was added to a solution of compound 3.11 (3.69 g, 8.02 mmol) in DCM (150 
mL). After stirring for 3 h, the mixture was evaporated to dryness under reduced pressure, 
yielding 3.12 di(hydrotrifluoroacetate) as a white solid (3.0 g, 8.06 mmol, 100%); mp 157 °C. 
1H-NMR (300 MHz, DMSO-d6) δ [ppm]: 8.11 (d, J = 2.3 Hz, 1H), 7.53-7.48 (m, 1H), 7.38-7.34 
(m, 1H), 7.27 (d, J = 8.9 Hz, 1H), 7.08 (d, J = 2.5 Hz, 1H), 6.98-6.93 (m, 1H), 4.83 (d, J = 5.6 
Hz, 2H), 3.83-3.75 (d, J = 4.7 Hz, 4H), 2.82-2.78 (m, 4H). 
 
2,2'- [Decane- 1,10- diylbis(piperazine- 4,1- diyl)]bis[6- chloro- N- (thiophen- 2- ylmethyl) 
quinazolin- 4- amine] (3.13a).  
Compound 3.13a was prepared from compound 3.12 (360 mg, 1 mmol) and 
1,10-diiododecane (182 mg, 0.5 mmol) by analogy with the procedure for the preparation of 
compound 3.7a. Yellow oil (30 mg, 0.03 mmol, 7%). 1H-NMR (300 MHz, CDCl3) δ [ppm]: 7.52 
(d, J = 1.8 Hz, 2H), 7.42-7.38 (m, 4H), 7.24-7.20 (m, 2H), 7.06-7.04 (m, 2H), 4.93 (d, J = 5.4 
Hz, 4H), 4.02-3.97 (m, 8H), 3.06-2.96 (m, 4H), 2.59 (t, J = 5.0 Hz, 8H), 2.46-2.40 (m, 4H), 
1.32-1.29 (m, 12H). 13C-NMR (75 MHz, CDCl3) δ [ppm]: 158.60 (6Cquat), 141.18 (2Cquat), 
133.15 (+, 2Ar-CH), 127.48 (+, 2Ar-CH), 126.69 (+, 2Ar-CH), 126.25 (+, 2Ar-CH), 125.87 
(2Cquat), 125.39 (+, 2Ar-CH), 120.51 (+, 2Ar-CH), 110.98 (2Cquat), 58.71 (-, 2CH2), 53.07 (-, 
2CH2), 45.42 (-, 4CH2), 43.50 (-, 2CH2), 39.74 (-, 2CH2), 34.46 (-, 2CH2), 29.49 (-, 2CH2), 
27.60 (-, 2CH2), 26.24 (-, 2CH2). HRMS (EI-MS) calcd for C44H54Cl2N10S2 [MH+] 857.3424, 
found 857.3417. 
 
2,2'-[Dodecane-1,12-diylbis(piperazine-4,1-diyl)]bis[6-chloro-N-(thiophen-2-ylmethyl) 
quinazoline-4-amine] (3.13b).  
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Compound 3.13b was prepared from compound 3.12 (360 mg, 1 mmol) and 
1,12-dibromododecane (164 mg, 0.5 mmol) by analogy with the procedure for the preparation 
of compound 3.7a. Yellow oil (22 mg, 0.02 mmol, 4%). 1H-NMR (300 MHz, CDCl3) δ [ppm]: 
7.47 (s, 2H), 7.41 (d, J = 2.7 Hz, 4H), 7.24-7.20 (m, 2H), 7.07-7.03 (m, 2H), 6.98-6.94 (m, 2H), 
4.93 (d, J = 5.3 Hz, 4H), 4.05-3.93 (m, 8H), 3.63 (t, J = 6.6 Hz, 4H), 2.61-2.52 (m, 8H), 
2.45-2.39 (m, 4H), 1.28-1.21 (m, 16H). 13C-NMR (75 MHz, CDCl3) δ [ppm]: 158.54 (6Cquat), 
141.09 (2Cquat), 133.20 (+, 2Ar-CH), 127.34 (+, 2Ar-CH), 126.73 (+, 2Ar-CH), 126.32 (+, 
2Ar-CH), 125.86 (+, 2Ar-CH), 125.47 (2Cquat), 120.38 (+, 2Ar-CH), 110.98 (2Cquat), 62.99 (-, 
2CH2), 58.90 (-, 2CH2), 53.27 (-, 2CH2), 43.64 (-, 4CH2), 43.50 (-, 2CH2), 39.94 (-, 2CH2), 
32.80 (-, 2CH2), 29.53 (-, 2CH2), 27.53 (-, 2CH2), 25.75 (-, 2CH2). HRMS (EI-MS) calcd for 
C46H58Cl2N10S2 [MH+] 885.3737, found 885.3736. 
 
tert-Butyl [2-(4-{6-chloro-4-[(thiophen-2-ylmethyl)amino]quinazolin-2-yl}piperazin-1-yl) 
ethyl]carbamate (3.14a).  
To a solution of compound 3.12 (910 mg, 2.5 mmol) in acetonitrile, DIPEA (323 mg, 2.51 
mmol), tert-butyl (2-bromoethyl)carbamate (614 mg, 2.75 mmol) and sodium iodide (375 mg, 
2.51 mmol) were added. The reaction mixture was heated to reflux for 2 h (control by TLC), 
the solvent was evaporated, and the remaining mixture was poured into water. The product 
was extracted with DCM, the combined organic layers were dried over Na2SO4, the solvent 
was removed under reduced pressure, and the residue was subjected to column 
chromatography (DCM/MeOH/25% aqueous ammonia, 100/2.5/1), yielding a yellow solid 
(680 mg, 1.35 mmol, 54.8%). m.p. 171 °C. 1H-NMR (300 MHz, CDCl3) δ [ppm]: 7.45-7.41 (m, 
2H), 7.40-7.35 (m, 1H), 7.25-7.21 (m, 1H), 7.06-7.04 (m, 1H), 6.99-6.94 (m, 1H), 4.94 (d, J = 
5.3 Hz, 2H), 3.99-3.89 (m, 4H), 3.33-3.21 (m, 2H), 2.55-2.45 (m, 6H), 1.46 (s, 9H). 
 
tert-Butyl [3-(4-{6-chloro-4-[(thiophen-2-ylmethyl)amino]quinazolin-2-yl}piperazin-1-yl) 
propyl]carbamate (3.14b).  
Compound 3.14b was prepared by analogy with the procedure for the preparation of 3.14a, 
using compound 3.12 (579 mg, 1.59 mmol) and tert-butyl(3-bromopropyl)carbamate (530 mg, 
1.59 mmol). After purification of column chromatography (DCM/MeOH/25% aqueous 
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ammonia, 100/2.5/1), a white solid was obtained (501 mg, 0.97 mmol, 61.3%). m.p. 167 °C. 
1H-NMR (300 MHz, CDCl3) δ [ppm]: 7.55-7.50 (m, 1H), 7.44-7.35 (m, 2H), 7.22-7.18 (m, 1H), 
7.06-7.03 (m, 1H), 6.96-6.92 (m, 1H), 4.93 (d, J = 5.4 Hz, 2H), 4.00-3.89 (m, 4H), 3.26-3.15 
(m, 2H), 2.56-2.40 (m, 6H), 1.74-1.63 (m, 2H), 1.43 (s, 9H). 13C-NMR (75 MHz, CDCl3) δ 
[ppm]: 158.57 (Cquat), 158.51 (Cquat), 156.16 (Cquat), 150.71 (Cquat), 141.24 (Cquat), 133.15 (+, 
Ar-CH), 127.24 (+, Ar-CH), 126.66 (+, Ar-CH), 126.30 (+, Ar-CH), 125.77 (Cquat), 125.38 (+, 
Ar-CH), 120.59 (+, Ar-CH), 110.97 (Cquat), 78.94 (Cquat), 66.83 (-, CH2), 57.01 (-, CH2), 53.33 
(-, 2CH2), 43.90 (-, 2CH2), 42.75 (-, CH2), 39.83 (-, CH2), 28.48 (+, 3CH3). HRMS (EI-MS) 
calcd for C25H33ClN6O2S [MH+] 517.2147, found 517.2148. 
 
N1,N4-Bis[2-(4-{6-chloro-4-[(thiophen-2-ylmethyl)amino]quinazolin-2-yl}piperazin-1-yl) 
ethyl]succinamide (3.15a).  
Compound 3.14a (251 mg, 0.50 mmol) was dissolved in 10 mL DCM, 10 mL of TFA was 
added dropwise, the mixture was stirred at rt for 3 h (control by TLC). The solvent was 
evaporated, the remaining oil was dissolved in anhydrous THF, succinyl dichloride (32 mg, 
0.20 mmol) were added dropwise in presence of TEA (128 mg, 0.80 mmol) at 0 °C. The 
reaction mixture was stirred at 0 °C for another 30 min, then allowed to warm to room 
temperature with stirring for 2 h (control by TLC). The solvent was evaporated, and the 
remaining mixture was poured into water. The aqueous layer was extracted with DCM, and 
the combined organic layers were dried over Na2SO4. The solvent was removed under 
reduced pressure, and the product was purified by column chromatography (DCM/MeOH/25% 
aqueous ammonia, 100/2/1). White solid (40 mg, 0.05 mmol, 20.3%), m.p. 112 °C. 1H-NMR 
(300 MHz, DMSO-d6) δ [ppm]: 8.19 (d, J = 2.0 Hz, 2H), 7.52-7.44 (m, 2H), 7.37-7.31 (m, 2H), 
7.26 (d, J = 8.9 Hz, 2H), 7.07 (d, J = 2.9 Hz, 2H), 6.95-6.91 (m, 2H), 4.81 (d, J = 5.5 Hz, 4H), 
3.94-3.66 (m, 8H), 3.42-3.35 (m, 4H), 3.26-3.12 (m, 4H), 2.53-2.47 (m, 8H), 2.33-2.30 (m, 4H). 
13C-NMR (75 MHz, DMSO-d6) δ [ppm]:171.24 (2Cquat),158.54 (2Cquat), 158.18 (2Cquat), 150.46 
(2Cquat), 142.24 (4Cquat), 132.57 (+, 2Ar-CH), 126.83 (+, 2Ar-CH), 126.22 (+, 2Ar-CH), 125.87 
(+, 2Ar-CH), 125.07 (+, 2Ar-CH), 122.13 (+, 2Ar-CH), 111.11 (2Cquat), 56.98 (-, 2CH2), 52.64 
(-, 2CH2), 43.25 (-, 2CH2), 38.53 (-, 4CH2), 35.85 (-, 2CH2), 30.80 (-, 4CH2). HRMS (EI-MS) 
calcd for C42H48Cl2N12O2S2 [MH+] 887.2914, found 887.2908.  
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N1,N6-Bis[2-(4-{6-chloro-4-[(thiophen-2-ylmethyl)amino]quinazolin-2-yl}piperazin-1-yl) 
ethyl]adipamide (3.15b).  
Compound 3.15b was prepared by analogy with the procedure for the preparation of 3.15a, 
using compound 3.14a (407 mg, 0.81 mmol) and adipoyl dichloride (33 mg, 0.17 mmol). 
White solid (117 mg, 0.13 mmol, 32.0 %), m.p. 192 °C. 1H-NMR (300 MHz, CH3OD) δ [ppm]: 
8.23 (d, J = 2.2 Hz, 2H), 7.85-7.80 (m, 2H), 7.64 (d, J = 8.9 Hz, 2H), 7.34-7.30 (m, 2H), 
7.15-7.12 (m, 2H), 7.00-6.96 (m, 2H), 5.04 (s, 4H), 4.40-4.20 (m, 8H), 3.67-3.45 (m, 12H), 
3.36-3.32 (m, 4H), 2.35-2.25 (m, 4H), 1.70-1.63 (m, 4H). 13C-NMR (75 MHz, CH3OD) δ 
[ppm]:177.32 (2Cquat), 160.43 (2Cquat), 153.38 (2Cquat), 140.70 (4Cquat), 136.88 (+, 2Ar-CH), 
132.22 (2Cquat), 128.11 (+, 2Ar-CH), 127.88 (+, 2Ar-CH), 126.71 (+, 2Ar-CH), 124.43 (+, 
2Ar-CH), 120.82 (+, 2Ar-CH), 112.60 (2Cquat), 58.00 (-, 2CH2), 52.48 (-, 4CH2), 43.45 (-, 
4CH2), 41.35 (-, 2CH2), 36.42 (-, 2CH2), 35.36 (-, 2CH2), 26.06 (-, 2CH2). HRMS (EI-MS) 
calcd for C44H52Cl2N12O2S2 [MH+] 915.3227, found 915.3226. 
 
N1,N8-Bis[2-(4-{6-chloro-4-[(thiophen-2-ylmethyl)amino]quinazolin-2-yl}piperazin-1-yl) 
ethyl]octanediamide (3.15c).  
Compound 3.15c was prepared by analogy with the procedure for the preparation of 3.15a, 
using compound 3.14a (231 mg, 0.46 mmol) and octanedioyl dichloride (42 mg, 0.20 mmol). 
White solid (110 mg, 0.12 mmol, 52.1%), m.p. 194 °C. 1H-NMR (300 MHz, DMSO-d6) δ [ppm]: 
8.10 (d, J = 2.3 Hz, 2H), 7.51-7.46 (m, 2H), 7.37-7.33 (m, 2H), 7.26 (d, J = 8.9 Hz, 2H), 
7.09-7.05 (m, 2H), 6.96-6.92 (m, 2H), 4.82 (d, J = 5.6 Hz, 4H), 3.83-3.76 (m, 8H), 3.23-3.14 
(m, 4H), 2.46-2.31 (m, 12H), 2.04 (t, J = 7.3 Hz, 4H), 1.53-1.40 (m, 4H), 1.26-1.18 (m, 4H). 
13C-NMR (75 MHz, DMSO-d6) δ [ppm]: 171.91 (2Cquat), 158.52 (2Cquat), 158.22 (2Cquat), 
150.52 (2Cquat), 142.22 (2Cquat), 132.56 (+, 2Ar-CH), 126.89 (+, 2Ar-CH), 126.24 (+, 2Ar-CH), 
125.84 (+, 2Ar-CH), 125.10 (+, 2Ar-CH), 123.97 (2Cquat), 121.91 (+, 2Ar-CH), 111.03 (2Cquat), 
57.14 (-, 2CH2), 52.71 (-, 4CH2), 43.32 (-, 4CH2), 38.67 (-, 2CH2), 35.91 (-, 2CH2), 35.28 (-, 
2CH2), 28.30 (-, 2CH2), 25.12 (-, 2CH2). HRMS (EI-MS) calcd for C46H56Cl2N12O2S2 [MH+] 
943.3540, found 943.3533.  
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N1,N10-bis[2-(4-{6-chloro-4-[(thiophen-2-ylmethyl)amino]quinazolin-2-yl}piperazin-1-yl) 
ethyl]decanediamide (3.15d).  
Compound 3.15d was prepared by analogy with the procedure for the preparation of 3.15a, 
using compound 3.14a (231 mg, 0.46 mmol) and decanedioyl dichloride (57 mg, 0.24 mmol). 
White solid (140 mg, 0.14 mmol, 61.4 %), m.p. 219 °C. 1H-NMR (300 MHz, CDCl3) δ [ppm]: 
7.62 (d, J = 1.5 Hz, 2H), 7.37 (d, J = 8.9 Hz, 2H), 7.26-7.19 (m, 4H), 7.07-7.03 (m, 2H), 
6.98-6.93 (m, 2H), 4.90 (d, J = 5.3 Hz, 4H), 3.99-3.91 (m, 8H), 3.44-3.35 (m, 4H), 2.60-2.52 
(m, 12H), 2.19 (t, J = 7.6 Hz, 4H), 1.66-1.56 (m, 4H), 1.32-1.27 (m, 8H). 13C-NMR (75 MHz, 
CDCl3) δ [ppm]:173.47 (6Cquat),158.52 (2Cquat), 140.69 (2Cquat), 133.42 (+, 2Ar-CH), 126.79 (+, 
2Ar-CH), 126.55 (+, 2Ar-CH), 125.43 (+, 4Ar-CH),  121.22 (+, 2Ar-CH), 110.92 (4Cquat), 
56.74 (-, 2CH2), 52.79 (-, 4CH2), 45.71 (-, 2CH2), 43.92 (-, 2CH2), 39.86 (-, 2CH2), 36.70 (-, 
2CH2), 35.73 (-, 2CH2), 29.19 (-, 2CH2), 29.19 (-, 2CH2), 25.71 (-, 2CH2). HRMS (EI-MS) 
calcd for C48H60Cl2N12O2S2 [MH+] 971.3853, found 971.3848. 
 
N1,N4-Bis[3-(4-{6-chloro-4-[(thiophen-2-ylmethyl)amino]quinazolin-2-yl}piperazin-1-yl) 
propyl]succinamide (3.16a).  
Compound 3.16a was prepared by analogy with the procedure for the preparation of 3.15a, 
using compound 3.14b (345 mg, 0.67 mmol) and succinyl dichloride (46 mg, 0.30 mmol). 
White solid (180 mg, 0.20 mmol, 59.7%), m.p. 106 °C. 1H-NMR (300 MHz, CDCl3) δ [ppm]: 
7.50 (d, J = 1.9 Hz, 2H), 7.43-7.33 (m, 4H), 7.22-7.19 (m, 2H), 7.05-7.01 (m, 2H), 6.96-6.92 
(m, 2H), 4.91 (d, J = 5.4 Hz, 4H), 4-3.85 (m, 8H), 3.41-3.25 (m, 4H), 2.60-2.40 (m, 16H), 
1.77-1.60 (m, 4H). 13C-NMR (75 MHz, CDCl3) δ [ppm]: 172.02 (2Cquat), 158.59 (4Cquat), 
150.77 (2Cquat), 141.23 (2Cquat), 133.15 (+, 2Ar-CH), 127.33 (+, 2Ar-CH), 126.69 (+, 2Ar-CH), 
126.26 (+, 2Ar-CH), 125.79 (2Cquat), 125.44 (+, 2Ar-CH), 120.53 (+, 2Ar-CH), 111.01 (2Cquat), 
57.29 (-, CH2), 53.31 (-, 2CH2), 43.99 (-,2CH2), 39.92 (-, CH2), 39.28 (-, CH2), 31.95 (-, CH2), 
25.32 (-, 2CH2). HRMS (EI-MS) calcd for C44H52Cl2N12O2S2 [MH+] 915.3227, found 915.3227. 
N1,N6-Bis[3-(4-{6-chloro-4-[(thiophen-2-ylmethyl)amino]quinazolin-2-yl}piperazin-1-yl) 
propyl]adipamide (3.16b).  
Compound 3.16b was prepared by analogy with the procedure for the preparation of 3.15a, 
using compound 3.14b (306 mg, 0.59 mmol) and adipoyl dichloride (46 mg, 0.25 mmol). 
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White solid (210 mg, 0.22 mmol, 74.1%), m.p. 91 °C. 1H-NMR (300 MHz, CDCl3) δ [ppm]: 
7.50 (d, J = 2.0 Hz, 2H), 7.44-7.34 (m, 4H), 7.23-7.19 (m, 2H), 7.06-7.00 (m, 2H), 6.97-6.92 
(m, 2H), 4.92 (d, J = 5.4 Hz, 4H), 4.00-3.85 (m, 8H), 3.43-3.34 (m, 4H), 2.60-2.39 (m, 12H), 
2.20-2.10 (m, 4H), 1.73-1.61 (m, 8H). 13C-NMR (75 MHz, CDCl3) δ [ppm]: 172.63 (2Cquat), 
158.74 (2Cquat), 158.62 (2Cquat), 150.91 (2Cquat), 141.25 (2Cquat), 133.16 (+, 2Ar-CH), 127.40 
(+, 2Ar-CH), 126.69 (+, 2Ar-CH), 126.25 (+, 2Ar-CH), 125.81 (2Cquat), 125.43 (+, 2Ar-CH), 
120.54 (+, 2Ar-CH), 111.05 (2Cquat), 57.59 (-, CH2), 53.36 (-, 2CH2), 44.06 (-, 2CH2), 39.93 (-, 
CH2), 39.45 (-, CH2), 36.47 (-, CH2), 25.23 (-, 4CH2). HRMS (EI-MS) calcd for 
C46H56Cl2N12O2S2 [MH+] 943.3540, found 943.3535. 
 
N1,N8-Bis[3-(4-{6-chloro-4-[(thiophen-2-ylmethyl)amino]quinazolin-2-yl}piperazin-1-yl) 
propyl]octanediamide (3.16c).  
Compound 3.16c was prepared by analogy with the procedure for the preparation of 3.15a, 
using compound 3.14b (327 mg, 0.63 mmol) and octanedioyl dichloride (45 mg, 0.21 mmol). 
White solid (130 mg, 0.13 mmol, 41.0%), m.p. 97 °C. 1H-NMR (300 MHz, CDCl3) δ [ppm]: 
7.52 (d, J = 2.0 Hz, 2H), 7.47-7.41 (m, 4H), 7.22-7.18 (m, 2H), 7.04-7.00 (m, 2H), 6.96-6.92 
(m, 2H), 4.92 (d, J = 5.4 Hz, 4H), 4.01-3.84 (m, 8H), 3.40-3.27 (m, 4H), 2.58-2.40 (m, 12H), 
2.13-2.06 (m, 4H), 1.72-1.69 (m, 4H), 1.63 – 1.54 (m, 4H), 1.27-1.23 (m, 4H). 13C-NMR (75 
MHz, CDCl3) δ [ppm]: 172.95 (2Cquat), 158.76 (2Cquat), 158.65 (2Cquat), 150.92 (2Cquat), 141.27 
(2Cquat), 133.19 (+, 2Ar-CH), 127.38 (+, 2Ar-CH), 126.68 (+, 2Ar-CH), 126.22 (+, 2Ar-CH), 
125.84 (2Cquat), 125.40 (+, 2Ar-CH), 120.60 (+, 2Ar-CH), 111.08 (2Cquat), 57.76 (-, CH2), 
53.38 (-, 2CH2), 44.05 (-, 2CH2), 39.92 (-, CH2), 39.55 (-, CH2), 36.88 (-, 2CH2), 28.97 (-, 
2CH2), 25.73 (-, 2CH2), 25.16 (-, CH2). HRMS (EI-MS) calcd for C48H60Cl2N12O2S2 [MH+] 
971.3853, found 971.3852. 
 
N1,N10-Bis[3-(4-{6-chloro-4-[(thiophen-2-ylmethyl)amino]quinazolin-2-yl}piperazin-1-yl)
propyl]decanediamide (3.16d).  
Compound 3.16d was prepared by analogy with the procedure for the preparation of 3.15a, 
using compound 3.14b (339 mg, 0.66 mmol) and decanedioyl dichloride (87 mg, 0.36 mmol). 
White solid (250 mg, 0.25 mmol, 76.0%), m.p. 110 °C. 1H-NMR (300 MHz, CDCl3) δ [ppm]: 
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7.55 (d, J = 2.0 Hz, 2H), 7.46-7.41 (m, 4H), 7.22-7.18 (m, 2H), 7.03-7.00 (m, 2H), 6.96-6.91 
(m, 2H), 4.91 (d, J = 5.4 Hz, 4H), 3.97-3.85 (m, 8H), 3.43-3.27 (m, 4H), 2.59-2.41 (m, 12H), 
2.13-2.03 (m, 4H), 1.75-1.62 (m, 4H), 1.63-1.50 (m, 4H), 1.30-1.15 (m, 8H). 13C-NMR (75 
MHz, CDCl3) δ [ppm]: 173.08 (2Cquat), 158.78 (2Cquat), 158.68 (2Cquat), 150.90 (2Cquat), 141.31 
(2Cquat), 133.18 (+, 2Ar-CH), 127.36 (+, 2Ar-CH), 126.66 (+, 2Ar-CH), 126.19 (+, 2Ar-CH), 
125.85 (2Cquat), 125.36 (+, 2Ar-CH), 120.66 (+, 2Ar-CH), 111.11 (2Cquat), 57.89 (-, CH2), 
53.39 (-, 2CH2), 44.07 (-, 2CH2), 39.89 (-, CH2), 39.68 (-, CH2), 37.06 (-, 2CH2), 29.29 (-, 
2CH2), 29.23 (-, 2CH2), 25.93 (-, 2CH2), 25.04 (-, CH2). HRMS (EI-MS) calcd for 
C50H64Cl2N12O2S2 [MH+] 999.4166, found 999.4166. 
 
3.3.2. Pharmacology 
3.3.2.1. Competition binding experiments  
Competition binding experiments were performed on membrane preparations of Sf9 insect 
cells expressing the hH1R + RGS4 or the hH4R + Gαi2 + β1γ2. General procedures for the 
generation of recombinant baculoviruses, culture of Sf9 cells and membrane preparation are 
described elsewhere.49 The respective membranes were thawed and sedimented by 
centrifugation at 4 °C and 13000 rpm for 10 min. Membranes were re-suspended in binding 
buffer (12.5 mM MgCl2, 1 mM EDTA, and 75 mM Tris/HCl, pH 7.4). Each tube (total volume 
100 μL) contained 30 μg (hH1R) or 100 μg (hH4R) of membrane protein and increasing 
concentrations of unlabeled ligands. Radioligands: H1R: [3H]pyrilamine, specific activity 20.0 
Ci/mmol, Kd = 4.5 nM,50 c = 5 nM, nonspecific binding determined in the presence of 10 μM of 
diphenhydramine; H4R: [3H]histamine, specific activity 25 Ci/mmol, Kd = 10 nM,43 c = 10 nM, 
nonspecific binding determined in the presence of 10 μM of histamine. Filtration through glass 
microfiber filters (for hH4R, glass microfiber filters was pretreated with 0.3% polyethylenimine, 
Whatman GF/B, Maidstone, UK) using a Brandel 96 sample harvester (Brandel, Gaithersburg, 
MD) separated unbound from membrane associated radioligand. After three washing steps 
with binding buffer, filter pieces for each well were punched out and transferred into 96-well 
sample plates 1450-401 (Perkin Elmer, Rodgau Germany). Each well was supplemented with 
200 μL of scintillation cocktail (Rotiscint Eco plus, Roth, Karlsruhe, Germany) and incubated 
in the dark. Radioactivity was measured with a Micro Beta2 1450 scintillation counter (Perkin 
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Elmer, Rodgau, Germany). Protein concentration was determined by the method of Lowry 
using bovine serum albumin as standard.51 Data analysis of the resulting competition curves 
was accomplished by non-linear regression analysis using the algorithms in PRISM 
GraphPad Software (GraphPad Prism 5.0 software, San Diego, CA). Ki values were 
calculated according to the Cheng-Prusoff equation.52 Values represent the mean ± SEM of 3 
independent experiments each performed in triplicate. 
 
3.3.2.2. Preparation of compound stock solutions 
All compounds were dissolved in 50% DMSO and 50% double distilled water (v/v) with 
appropriate equivalents of aqueous HCl. The final DMSO concentration was adjusted to 5% 
(v/v) in all assays. As demonstrated previously, DMSO concentrations up to 5% (v /v) are 
tolerated and have no influence on pKi and pEC50 values.50, 53 Ligand concentrations were 
used in the range from 0.1 nM up to 1 mM. 
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4. Benzimidazole- and Quinazoline-type histamine 
H1/H4 receptor ligands: Dual vs. subtype selective 
antagonism 
4.1. Introduction 
 
Histamine (4.1, Figure 1) is a mediator and neurotransmitter involved in numerous 
physiological and pathological processes mediated via four histamine receptor subtypes, 
which all belong to class A of G-protein-coupled receptors.1-4 The human histamine H1 
receptor is expressed on various cell types including endothelial cells and smooth muscle 
cells5 and involved in allergic and inflammatory reactions, e.g., bronchial asthma, allergic 
rhinitis, and urticaria.6 The human histamine H4 receptor which was identified and cloned 
around 2001,7-13 is mainly localized in cells of the immune system, such as neutrophils, 
eosinophils, basophils, dendritic cells, mast cells and monocytes.7-14 As a major player in 
histamine-induced immunological and inflammatory reactions, the hH4R was suggested as a 
potential target for the treatment of asthma, pruritus, and rheumatoid arthritis.5, 15-22 Due to the 
complementary and overlapping functions of hH1R and hH4R, it has been speculated that the 
combination of hH1R and hH4R antagonists in treating allergic diseases might be superior to 
monotherapy.5, 23 In various experimental models of allergy, a synergistic effect of 
co-administered hH1R and hH4R antagonists was observed regarding inhibition of pruritus 
and skin inflammation from chronic dermatitis,24 acute hapten-induced scratching,25 and 
peanut-induced intestinal allergy.26 Thus, dual hH1R/hH4R antagonists with balanced high 
affinities at both receptors might harbor a great potential for the treatment of allergic 
diseases.  
In order to reach multiple molecular targets simultaneously, a prevailing way is to use 
cocktails of drugs. But this approach may be hampered by poor patient compliance27 and the 
risk of drug-drug interactions. In principle, dual or multiple target ligands28 capable of 
addressing multiple desired biological targets are suggested to be superior with respect to 
higher affinity, potency, efficacy and reduced reliance on multiple drug regimens upon 
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administration,29, 30 and enhanced or modified physiological responses.31-34 Besides their 
potential clinical value, such hybrid compounds may be useful pharmacological tools for in 
vitro investigations. Previously, ligands showing affinities at both histamine receptor subtypes, 
hH1R and hH4R, were described, e.g. quinazoline,35 aminopyrimidine,36 astemizole,37, 38 and 
loxapine derivatives39, 40 (Figure 1). But due to the low homology between hH1R and hH4R 
(23.0%),7 most of the putative dual receptor ligands preferred one of the receptor subtypes 
and failed to bind with adequate balanced affinities to both, hH1R and hH4R. 
 
Figure 1 Structures and affinities of selected H1R and/or H4R ligands. Pharmacological data were 
taken from a) Strasser et al.41 b) Igel et al.18 c) Smits et al.35 d) Wagner et al.37 e) Hammer et al.36 f) 
Smits et al.39 g) Naporra et al.40 h) Baumeister 42 i) Geyer et al.43 
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In the present work, aiming at ligands with dual actions on hH1R and hH4R, compounds 
derived from high affinity hH1R and/or hH4R ligands were synthesized and characterized at 
the four human histamine receptors. For this purpose, benzimidazole-type derivatives 4.3 
and 4.4 (Figure 1) were employed. Compound 4.4, a ‘truncated’ analog of astemizole 4.7 
(Figure 1), shows high affinity to the hH1R (pKi 8.77) but almost no affinity to the hH4R (pKi 
4.41), compound 4.3 is a modified version of compound 4.4 with higher hH4R affinity (pKi 5.61) 
but reduced hH1R affinity (pKi 7.07).37, 38 Twenty-four derivatives with different substituents at 
various positions of the benzimidazole scaffold were synthesized, aiming at compounds with 
increased hH4R affinity but retained hH1R affinity (Figure 2). In addition, several compounds 
derived from 4.8 (Figure 1), a potent and selective hH4R ligand,42, 44 were prepared. The H1R 
ligand 4.4 and the H4R ligand 4.8 share structural features, suggesting a combination of 
these two moieties to increase the affinity at both receptors. In a second approach, structural 
modifications in 2-position of the quinazoline scaffold of compound 3.3 (Figure 1) were 
carried out. For both approaches, imidazole containing building blocks, e.g., histamine 4.1 
and homohistamine 4.9 (Figure 1), were employed to boost the hH4R affinity. By linking these 
pharmacophoric moieties to benzimidazole or quinazoline scaffold with or without a spacer, 
series of putative dual target ligands28 were synthesized. 
 
Figure 2 Structural variations of benzimidazoles and quinazolines synthesized as putative dual H1 and 
H4 receptor ligands. 
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4.2. Results and discussion 
4.2.1. Chemistry For the synthesis of benzimidazole derivatives (Scheme 1 and 2), 
N-substituted 2-chlorobenzimidazoles 4.12a-e were allowed to react with various amines 
under microwave radiation in the presence of a base to obtain compounds 4.19a, 4.19b, 
4.20a, 4.20b, 4.23 and intermediates 4.21a, 4.21b, 4.31a-c. In case of intermediate 4.28, the 
reaction was performed under acidic conditions in order to increase the nucleophilic attack in 
favor of the amino group compared to the hydroxy group of 4-aminophenol.45  
 Building blocks 4.3, 4.4, 4.14a-c were synthesized in two steps according to a procedure 
described by Rainer et al.46 The 2-phenylbenzimidazole scaffold 4.24 was built based on a 
procedure described by Xu, et al.47 The propylamine moiety was introduced to compounds 
4.3, 4.4, 4.24 and 4.28 by alkylation with tert-butoxycarbonyl protected bromopropylamine. In 
case of compound 4.26, the benzimidazole was alkylated with 
1-(chloromethyl)-4-fluorobenzene prior to the cleavage of the Boc group. Compounds 4.16a, 
4.16b, 4.27, 4.30, 4.32a, 4.32b were prepared by alkylation of respective amine precursors 
and 4-(2-bromoethyl)-1-tritylimidazole. The corresponding intermediates were not isolated 
but directly subjected to de-protection, followed by column chromatography or preparative 
HPLC to yield the title compounds. In some cases (compounds 4.18a, 4.18b, 4.22a, 4.22b), 
higher yields were obtained when the imidazole moiety was left unprotected, that is, 
4-(2-bromoethyl)imidazole was used instead of 4-(2-bromoethyl)-1-tritylimidazole. Urocanic 
acid was coupled to compounds 4.31a, 4.31c affording the corresponding amides (4.33a, 
4.33b), which were subjected to hydrogenation or reduction with lithium aluminum hydride to 
give compounds 4.34 and 4.35a, 4.35b, respectively. 
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Scheme 1 Synthesis of the benzimidazole derivatives 4.16-20, 4.22 and 4.23a  
 
aReagents and conditions: (i) R2-Cl, NaOH, ACN, 95 °C, 2 h; (ii) ethyl 4-aminopiperidine-1-carboxylate, 
170 °C, overnight; (iii) 47% HBr in H2O, 126 °C, 3 h; (iv) tert-butyl (3-bromopropyl)carbamate, NaI, 
DIPEA, ACN, reflux, 2 h; (v) TFA, DCM, rt, 3 h; (vi) 4-(2-bromoethyl)-1-tritylimidazole, NaI, DIPEA, 
ACN, reflux, 48 h; (vii) MeI, DIPEA, ACN, 0.5 h, rt; (viii) 4-(2-bromoethyl)imidazole, DIPEA, ACN, 
microwave, 120 °C, 10 min; (ix) histamine dihydrochloride, DIPEA, NMP, microwave, 200 °C, 10 min; 
(x) 2-(4-methylpiperazin-1-yl)ethan-1-amine, DIPEA, NMP, microwave, 180 °C, 2 h; (xi) piperazine, 
DIPEA, NMP, microwave, 180 °C, 1 h; (xii) 4-(2-bromoethyl)imidazole, DIPEA, NMP, microwave, 
120 °C, 50 min; (xiii) 1-methylpiperazine, DIPEA, NMP, microwave, 180 °C, 1 h. 
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Scheme 2 Synthesis of the benzimidazole derivatives 4.26, 4.27, 4.30, 4.32, 4.33, 4.34 and 
4.35 a 
 
aReagents and conditions: (i) Na2S2O5, DMF, 90 °C, 2 h, H2O, 4 h, 0 °C; (ii) 
tert-butyl(3-bromopropyl)carbamate, K2CO3, aceton, 60 °C, 17 h; (iii) 1-(chloromethyl)-4-fluorobenzene, 
NaOH, ACN, reflux, 2 h; (iv) TFA, DCM, rt, 3 h; (v) 4-(2-bromoethyl)-1-trityl-imidazole, NaI, DIPEA, 
ACN, reflux, 48 h; (vi) 4-aminophenol, EtOH, HCl in iso-propanol, 48 h; (vii) diamine, DIPEA, 
microwave, 160-180 °C, 10 min - 3 h; (viii) urocanic acid, HOBT, TBTU, DIPEA, rt, 30 min; (ix) 5% 
Pd/C, H2, MeOH, rt, 19 h; (x) LiAlH4, THF, 0 °C to rt to 70 °C, 3h, 15% NaOH in H2O, H2O, 0 °C to rt, 30 
min. 
 
Quinazoline derivatives 4.40, 4.41, 4.42 and 4.4435 (Scheme 3) as well as the required 
building blocks 4-(2-bromoethyl)-imidazole,48 4-(2-bromoethyl)-1-trityl-imidazole,49 
4-methyl-1-piperazineethanamine,50 tert-butyl piperazine-1-carboxylate51 and 
2-(1-trityl-imidazol-4-yl)ethan-1-amine,52 were synthesized according to described 
procedures. 
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Scheme 3 Synthesis of the quinazoline derivatives 4.40, 4.41, 4.42 and 4.44a 
 
aReagents and conditions: (i) thiophen-2-ylmethanamine, DIPEA, EtOAc, rt, 0.5 h; (ii) tert-butyl 
piperazine-1-carboxylate, DIPEA, EtOAc, microwave, 120 °C, 10 min; (iii) TFA, DCM, rt, 3 h; (iv) 
4-(2-bromoethyl)-imidazole, DIPEA, EtOAc, microwave, 120 °C, 30 min; (v) 
2-(4-methylpiperazin-1-yl)ethan-1-amine, DIPEA, NMP, microwave, 180 °C, 2 h; (vi) 
1-methylpiperidin-4-amine, DIPEA, NMP, microwave, 180 °C, 50 min; (vii) 
2-(1-tritylimidazol-4-yl)ethan-1-amine, DMF, microwave, 160 °C, 10 min. 
 
4.2.2. Pharmacology 
The title compounds were analyzed by radioligand competition binding assays on hH1R 
and hH4R, and selected compounds were additionally tested on hH2R and hH3R. For 
functional characterization, the compounds were investigated for agonism and antagonism in 
[35S]GTPγS binding assays at the four human histamine receptor subtypes. All assays were 
performed using membrane preparations of Sf9 insect cells expressing the hH1R + RGS4 
(regulator of G-protein signaling 4),53 hH2R-Gsαs,54 hH3R + Gαi2 + Gβ1γ255 or the hH4R + Gαi2 + 
Gβ1γ256. 
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4.2.2.1. Competition binding data at the hH1R and hH4R. 
The affinities of the title compounds at the hH1R and the hH4R are summarized in Table 1. 
Based on the substituents at the 2-position of compounds 4.3 and 4.4 the benzimidazoles 
can be grouped into four types (Figure 4, red box). A piperazine moiety (“Type A”), attached 
directly or via a spacer decreased the affinity at both, the hH1R and the hH4R (e.g. 
compounds 4.20a, 4.20b, 4.22b, 4.23). In case of compounds bearing a piperidin-4-ylamino 
group (“Type B”), an aminopropyl substituent at the piperidine nitrogen (4.3) increased the 
hH1R affinity but decreased hH4R binding (4.15b). Further extension of the substituent by 
imidazolylethyl moiety led to a moderate increase in hH4R affinity, whereas the pKi at the 
hH1R remained unchanged (4.16a and 4.16b). The structural modifications of “Type C” 
compounds, which are derived from 2-aryl benzimidazole 4.8, were not tolerated at the hH1R, 
unless benzimidazole and phenyl ring were connected by a NH group (cf. 4.26, 4.27 and 
4.30). Interestingly, compounds 4.27 and 4.30 showed a considerable increase in hH4R 
affinity. Among the investigated benzimidazoles, 4.30 represented the first dual hH1R/hH4R 
ligand with nearly balanced affinities in the range of pKi  8 (4.30, pKi: hH1R 8.04, hH4R 7.74). 
Comparing compounds with and without an imidazole moiety (cf. 4.16b, 4.27 vs. 4.15b, 4.26), 
it becomes obvious that this substructure substantially contributes to H4R binding, provided 
that the benzimidazole and the imidazole moieties are connected by appropriated linkers (cf. 
4.16a, 4.16b vs. 4.18a, 4.18b). With this information, compounds of “Type D” were 
synthesized to further investigate the influence of the linker. Extending the linker length was 
beneficial with respect to H4R affinity (cf. 4.19a, 4.19b, 4.32a, 4.32b, 4.35a, 4.35b). However, 
the decrease in hH1R was comparable to that observed for Type C analogs. Compound 
4.35b, with a distance between the imidazole and the benzimidazole ring which is 13Å, 
similar to that of 4.30, was identified as a dual hH1R/hH4R ligand with balanced affinity (Ki 
values in the two-digit nM range). 
Replacing the 4-fluorobenzyl substituent in position 1 of the benzimidazole by 2-thienylethyl 
phenethyl or 4-chlorobenzyl moiety (Figure 4, purple box), however, no positive influence 
was observed (cf. 4.14c, 4.17c vs. 4.3, 4.17b). A 4-fluorobenzyl moiety was most favorable 
with respect to hH1R binding (cf. 4.4, 4.16a, 4.18a, 4.19a, 4.20a, 4.22a compare with their 
counterpart 4.3, 4.16b, 4.18b, 4.19b, 4.20b, 4.22b). Chlorine atom introduced at 5- or 
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6-position of benzimidazole (Figure 4, blue box) proved detrimental to hH1R and hH4R affinity 
(cf. 4.14a, 4.14b, 4.17a vs. 4.3, 4.17b). Thus, introducing a piperazine moiety at 2-position, 
thienylethyl at 1-position and a chlorine atom at 5- or 6-position of the benzimidazole core by 
analogy with a report by Smits et al.35 on quinazoline-type ligands proved unsuccessful. 
All variations of the quinazoline-type ligands (Table 2) led to a decrease in affinity at both, 
the hH1R and hH4R, except for compound 4.44, which showed a three-fold higher hH4R 
affinity, compared to compound 3.3. 
 
Table 1 hH1R and hH4R affinities of benzimidazole-type ligands  
 
The compounds were characterized in radioligand competition binding assays using membrane 
preparations of Sf9 insect cells expressing the hH1R + RGS4 or the hH4R + Gαi2 + Gβ1γ2. Radioligands: 
H1R: [3H]pyrilamine, Kd = 4.5 nM, c = 5 nM; H4R: [3H]histamine, Kd = 10 nM, c = 10 nM. Data represent 
mean values ± SEM of at least three independent experiments performed in triplicate. a Reference data 
from Wagner et al.37  
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Figure 4 Summarized structure-activity relationships of the benzimidazole-type ligands at hH1R and 
hH4R 
 
Table 2 hH1R and hH4R affinities of quinazoline-type ligands 
 
a (pKi) hH1R = 7.70, hH4R = 8.12 (Smits et al.35) 
The compounds were characterized in radioligand competition binding assays using membrane 
preparations of Sf9 insect cells expressing the hH1R + RGS4 or the hH4R + Gαi2 + Gβ1γ2. Radioligands: 
48                                 Chapter 4 
H1R: [3H]pyrilamine, Kd = 4.5 nM, c = 5 nM; H4R: [3H]histamine, Kd = 10 nM, c = 10 nM. Values 
represent the mean ± SEM of at least three independent experiments performed in triplicate.  
4.2.2.2. Histamine receptor subtype selectivity and activity of selected compounds. 
Table 3 Binding and functional data of selected compounds at hHxR, determined by 
radioligand-competition binding and [35S]GTPγS-binding assays. 
The compounds were characterized in radioligand competition binding and [35S]GTPγS binding assays, 
performed on membrane preparations of Sf9 insect cells expressing the hH1R + RGS4, hH2R-GsαS, 
hH3R + Gαi2 + Gβ1γ2 or the hH4R + Gαi2 + Gβ1γ2. Radioligands: H1R: [3H]pyrilamine, Kd = 4.5 nM, c = 5 
nM; H2R: [3H]UR-DE 257 
(N-[6-(3,4-dioxo-2-{3-[3-(piperidin-1-ylmethyl)phenoxy]propylamino}-cyclobut-1-enylamino)hexyl]-[2,3-
3H2]-propion-amide)57, Kd = 12.1 nM, c = 20 nM; H3R: [3H]UR-PI 294 
(N1-[3-(1H-imidazol-4-yl)propyl]-N2-propionylguanidine)58, Kd = 3.3 nM, c = 3.5 nM; H4R: [3H]histamine, 
Kd = 10 nM, c = 10 nM. The pKb values of neutral antagonists and inverse agonists were determined in 
the antagonist mode in presence of histamine (10 μM for the hH1R, 1 μM for the hH2R, and 100 nM for 
the hH3R and the hH4R, respectively). Values represent the mean ± SEM of at least three independent 
experiments each performed in triplicate. α = 0 (neutral antagonism): the measured values were in the 
range between ± 0.15 and not significantly different from zero. 
 
cpd. 
hH1R hH2R hH3R hH4R 
[pKi], 
(pEC50) or pKb 
α 
[pKi], 
(pEC50) or pKb 
α 
[pKi], 
(pEC50) or pKb 
α 
[pKi], 
(pEC50) or pKb 
α 
Histamine (5.43±0.15) 1 (6.07±0.10) 1 (7.97±0.04) 1 (7.73±0.06) 1 
Thioperamide n.d. n.d. n.d. n.d. 7.00±0.11 -0.61±0.09 6.78±0.06 -1.03±0.08 
Famotidine n.d. n.d. 6.53±0.06 -0.33±0.06 n.d. n.d. n.d. n.d. 
Levocetirizine 7.17±0.15 -0.23±0.09 n.d. n.d. n.d. n.d. n.d. n.d. 
4.16a 
[8.50±0.04] 
 
[5.06±0.03] 
 
[6.79±0.05] 
 
[6.61±0.21] 
 
7.09±0.10 0 <5 0 6.77±0.05 -0.41±0.08 5.82±0.06 0 
4.19a 
[7.92±0.01] 
 
[5.34±0.06] 
 
[7.34±0.02] 
 
[6.05±0.08] 
 
7.42±0.17 0 <5 0 7.38±0.01 -0.82±0.06 5.27±0.15 -0.67±0.07 
4.27 
[5.51±0.18] 
 
[5.50±0.02] 
 
[7.39±0.03] 
 
[7.90±0.04] 
 
<5 0 5.18±0.07 0 7.37±0.06 0 (7.57±0.19) 0.99±0.08 
4.30 
[8.04±0.06] 
 
[5.48±0.05] 
 
[7.26±0.01] 
 
[7.74±0.05] 
 
7.70±0.17 0 5.27±0.09 0 7.94±0.11 -0.34±0.05 (7.01±0.15) 0.84±0.08 
4.32b 
[8.25±0.17] 
 
[5.74±0.14] 
 
[5.88±0.05] 
 
[6.01±0.05] 
 
8.00±0.16 0 (6.29±0.07) 0.44±0.04 6.10±0.06 -0.66±0.05 <5 0 
4.35a 
[7.93±0.10] 
 
[6.11±0.06] 
 
[6.89±0.03] 
 
[6.72±0.05] 
 
7.05±0.09 0 <5 0 7.20±0.17 -0.63±0.05 6.83±0.08 0 
4.35b 
[7.26±0.02] 
 
[5.28±0.06] 
 
[6.94±0.01] 
 
[7.31±0.07] 
 
7.37±0.09 0 <5 0 (5.31±0.07) 0.50±0.04 6.91±0.04 -0.55±0.01 
4.44 
[5.23±0.03] 
 
[6.70±0.03] 
 
[8.33±0.10] 
 
[7.90±0.02] 
 
<5 0 6.50±0.12 0 8.88±0.05 -0.98±0.06 7.64±0.10 -1.73±0.10 
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Eight compounds exhibiting high hH1R and/or hH4R affinities (4.16a, 4.19a, 4.27, 4.30, 
4.32b, 4.35a, 4.35b and 4.44) were selected for further pharmacological evaluations 
regarding hH2R and hH3R subtype affinity and functional activity at the four human histamine 
receptor subtypes (Table 3). Whereas hH2R binding was low to moderate, for all imidazole 
containing ligands, poor selectivity for the hH4R over the hH3R became obvious. The selected 
compounds showed binding affinities in the same range at the hH3R and the hH4R, except for 
compound 19a which exhibited a preference for the hH3R.  
In the functional assays compounds 4.16a, 4.32b and 4.35a were selective hH1R 
antagonists. Compound 4.19a turned out to be an hH1R antagonist and a potent inverse 
agonist at the hH3R (Table 2 and Figure 5). A dual hH1R/hH3R antagonist might be useful to 
treat allergic rhinitis59-61, e.g., a combined H1 and H3 receptor blockade was reported to 
reduce histamine-induced nasal congestion62-64. 
 
 
Figure 5 Binding and function of compound 4.19a at histamine receptors. Curves shown represent 
mean values of at least three independent experiments performed in triplicate. A) Competition binding 
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curves of compound 4.19a at hHxR. Concentration-response curves of histamine and compound 4.19a 
at the B) hH1R, C) hH2R, D) hH3R and E) hH4R, determined in the [35S]GTPγS binding assay. All 
assays were performed on membrane preparations of Sf9 insect cells expressing the hH1R + RGS4, 
hH2R-GsαS, hH3R + Gαi2 + Gβ1γ2 or the hH4R + Gαi2 + Gβ1γ2. Radioligands: H1R: [3H]pyrilamine, Kd = 4.5 
nM, c = 5 nM; H2R: [3H]UR-DE 25757, Kd = 12.1 nM, c = 20 nM; H3R: [3H]UR-PI 29458, Kd = 3.3 nM, c = 
3.5 nM; H4R: [3H]histamine, Kd = 10 nM, c = 10 nM. The pKb values of neutral antagonists and inverse 
agonists were determined in the antagonist mode in the presence of histamine (10 μM for the hH1R, 1 
μM for the hH2R, and 100 nM for the hH3R and the hH4R, respectively). In the antagonist mode of 
[35S]GTPγS binding assay, the signal of histamine is referred to 100%. 
 
The quinazoline derivative 4.44 (Table 2 and Figure 6) was a more potent dual hH3R/hH4R 
inverse agonist than thioperamide. 
 
 
Figure 6 Binding and function of compound 4.44 at histamine receptors. Curves shown represent 
mean values of at least three independent experiments performed in triplicate. A) Competition binding 
curves of compound 4.44 at hHxR. Concentration-response curves of histamine and compound 4.44 at 
the B) hH1R, C) hH2R, D) hH3R and E) hH4R, determined in the [35S]GTPγS binding assay. For details 
cf. legend to Figure 5.  
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Compound 4.35b was an antagonist at the hH1R, an inverse agonist at the hH4R, but a 
weak hH3R partial agonist. Thus, functional characterization revealed opposite qualities of 
action for compound 4.35b at the hH3R and the hH4R (Table 2 and Figure 7). Among the 
studied ligands compounds 4.30 and 4.35b showed the highest (nearly) balanced affinities at 
both, the hH1R and the hH4R (Figure 8).  
 
 
Figure 7 Binding and function of compound 4.35b at histamine receptors. Curves shown represent for 
mean values of at least three independent experiments performed in triplicate. A) Competition binding 
curves of compound 4.35b at hHxR.Concentration-response curves of histamine and compound 4.35b 
at the B) hH1R, C) hH2R, D) hH3R and E) hH4R respectively, determined in the [35S]GTPγS binding 
assay. For details cf. legend to Figure 5. 
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Figure 8 Affinity-selectivity profile of the compounds 3.3, 4.3-4.8, 4.14a-c, 4.15b, 4.16a, 4.16b, 
4.17a-c, 4.18a, 4.18b, 4.19a, 4.19b, 4.20a, 4.20b, 4.22a, 4.22b, 4.23, 4.26, 4.27, 4.30, 4.32a, 4.32b, 
4.34, 4.35a, 4.35b, 4.40, 4.41, 4.42, 4.44. The data were obtained from competition binding assays at 
hH1R or hH4R under comparable conditions. 
 
4.3. Conclusion 
 
Aiming at dual hH1R/hH4R antagonists, benzimidazole- and quinazoline-type compounds 
were synthesized and pharmacologically characterized at the four human histamine receptor 
subtypes. All compounds with high hH1R and/or hH4R affinities showed only weak affinity to 
the hH2R. Unfortunately, ligands comprising imidazolylalkyl moieties did not discriminate 
between hH3 and hH4 receptors. Regardless of that, compounds 4.30 and 4.35b were 
identified as balanced dual hH1R/hH4R ligands with the highest affinities among the 
investigated ligands. The data of the presented benzimidazole and quinazoline derivatives 
are indicative of the complexity of the structure-activity relationships. It appears extremely 
difficult to identify a common H1R/H4R pharmacophore at a high level of affinity. Introducing 
an imidazole moiety may result in balanced H1R/H4R affinities. However, binding and 
    Chapter 4                                             53 
functional properties of such hybrid compounds become even more complex due to poor 
discrimination between H4 and H3 receptors. 
 
4.4. Experimental section 
4.4.1. Chemistry  
4.4.1.1. General conditions. 
See section 3.3.1.1. 
 
4.4.1.2. Synthesis  
4-(2-Bromoethyl)imidazole monohydrochloride.48  
A 250 mL round bottom flask containing 42.4 mL of 1.5 M sulfuric acid, histamine 
dihydrochloride (5.34 g, 28.9 mmol) and potassium bromide (11.52 g, 96.0 mmol) was fitted 
with a magnetic stirrer and cooled to -15 °C. A saturated solution of sodium nitrite (2.58 g, 
37.2 mmol) in 3.8 mL of water was added in one portion to the magnetically stirred sulfuric 
acid/histamine solution at -15 °C. A color change from colorless to a deep orange-brown was 
observed, and a gas evolved in the reaction flask immediately upon addition. After a period of 
30 minutes, the reaction mixture was warmed to room temperature. After a total of 3 hours, 
no more bubbling was observed and the reaction mixture had changed from a deep 
orange-brown to almost colorless light yellow. The reaction mixture was cooled to -15 °C and 
adjusted to a pH of 10 by dropwise addition of 27.6 mL of 5 M sodium hydroxide solution. This 
basic solution was transferred to a 100 mL separation funnel where the desired product was 
quickly extracted with chloroform (5 x 10 mL). The colorless chloroform layer was added 
directly from the separation funnel to 64 mL of 0.5 N HCl in isopropanol in a 250 mL round 
bottom flask. Concentration of this solution under reduced pressure gave white crystals (1.70 
g, 6.72 mmol, yield 23.2%). 1H-NMR (300 MHz, DMSO-d6) δ [ppm]: 9.08 (d, J = 1.2 Hz, 1H), 
7.54 (s, 1H), 3.91-3.76 (m, 2H), 3.27-3.12 (m, 2H). HRMS (EI-MS) m/z: calcd for C5H8BrN2 
[MH+] 174.9865, found 174.9864. 
 
4-(2-Bromoethyl)-1-tritylimidazole.49  
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A mixture of 4-(2-bromoethyl)imidazole hydrochloride (1.68 g, 9 mmol), 
triphenylmethylchloride (3.69 g, 13.4 mmol) and TEA (2.73 g, 27 mmol) in DMF (15 mL) was 
stirred at rt overnight. The mixture was poured into brine, extracted with DCM (90 mL), and 
the evaporated organic phase was subjected to column chromatography (PE/EE, 2/1). White 
solid (2.67g, 6.42mmol, yield 22.2%); mp 143°C. 1H-NMR (300 MHz, CDCl3) δ [ppm]: 7.39 (d, 
J = 1.3 Hz, 1H), 7.36-7.29 (m, 9H), 7.15 (m, 6H), 6.65 (d, J = 0.5 Hz, 1H), 3.80-3.60 (m, 2H), 
3.12-2.95 (m, 2H). 13C-NMR (75 MHz, CDCl3) δ [ppm]: 142.38 (2Cquat), 138.55 (+, Ar-CH), 
138.37 (Cquat), 137.62 (Cquat), 129.81 (+, 6Ar-CH), 128.07 (+, 9Ar-CH), 119.39 (+, Ar-CH), 
75.29 (Cquat), 44.07 (-, CH2), 32.14 (-, CH2). HRMS (EI-MS) m/z: calcd for C24H21BrN2 [MH+] 
417.0961, found 417.0962. 
 
tert-Butyl [2-(4-methylpiperazin-1-yl)ethyl]carbamate.65  
To a solution of 1-methylpiperazine (500 mg, 5 mmol) and DIPEA (2 g, 15 mmol) in 
acetonitrile (50 mL), tert-butyl (2-bromoethyl)carbamate (1.4 g, 6 mmol) was added. The 
reaction mixture was heated at 50 °C overnight, the solvent was evaporated, and the 
remaining mixture was poured into water. The aqueous layer was extracted with DCM, and 
the combined organic layers were dried over Na2SO4. The solvent was removed under 
reduced pressure. Purification of the product by column chromatography (DCM/MeOH/25% 
aqueous ammonia, 100/4/1) yielded a yellow oil (140 mg, 0.20 mmol, yield 17.4%). 1H-NMR 
(300 MHz, CDCl3) δ [ppm]: 3.25-3.10 (m, 2H), 2.55-2.31 (m, 10H), 2.24 (s, 3H), 1.38 (s, 9H). 
13C-NMR (75 MHz, CDCl3) δ [ppm]: 155.95 (Cquat), 79.12 (Cquat), 57.07 (-, CH2), 55.00 (-, 
2CH2), 52.73 (-, 2CH2), 45.94 (+, CH3), 37.10 (-, CH2), 28.43 (+, 3CH3). HRMS (EI-MS) m/z: 
calcd for C12H25N3O2 [MH+] 244.2020, found 244.2021. 
 
N-[2-(1-Triphenylmethylimidazol-4-yl)ethyl]phthalimide.52  
Ethyl phthalimide-N-carboxylate (2.4 g, 11 mmol) was added potion-wise to a stirred 
solution of histamine dihydrochloride (1.84 g, 10 mmol), and Na2CO3 (2.12 g, 20 mmol) in 
distilled water (50 mL) at rt. The resulting snow-white suspension was stirred vigorously at rt 
for 90 min. The solid was filtered off and thoroughly washed with ice-cold water (20 mL). The 
solid was collected and dried. The obtained white solid was dissolved in DMF (15 mL), TEA 
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(1.47 g, 14.6 mmol) and triphenylmethylchloride (3 g, 11 mmol) was introduced, the reaction 
was stirred at rt overnight. After the reaction was finished, the mixture was poured into brine 
and extracted with DCM (90 mL), then subjected to column chromatography (PE/EE, 1/1). 
White solid (2.85 g, 5.9 mmol, 81%). 1H-NMR (300 MHz, CDCl3) δ [ppm]: 7.83-7.76 (m, 2H), 
7.73-7.65 (m, 2H), 7.35-7.21 (m, 10H), 7.10-7.01 (m, 6H), 6.58-6.48 (m, 1H), 3.97 (t, J = 7.1 
Hz, 2H), 2.94 (t, J = 7.0 Hz, 2H). 
 
2,5-Dichloro-1H-benzo[d]imidazole and 2,6-dichloro-1H-benzo[d]imidazole (4.10).66  
A mixture of urea (6 g, 100 mmol), 4-chloro-o-phenylenediamine (14.2 g, 100 mmol) and 
n-butanol (100 mL) was stirred at 120 °C for 16 h and subsequently cooled to 0 °C. The 
precipitate was collected and washed with n-butanol (5 mL) and water (200 mL). After drying, 
the precipitated white solid was added to 50 mL POCl3 and heated at 100 °C for 18 h. The 
reaction mixture was cooled to rt, and the excess of POCl3 was removed in vacuum. The 
residue was neutralized with 100 mL of saturated NaHCO3 solution and extracted with EtOAc. 
The organic phase was washed with brine and dried over Na2SO4. A mixture of 
2,5-dichlorobenzimidazole and 2,6-dichlorobenzimidazole was obtained as brown solid (4.62 
g, 24.8 mmol, 86.1%); mp 205 °C. 1H-NMR (300 MHz, DMSO-d6) δ [ppm]: 7.58 (d, J = 1.9 Hz, 
1H), 7.55-7.49 (m, 1H), 7.26-7.20 (m, 1H). 13C-NMR (75 MHz, DMSO-d6) δ [ppm]: 139.86 
(2Cquat), 126.66 (2Cquat), 122.54 (+, 3Ar-CH). 
 
2,5-Dichloro-1-phenethyl-1H-benzo[d]imidazole and 
2,6-dichloro-1-phenethyl-1H-benzo[d]imidazole (4.12a).  
To a solution of compound 4.10 (2.23 g, 12 mmol) in ACN (100 mL), 
(2-bromoethyl)benzene (4.44 g, 24 mmol) and NaOH (2.4 g, 60 mmol) was added inside, the 
mixture was stirred at 95 °C for 2 h (control by TLC). The solvent was evaporated yielding a 
yellow solid (1.12 g, 3.86 mmol, 32.2%); mp 97 °C. 1H-NMR (300 MHz, CDCl3) δ [ppm]: 7.61 
(m, 1H), 7.32-7.16 (m, 4H), 7.13-6.99 (m, 3H), 4.43-4.30 (m, 2H), 3.07 (t, J = 7.2 Hz, 2H). 
 
2-Chloro-1-phenethyl-1H-benzo[d]imidazole (4.12b).67  
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Synthesized from 2-chloro-benzoimidazole (2 g, 13.16 mmol) and (2-bromoethyl)benzene 
(7.3 g, 37.5 mmol) by analogy with the procedure for the preparation of 4.12a. White solid 
(3.21 g, 12.54 mmol, 95%); mp 85 °C. 1H-NMR (300 MHz, CDCl3) δ [ppm]: 7.74-7.65 (m, 1H), 
7.33-7.17 (m, 6H), 7.12-7.04 (m, 2H), 4.45-4.33 (m, 2H), 3.09 (t, J = 7.4 Hz, 2H). 
 
2-Chloro-1-(4-fluorobenzyl)-1H-benzo[d]imidazole (4.12c).68  
Synthesized from 2-chloro-benzoimidazole (6 g, 40 mmol) and 
1-(chloromethyl)-4-fluorobenzene (17.3 g, 120 mmol) by analogy with the procedure for the 
preparation of 4.12a. White solid (10.17 g, 39 mmol, 97%); mp 94 °C. 1H-NMR (300 MHz, 
CDCl3) δ [ppm]: 7.76-7.67 (m, 1H), 7.32-7.20 (m, 3H), 7.20-7.13 (m, 2H), 7.06-6.97 (m, 2H), 
5.35 (s, 2H). 13C-NMR (75 MHz, CDCl3) δ [ppm]: 160.85 (Cquat), 141.84 (Cquat), 140.65 (Cquat), 
134.99 (Cquat), 130.85 (Cquat), 128.71 (+, Ar-CH), 128.60 (+, Ar-CH), 123.49 (+, Ar-CH), 
122.99 (+, Ar-CH), 119.66 (+, Ar-CH), 116.18 (+, Ar-CH), 115.89 (+, Ar-CH), 109.74 (+, 
Ar-CH), 47.27 (-, CH2). HRMS (EI-MS) m/z: calcd for C14H10FN2 [MH+] 261.0589, found 
261.0589. 
 
2-Chloro-1-(4-chlorophenethyl)-1H-benzo[d]imidazole (4.12d).  
Synthesized from 2-chlorobenzimidazole (760 mg, 5 mmol) and 
1-(2-bromoethyl)-4-chlorobenzene (2.18 g, 10 mmol) by analogy with the procedure for the 
preparation of 4.12a. Yellow-white solid (370 mg, 1.28 mmol, 25.6%); mp 69 °C. 1H-NMR 
(300 MHz, CDCl3) δ [ppm]: 7.79-7.61 (m, 1H), 7.31-7.15 (m, 5H), 7.06-6.91 (m, 2H), 4.37 (m, 
2H), 3.06 (t, J = 7.2 Hz, 2H). 13C-NMR (75 MHz, CDCl3) δ [ppm]: 141.68 (Cquat), 140.49 (Cquat), 
135.52 (Cquat), 134.69 (Cquat), 133.06 (Cquat), 130.15 (+, 2Ar-CH), 128.98 (+, 2Ar-CH), 123.25 
(+, Ar-CH), 122.79 (+, Ar-CH), 119.61 (+, Ar-CH), 109.25 (+, Ar-CH), 45.76 (-, CH2), 34.95 (-, 
CH2). HRMS (EI-MS) m/z: calcd for C15H12Cl2N2 [MH+] 291.0450, found 291.0455. 
 
2-Chloro-1-[2-(thiophen-2-yl)ethyl]-1H-benzo[d]imidazole (4.12e).  
Synthesized from 2-chlorobenzimidazole (1 g, 6.58 mmol) and 2-(2-bromoethyl)thiophene 
(3.75 g, 19.74 mmol) by analogy with the procedure for the preparation of 4.12a. Yellow-white 
solid (730 mg, 2.79 mmol, 42.3%); mp 91 °C. 1H-NMR (300 MHz, CDCl3) δ [ppm]: 7.73-7.65 
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(m, 1H), 7.30-7.19 (m, 3H), 7.18-7.13 (m, 1H), 6.93-6.85 (m, 1H), 6.69-6.66 (m, 1H), 
4.51-4.34 (m, 2H), 3.31 (t, J = 7.2 Hz, 2H). 13C-NMR (75 MHz, CDCl3) δ [ppm]: 141.68 (Cquat), 
140.56 (Cquat), 138.69 (Cquat), 134.80 (Cquat), 127.32 (+, Ar-CH), 126.17 (+, Ar-CH), 124.70 (+, 
Ar-CH), 123.25 (+, Ar-CH), 122.77 (+, Ar-CH), 119.56 (+, Ar-CH), 109.25 (+, Ar-CH), 45.99 (-, 
CH2), 29.57 (-, CH2). HRMS (EI-MS) m/z: calcd for C13H11ClN2S [MH+] 263.0404, found 
263.0405. 
 
Ethyl 4- [(5- chloro- 1- phenethyl- 1H- benzo[d]imidazol- 2- yl)amino]piperidine- 1- 
carboxylate (4.13a).  
Compound 4.12a (1.11 g, 3.83 mmol) was added to ethyl 4-aminopiperidine-1-carboxylate 
(3.3 g, 19.15 mmol). The reaction mixture was heated to 170 °C overnight. Afterwards the 
mixture was poured into brine and extracted with DCM, the combined organic layers were 
dried over Na2SO4. The solvent was removed under reduced pressure, and the remaining 
mixture was subjected to column chromatography (DCM/MeOH = 50/1). White solid (360 mg, 
0.85 mmol, 22.2%); mp 61 °C. 1H-NMR (300 MHz, CDCl3) δ [ppm]: 7.42 (d, J = 1.9 Hz, 1H), 
7.29-7.26 (m, 3H), 7.03-7.00 (m, 3H), 6.96 (m, 3.5 Hz, 1H), 4.12 (q, J = 7.2 Hz, 2H), 4.09-4.06 
(m, 2H), 4.05-3.85 (m, 2H), 3.78-3.69 (m, 1H), 3.03-3.00 (m, 2H), 2.93-2.83 (m, 2H), 
1.86-1.77 (m, 2H), 1.26 (t, J = 7.1 Hz, 4H), 1.02-0.92 (m, 2H). 13C-NMR (75 MHz, CDCl3) δ 
[ppm]: 155.51 (Cquat), 154.14 (Cquat), 143.39 (Cquat), 138.37 (Cquat), 132.78 (Cquat), 129.32 (+, 
2Ar-CH), 128.94 (+, 2Ar-CH), 127.45 (+, Ar-CH), 126.81 (Cquat), 119.62 (+, Ar-CH), 116.51 (+, 
Ar-CH), 107.60 (+, Ar-CH), 61.38 (-, CH2), 49.42 (+, CH), 44.90 (-, CH2), 42.57 (-, 2CH2), 
35.37 (-, CH2), 32.12 (-, 2CH2), 14.74 (+, CH3). 
 
Ethyl 4- [(6- chloro- 1- phenethyl- 1H- benzo[d]imidazol- 2- yl)amino]piperidine- 1- 
carboxylate (4.13b).  
Synthesized from compound 4.12a (1.11 g, 3.83 mmol) and ethyl 
4-aminopiperidine-1-carboxylate (3.3 g, 19.15 mmol) by analogy with the procedure for the 
preparation of 4.13a. White solid (270 mg, 0.63 mmol, 10.3%); mp 58 °C. 1H-NMR (300 MHz, 
CDCl3) δ [ppm]: 7.36-7.32 (m, 1H), 7.30-7.26 (m, 3H), 7.11-7.04 (m, 2H), 7.04-7.00 (m, 2H), 
4.12 (q, J = 7.1 Hz, 2H), 4.07-4.04 (m, 2H), 4.03-3.89 (m, 2H), 3.77-3.69 (m, 1H), 3.03-3.01 
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(m, 2H), 2.88 (s, 2H), 1.85-1.78 (m, 2H), 1.26 (t, J = 7.1 Hz, 4H), 1.01-0.91 (m, 2H). 13C-NMR 
(75 MHz, CDCl3) δ [ppm]: 155.51 (Cquat), 153.86 (Cquat), 141.01 (Cquat), 138.37 (Cquat), 134.85 
(Cquat), 129.33 (+, 2Ar-CH), 128.96 (+, 2Ar-CH), 127.46 (+, Ar-CH), 125.01 (Cquat), 121.61 (+, 
Ar-CH), 117.08 (+, Ar-CH), 107.47 (+, Ar-CH), 61.37 (-, CH2), 49.44 (+, CH), 44.93 (-, CH2), 
42.57 (-, 2CH2), 35.35 (-, CH2), 32.10 (-, 2CH2), 14.73 (+, CH3). 
 
Ethyl 4- [(1- phenethyl- 1H- benzo[d]imidazol- 2- yl)amino]piperidine- 1- carboxylate 
(4.13c).37 
Synthesized from 4.12b (385 mg, 1.5 mmol) and ethyl 4-aminopiperidine-1-carboxylate 
(1.27 g, 7.5 mmol) by analogy with the procedure for the preparation of 4.13a. Yellow-white 
solid (380 mg, 0.97 mmol, 65%); mp 74 °C. 1H-NMR (300 MHz, CDCl3) δ [ppm]: 7.51-7.45 (m, 
1H), 7.31-7.24 (m, 3H), 7.18-6.96 (m, 5H), 4.17-4.07 (m, 4H), 4.06-3.88 (m, 2H), 3.85-3.70 (m, 
1H), 3.04 (t, J = 5.4 Hz, 2H), 2.96-2.81 (m, 2H), 1.91-1.75 (m, 2H), 1.26 (t, J = 7.1 Hz, 3H), 
1.08-0.87 (m, 2H). 13C-NMR (75 MHz, CDCl3) δ [ppm]: 155.52 (Cquat), 153.34 (Cquat), 142.33 
(Cquat), 138.64 (Cquat), 134.10 (Cquat), 129.25 (+, 2Ar-CH), 129.00 (+, 2Ar-CH), 127.33 (+, 
Ar-CH), 121.40 (+, Ar-CH), 119.69 (+, Ar-CH), 116.53(+, Ar-CH), 107.15 (+, Ar-CH), 61.34 (-, 
CH2), 49.31 (+, CH), 44.77 (-, CH2), 42.60 (-, 2CH2), 35.46 (-, CH2), 32.17 (-, 2CH2), 14.75 (+, 
CH3). HRMS (EI-MS) m/z: calcd for C23H28N4O2 [MH+] 393.2285, found 393.2295. 
 
Ethyl 4- ({1- [2- (thiophen- 2- yl)ethyl]- 1H- benzo[d]imidazol- 2- yl}amino)piperidine- 1- 
carboxylate (4.13d).  
Synthesized from compound 4.12e (350 mg, 1.34 mmol) and ethyl 
4-aminopiperidine-1-carboxylate (919 mg, 5.34 mmol) by analogy with the procedure for the 
preparation of 4.13a. White solid (500 mg, 1.26 mmol, 93%); mp 97 °C. 1H-NMR (300 MHz, 
CDCl3) δ [ppm]: 7.51-7.45 (m, 1H), 7.22-7.18 (m, 1H), 7.17-7.05 (m, 3H), 6.91 (dd, J = 5.1, 
3.4 Hz, 1H), 6.67-6.62 (m, 1H), 4.20-4.04 (m, 6H), 3.91-3.80 (m, 1H), 3.30-3.23 (m, 2H), 
3.00-2.83 (m, 2H), 2.00-1.85 (m, 2H), 1.25 (t, J = 7.0 Hz, 3H), 1.17-1.04 (m, 2H). 13C-NMR 
(75 MHz, CDCl3) δ [ppm]: 155.55 (Cquat), 153.45 (Cquat), 142.32 (Cquat), 140.11 (Cquat), 133.95 
(Cquat), 127.91 (+, Ar-CH), 126.77 (+, Ar-CH), 125.06 (+, Ar-CH), 121.52 (+, Ar-CH), 119.73 (+, 
Ar-CH), 116.53 (+, Ar-CH), 107.04 (+, Ar-CH), 61.39 (-, CH2), 49.45 (+, CH), 44.83 (-, CH2), 
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42.65 (-, 2CH2), 32.28 (-, 2CH2), 29.53 (-, CH2), 14.75 (+, CH3). HRMS (EI-MS) m/z: calcd for 
C21H26N4O2S [MH+] 399.1849, found 399.1849. 
 
Ethyl 4- {[1- (4- chlorophenethyl)- 1H- benzo[d]imidazol- 2- yl]amino}piperidine- 1- 
carboxylate (4.13e).  
Synthesized from compound 4.12d (350 mg, 1.21 mmol) and ethyl 
4-aminopiperidine-1-carboxylate (417 mg, 2.42 mmol) by analogy according the procedure 
for the preparation of 4.13a. Yellow-white solid (460 mg, 1.08 mmol ,89.3%); mp 64 °C. 
1H-NMR (300 MHz, CDCl3) δ [ppm]: 7.48 (d, J = 7.6 Hz, 1H), 7.27-7.22 (m, 2H), 7.17-7.06 (m, 
3H), 6.97-6.91 (m, 2H), 4.24-4.01 (m, 6H), 3.91-3.76 (m, 1H), 3.01 (t, J = 6.2 Hz, 2H), 
2.98-2.84 (m, 2H), 1.88-1.82 (m, 2H), 1.26 (t, J = 7.0 Hz, 3H), 1.15-0.93 (m, 2H). 13C-NMR 
(75 MHz, CDCl3) δ [ppm]: 155.50 (Cquat), 153.09 (Cquat), 142.28 (Cquat), 136.89 (Cquat), 133.89 
(Cquat), 133.38 (Cquat), 130.36 (+, 2Ar-CH), 129.29 (+, 2Ar-CH), 121.54 (+, Ar-CH), 119.77 (+, 
Ar-CH), 116.61 (+, Ar-CH), 107.14 (+, Ar-CH), 61.39 (-, CH2), 49.56 (+, CH), 44.42 (-, CH2), 
42.66 (-, 2CH2), 34.67 (-, CH2), 32.35 (-, 2CH2), 14.74 (+, CH3). HRMS (EI-MS) m/z: calcd for 
C23H27ClN4O2 [MH+] 427.1895, found 427.1893. 
 
5-Chloro-1-phenethyl-N-(piperidin-4-yl)-1H-benzo[d]imidazol-2-amine (4.14a).  
Compound 4.13a (300 mg, 0.71 mmol) was added to 47% HBr (6 mL) and heated to 
126 °C for 3 h. The solvent was removed under reduced pressure, and the remaining mixture 
was subjected to column chromatography (DCM/MeOH/25% aqueous ammonia, 100/10/1). 
Yellow oil (140 mg, 0.4 mmol, 56.1%). 1H-NMR (300 MHz, CDCl3) δ [ppm]: 7.42 (d, J = 1.8 Hz, 
1H), 7.32-7.27 (m, 3H), 7.05-6.93 (m, 4H), 4.10-4.04 (m, 2H), 3.73-3.65 (m, 1H), 3.05-2.95 (m, 
4H), 2.73-2.60 (m, 2H), 1.90-1.80 (m, 2H), 1.06-0.92 (m, 2H). 13C-NMR (75 MHz, CDCl3) δ 
[ppm]: 154.26 (Cquat), 143.52 (Cquat), 138.29 (Cquat), 132.81 (Cquat), 129.29 (+, 2Ar-CH), 128.91 
(+, 2Ar-CH), 127.44 (+, Ar-CH), 126.69 (Cquat), 119.42 (+, Ar-CH), 116.41 (+, Ar-CH), 107.50 
(+, Ar-CH), 49.75 (+, CH), 45.27 (-, 2CH2), 44.85 (-, CH2), 35.34 (-, CH2), 33.62 (-, 2CH2). 
HRMS (EI-MS) m/z: calcd for C20H23ClN4 [MH+] 355.1684, found 355.1686. 
  
6-Chloro-1-phenethyl-N-(piperidin-4-yl)-1H-benzo[d]imidazol-2-amine (4.14b).  
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Synthesized from compound 4.13b (270 mg, 0.63 mmol) by analogy with the procedure for 
the preparation of 4.14a. Yellow oil (140 mg, 0.4 mmol, 63.2%). 1H-NMR (300 MHz, CDCl3) δ 
[ppm]: 7.38-7.24 (m, 4H), 7.10-6.96 (m, 4H), 4.17-3.95 (m, 2H), 3.78-3.56 (m, 1H), 3.06-2.99 
(m, 4H), 2.71-2.60 (m, 2H), 1.84-1.79 (m, 2H), 1.09-0.86 (m, 2H). 13C-NMR (75 MHz, CDCl3) 
δ [ppm]: 154.01 (Cquat), 141.17 (Cquat), 138.30 (Cquat), 134.89 (Cquat), 129.32 (+, 2Ar-CH), 
128.93 (+, 2Ar-CH), 127.47 (+, Ar-CH), 124.81 (Cquat), 121.50 (+, Ar-CH), 117.00 (+, Ar-CH), 
107.37 (+, Ar-CH), 49.82 (+, CH), 45.33 (-, 2CH2), 44.92 (-, CH2), 35.34 (-, CH2), 33.73 (-, 
2CH2). HRMS (EI-MS) m/z: calcd for C20H23ClN4 [MH+] 355.1684, found 355.1687. 
 
N-(Piperidin-4-yl)-1-(2-(thiophen-2-yl)ethyl)-1H-benzo[d]imidazol-2-amine (4.14c). 
Synthesized from compound 4.13d (500 mg, 1.26 mmol) by analogy according to the 
procedure for the preparation of 4.14a. Yellow oil (455 mg, 1.12 mmol, 89.2%). 1H-NMR (300 
MHz, CDCl3) δ [ppm]: 7.49-7.44 (m, 1H), 7.23-7.17 (m, 1H), 7.16-7.00 (m, 3H), 6.93-6.88 (m, 
1H), 6.67-6.63 (m, 1H), 4.14-4.06 (m, 2H), 3.87-3.73 (m, 1H), 3.29-3.22 (m, 2H), 3.08-2.99 (m, 
2H), 2.76-2.66 (m, 2H), 2.02-1.92 (m, 2H), 1.23-1.09 (m, 2H). 13C-NMR (75 MHz, CDCl3) δ 
[ppm]: 153.56 (Cquat), 142.46 (Cquat), 140.04 (Cquat), 134.00 (Cquat), 127.85 (+, Ar-CH), 126.68 
(+, Ar-CH), 125.02 (+, Ar-CH), 121.39 (+, Ar-CH), 119.54 (+, Ar-CH), 116.44 (+, Ar-CH), 
106.97 (+, Ar-CH), 49.65 (+, CH), 45.24 (-, 2CH2), 44.75 (-, CH2), 33.52 (-, 2CH2), 29.47 (-, 
CH2). HRMS (EI-MS) m/z: calcd for C18H22N4S [MH+] 327.1638, found 327.1640.  
 
1-(4-Chlorophenethyl)-N-(piperidin-4-yl)-1H-benzo[d]imidazol-2-amine (4.14d). 
Synthesized from compound 4.13e (460 mg, 1.08 mmol) by analogy with the procedure for 
the preparation of 4.14a gave 4.14d as a yellow-white solid (455 mg, 0.97 mmol, 90%). 
HRMS (EI-MS) m/z: calcd for C18H22N4S [MH+] 355.1684, found 355.1678. 
 
N-[1-(3-Aminopropyl)piperidin-4-yl]-1-phenethyl-1H-benzo[d]imidazol-2-amine (4.15a).  
To a solution of compound 4.3 (600 mg, 1.25 mmol) in acetonitrile (25 mL), tert-butyl 
(3-bromopropyl) carbamate (591 mg, 2.50 mmol), sodium iodide (373 mg, 2.50 mmol) and 
DIPEA (968 mg, 7.5 mmol) were added. The reaction mixture was heated to reflux for 2 h 
(control by TLC), the solvent was evaporated and the remaining mixture was poured into 
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water. The aqueous layer was extracted with DCM, and the combined organic layers were 
dried over Na2SO4. The solvent was removed under reduced pressure, the resulting mixture 
was re-dissolved in 10 mL DCM, 10 mL of TFA was added dropwise, and the mixture was 
stirred at rt for 3 h. Purification by column chromatography (DCM/MeOH/25% aqueous 
ammonia, 100/3/1) yielded a yellow oil (700 mg, 0.97 mmol, 77.6%). 1H-NMR (300 MHz, 
CD3OD) δ [ppm]: 7.48-7.29 (m, 4H), 7.23-7.16 (m, 3H), 7.04-6.95 (m, 2H), 4.54-4.42 (m, 2H), 
3.90-3.56 (m, 3H), 3.29-3.20 (m, 2H), 3.18-2.99 (m, 6H), 2.23-2.06 (m, 4H), 2.00-1.82 (m, 2H). 
13C-NMR (75 MHz, CD3OD) δ [ppm]: 150.04 (Cquat), 138.56 (Cquat), 131.81 (Cquat), 130.24 
(Cquat), 130.18 (+, 2Ar-CH), 129.89(+, 2Ar-CH), 128.27 (+, Ar-CH), 125.38 (+, Ar-CH), 125.17 
(+, Ar-CH), 112.90 (+, Ar-CH), 111.71 (+, Ar-CH), 52.84 (-, CH2), 50.13 (+, CH3), 45.21 (-, 
CH2), 37.87 (-, 2CH2), 34.59 (-, 2CH2), 30.18 (-, CH2), 23.54 (-, CH2). HRMS (EI-MS) m/z: 
calcd for C23H31N5 [MH+] 378.2652, found 378.2657.  
 
N-[1-(3-Aminopropyl)piperidin-4-yl]-1-(4-fluorobenzyl)-1H-benzo[d]imidazol-2-amine 
(4.15b).69  
Synthesized from compound 4.4 (390 mg, 0.98 mmol) in acetonitrile (25 mL) and tert-butyl 
(3-bromopropyl) carbamate (445 mg, 1.88 mmol) by analogy with the procedure for the 
preparation of 4.15a. Purification by HPLC yielded 4.15b tri(hydrotrifluoroacetate) as a 
colorless sticky solid (435 mg, 0.6 mmol, 60.1%). 1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 
7.56-7.52 (m, 1H), 7.42-7.35 (m, 3H), 7.32-7.13 (m, 4H), 5.50 (s, 2H), 4.14-4.00 (m, 1H), 
3.76-3.58 (m, 2H), 3.30-3.18 (m, 2H), 3.12-2.86 (m, 4H), 2.38-2.18 (m, 2H), 2.10-1.87 (m, 4H). 
13C-NMR (100 MHz, DMSO-d6) δ [ppm]: 172.93 (Cquat), 153.47 (Cquat), 142.38 (Cquat), 134.50 
(Cquat), 131.36 (Cquat), 128.30 (+, Ar-CH), 128.19 (+, Ar-CH), 121.50 (+, Ar-CH), 119.70 (+, 
Ar-CH), 116.38 (+, Ar-CH), 116.23 (+, Ar-CH), 115.94 (+, Ar-CH), 107.23 (+, Ar-CH), 52.97 (-, 
CH2), 50.84 (-, CH2), 48.98 (+, CH3), 44.6 (-, CH2), 36.15 (-, 2CH2), 28.56 (-, CH2), 21.69 (-, 
2CH2). HRMS (EI-MS) m/z: calcd for C22H28FN5 [MH+] 382.2402, found 382.2407. 
 
N-[1-(3-{[2-(1H-imidazol-4-yl)ethyl]amino}propyl)piperidin-4-yl]-1-(4-fluorobenzyl)-1H- 
benzo[d]imidazol-2-amine (4.16a).  
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To a solution of compound 4.15b (810 mg, 1.12 mmol) in ACN (25 mL), 
4-(2-bromoethyl)-1-trityl-1H-imidazole (700 mg, 1.67 mmol) and DIPEA (723 mg, 5.6 mmol) 
were added. The reaction mixture was heated at reflux for 48 h (control by TLC), the solvent 
was evaporated, and the remaining mixture was poured into water. The aqueous layer was 
extracted with DCM and the combined organic layers were dried over Na2SO4. The solvent 
was removed under reduced pressure. The mixture was dissolved in DCM (2 mL), TFA (2 mL) 
was added dropwise, and the mixture was stirred at rt for 3 h. Purification by HPLC yielded 
4.16a tetra(hydrotrifluoroacetate) as a pale-yellow sticky solid (70 mg, 0.075 mmol, 6.70%). 
1H-NMR (600 MHz, DMSO-d6) δ [ppm]: 9.01 (d, J = 1.1 Hz, 1H), 7.53-7.50 (m, 2H), 7.40-7.32 
(m, 3H), 7.29-7.14 (m, 4H), 5.48 (s, 2H), 4.07-4.00 (m, 1H), 3.65-3.57 (m, 2H), 3.29 (t, J = 7.5 
Hz, 2H), 3.24-3.17 (m, 2H), 3.08-3.02 (m, 6H), 2.29-2.23 (m, 2H), 2.11-2.03 (m, 2H), 
2.02-1.92 (m, 2H). 13C-NMR (151 MHz, DMSO-d6) δ [ppm]: 162.98 (Cquat), 161.36 (Cquat), 
159.56 (Cquat), 149.79 (Cquat), 134.79 (+, Ar-CH), 131.50 (Cquat), 131.04 (Cquat), 129.77 (+, 
Ar-CH), 129.71 (+, Ar-CH), 129.28 (+, Ar-CH), 124.11 (+, Ar-CH), 123.60 (+, Ar-CH), 117.35 
(+, Ar-CH), 116.17 (+, Ar-CH), 112.52 (+, Ar-CH), 110.90 (+, Ar-CH), 53.20 (-, CH2), 51.19 (-, 
CH2), 49.36 (+, CH3), 45.35 (-, CH2), 45.16 (-, CH2), 44.40 (-, CH2), 28.89 (-, CH2), 21.55 (-, 
2CH2), 20.85 (-, 2CH2). HRMS (EI-MS) m/z: calcd for C27H34FN7 [MH+] 476.2932, found 
476.2937.  
 
N-[1-(3-{[2-(1H-imidazol-4-yl)ethyl]amino}propyl)piperidin-4-yl]-1-phenethyl-1H- 
benzo[d]imidazol-2-amine (4.16b).  
Synthesized from compound 4.15a (170 mg, 0.23 mmol) by analogy with the procedure for 
the preparation of 4.15b. Yield 4.16b tetra(hydrotrifluoroacetate) as a yellow solid (90 mg, 
0.097 mmol 42.2%). 1H-NMR (600 MHz, DMSO-d6) δ [ppm]: 9.03 (d, J = 1.3 Hz, 1H), 7.52 (d, 
J = 0.7 Hz, 1H), 7.48-7.43 (m, 2H), 7.28-7.21 (m, 4H), 7.20-7.14 (m, 3H), 4.49 (t, J = 6.9 Hz, 
2H), 3.95-3.83 (m, 1H), 3.67-3.53 (m, 2H), 3.35-3.25 (m, 2H), 3.24-3.16 (m, 2H), 3.12-3.04 (m, 
4H), 3.04-2.94 (m, 4H), 2.16-2.04 (m, 4H), 1.94-1.84 (m, 2H). 13C-NMR (151 MHz, DMSO-d6) 
δ [ppm]: 158.64 (Cquat), 148.51 (Cquat), 137.11 (Cquat), 134.22 (+, Ar-CH), 130.28 (Cquat), 
128.92 (+, 2Ar-CH), 128.65 (Cquat), 128.19 (+, 2Ar-CH), 126.57 (+, Ar-CH), 123.38 (+, Ar-CH), 
123.06 (+, Ar-CH), 116.80 (+, Ar-CH), 111.54 (+, Ar-CH), 110.32 (+, Ar-CH), 52.52 (-, CH2), 
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50.57 (-, CH2), 48.41 (+, CH3), 44.74 (-, 2CH2), 43.80 (-, CH2), 43.16 (-, CH2), 32.86 (-, 2CH2), 
20.95 (-, 2CH2), 20.26 (-, CH2). HRMS (EI-MS) m/z: calcd for C28H37N7 [MH+] 472.3183, found 
472.3191.  
 
5-Chloro-N-(1-methylpiperidin-4-yl)-1-phenethyl-1H-benzo[d]imidazol-2-amine (4.17a).  
4.14a (230 mg, 0.65 mmol) was dissolved in ACN (10 mL), DIPEA (168 mg, 1.3 mmol) was 
added, and MeI (83 mg, 0.58 mmol) in ACN (5 mL) was dropped slowly into the mixture at rt. 
After stirring for 30 min, the mixture was concentrated and subjected by HPLC giving 4.17a 
hydrotrifluoroacetate as a white solid (57 mg, 0.12 mmol, 20.4%). 1H-NMR (300 MHz, 
DMSO-d6) δ [ppm]: 7.55-7.50 (m, 1H), 7.45-7.38 (m, 1H), 7.29-7.12 (m, 6H), 4.47-4.40 (m, 
2H), 3.85-3.75 (m, 1H), 3.63-3.52 (m, 2H), 3.05-2.90 (m, 4H), 2.81 (s, 3H), 2.19-1.70 (m, 4H). 
13C-NMR (75 MHz, DMSO-d6) δ [ppm]: 158.39 (Cquat), 149.41 (Cquat), 137.05 (Cquat), 129.65 
(Cquat), 128.93 (+, 2Ar-CH), 128.22 (+, 2Ar-CH), 127.27 (Cquat), 126.60 (+, Ar-CH), 122.66 (+, 
Ar-CH), 111.61 (+, Ar-CH), 111.51 (+, Ar-CH), 52.46 (-, 2CH2), 48.54 (+, CH3), 43.29 (-, CH2), 
42.43 (+, CH3), 32.83 (-, CH2), 28.63 (-, 2CH2). HRMS (EI-MS) m/z: calcd for C21H25ClN4 [MH+] 
369.1841, found 369.1842.  
 
N-(1-Methylpiperidin-4-yl)-1-phenethyl-1H-benzo[d]imidazol-2-amine (4.17b).  
Synthesized from compound 4.3 (240 mg, 0.50 mmol) by analogy with the procedure for 
the preparation of 4.17a. Purification by column chromatography (DCM/MeOH/25% aqueous 
ammonia, 100/5/1). White solid (171 mg, 0.41 mmol, 82.8%); mp 70 °C. 1H-NMR (300 MHz, 
CDCl3) δ [ppm]: 7.52-7.44 (m, 1H), 7.32-7.26 (m, 3H), 7.16-7.00 (m, 5H), 4.14-4.05 (m, 2H), 
3.71-3.56 (m, 1H), 3.07-3.01 (m, 2H), 2.77-2.63 (m, 2H), 2.25 (s, 3H), 2.12-2.01 (m, 2H), 
1.89-1.80 (m, 2H), 1.23-1.01 (m, 2H). 13C-NMR (75 MHz, CDCl3) δ [ppm]: 153.59 (Cquat), 
142.47 (Cquat), 138.52 (Cquat), 134.13 (Cquat), 129.24 (+, 2Ar-CH), 128.94 (+, 2Ar-CH), 127.38 
(+, Ar-CH), 121.29 (+, Ar-CH), 119.50 (+, Ar-CH), 116.48 (+, Ar-CH), 107.04 (+, Ar-CH), 
54.48 (-, 2CH2), 46.26 (+, CH3), 44.76 (-, CH2), 35.43 (-, CH2), 32.63 (-, 2CH2). HRMS (EI-MS) 
m/z: calcd for C21H26N4 [MH+] 335.2230, found 335.2234. 
 
1-(4-Chlorophenethyl)-N-(1-methylpiperidin-4-yl)-1H-benzo[d]imidazol-2-amine (4.17c). 
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Synthesized from compound 4.14d (344 mg, 0.97 mmol) by analogy with the procedure for 
the preparation of 4.17a. Purification by column chromatography (DCM/MeOH/25% aqueous 
ammonia, 100/5/1). Yellow-white solid (80 mg, 0.22 mmol, 22.0%); mp 58 °C. 1H-NMR (300 
MHz, CDCl3) δ [ppm]: 7.47 (d, J = 7.7 Hz, 1H), 7.25-7.17 (m, 2H), 7.16-7.09 (m, 1H), 
7.07-7.00 (m, 2H), 6.91 (d, J = 8.3 Hz, 2H), 4.05 (t, J = 6.3 Hz, 2H), 3.81-3.62 (m, 1H), 3.00 (t, 
J = 6.2 Hz, 2H), 2.75-2.63 (m, 2H), 2.25 (s, 3H), 2.15-2.03 (m, 2H), 1.92-1.80 (m, 2H), 
1.27-1.20 (m, 2H). 13C-NMR (75 MHz, CDCl3) δ [ppm]: 153.33 (Cquat), 142.42 (Cquat), 136.73 
(Cquat), 133.90 (Cquat), 133.31 (Cquat), 130.28 (+, 2Ar-CH), 129.25 (+, 2Ar-CH), 121.42 (+, 
Ar-CH), 119.58 (+, Ar-CH), 116.55 (+, Ar-CH), 107.07 (+, Ar-CH), 54.44 (-, 2CH2), 49.04 (+, 
CH), 46.22 (+, CH3), 44.27 (-, CH2), 34.53 (-, CH2), 32.77 (-, 2CH2). HRMS (EI-MS) m/z: calcd 
for C21H25ClN4 [MH+] 369.1841, found 369.1840. 
 
N-{1-[2-(1H-imidazol-4-yl)ethyl]piperidin-4-yl}-1-(4-fluorobenzyl)-1H-benzo[d]imidazol- 
2-amine (4.18a).  
Compound 4.4 (324 mg, 1 mmol) was added to a mixture of ACN (10 mL), DIPEA (1.29 g, 
10 mmol) and 4-(2-bromoethyl)-imidazole (720 mg, 3 mmol) in a 20-mL microwave tube. The 
microwave tube was sealed and subjected to irradiation (120 °C) for 10 min. The obtained 
suspension was poured into brine and extracted with EtOAc, the organic phase was dried 
over Na2SO4 and evaporated. Purification by HPLC yielded 4.18a tri(hydrotrifluoroacetate) as 
a white solid (77 mg, 0.10 mmol, 10%). 1H-NMR (300 MHz, CD3OD) δ [ppm]: 7.60-7.55 (m, 
1H), 7.30 (d, J = 7.6 Hz, 1H), 7.20-6.79 (m, 8H), 5.24 (s, 2H), 3.91-3.73 (m, 1H), 3.10-2.98 (m, 
2H), 2.89-2.60 (m, 4H), 2.31 (t, J = 11.0 Hz, 2H), 2.15-2.04 (m, 2H), 1.72-1.56 (m, 2H). 
13C-NMR (75 MHz, CD3OD) δ [ppm]: 155.36 (Cquat), 143.01 (2Cquat), 136.02 (+, Ar-CH), 
135.38 (Cquat), 133.90 (Cquat), 133.86 (Cquat), 129.72 (+, Ar-CH), 129.61 (+, Ar-CH), 122.52 (+, 
Ar-CH), 120.87 (+, Ar-CH), 116.65 (+, Ar-CH), 116.36 (+, Ar-CH), 116.10 (+, Ar-CH), 109.14 
(+, 2Ar-CH), 64.36 (-, CH2), 59.36 (-, CH2), 53.60 (-, CH2), 51.27 (+, CH), 45.28 (-, CH2), 
32.77 (-, 2CH2), 25.19 (-, CH2). HRMS (EI-MS) m/z: calcd for C24H27FN6 [MH+] 419.2354, 
found 419.2355. 
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N-{1-[2-(1H-imidazol-4-yl)ethyl]piperidin-4-yl}-1-phenethyl-1H-benzo[d]imidazol-2- 
amine (4.18b).  
Synthesized from compound 4.3 (480 mg, 1 mmol) and 4-(2-bromoethyl)-imidazole (290 
mg, 1.5 mmol) by analogy with the procedure for the preparation of 4.18a. Purification by 
column chromatography (DCM/MeOH/25% aqueous ammonia, 100/3/1), yielded a white 
solid (140 mg, 0.34 mmol, 33.8%); mp 61 °C. 1H-NMR (300 MHz, CD3OD) δ [ppm]: 7.57 (d, J 
= 1.1 Hz, 1H), 7.28-7.23 (m, 1H), 7.21-7.13 (m, 3H), 7.06-6.91 (m, 5H), 6.86-6.82 (m, 1H), 
4.22 (t, J = 6.8 Hz, 2H), 3.69-3.55 (m, 1H), 3.06-2.92 (m, 4H), 2.85-2.77 (m, 2H), 2.71-2.61 (m, 
2H), 2.28-2.16 (m, 2H), 1.99-1.88 (m, 2H), 1.57-1.41 (m, 2H). 13C-NMR (75 MHz, CD3OD) δ 
[ppm]: 155.16 (Cquat), 142.87 (Cquat), 139.71 (Cquat), 136.00 (Cquat), 135.99 (+, Ar-CH), 135.15 
(Cquat), 130.18 (+, 3Ar-CH), 129.66 (+, 2Ar-CH), 127.78 (+, Ar-CH), 122.17 (+, Ar-CH), 120.64 
(+, Ar-CH), 115.92 (+, Ar-CH), 108.92 (+, Ar-CH), 59.41 (-, CH2), 53.67 (-, 2CH2), 51.13 (+, 
CH), 44.33 (-, CH2), 35.58 (-, CH2), 32.84 (-, 2CH2), 25.25 (-, CH2). HRMS (EI-MS) m/z: calcd 
for C25H30N6 [MH+] 415.2605, found 415.2611. 
 
N-[2-(1H-imidazol-4-yl)ethyl]-1-(4-fluorobenzyl)-1H-benzo[d]imidazol-2-amine (4.19a). 
Compound 4.12c (260 mg, 1 mmol) was added to a mixture of NMP (8 mL), DIPEA (1.8 g, 
14 mmol) and histamine dihydrochloride (1.1 g, 6 mmol) in a 20-mL microwave tube. The 
microwave tube was sealed and subjected to irradiation (200 °C) for 10 min. The obtained 
suspension was poured into brine and extracted with EtOAc, the organic phase was dried 
over Na2SO4 and evaporated. Purification by column chromatography (DCM/MeOH/25% 
aqueous ammonia, 100/5/1) yielded a white solid (230 mg, 0.69 mmol, 68.7%); mp 194°C. 
1H-NMR (300 MHz, DMSO-d6) δ [ppm]: 7.57 (d, J = 1.1 Hz, 1H), 7.26-7.18 (m, 3H), 7.18-7.06 
(m, 2H), 7.06-6.97 (m, 1H), 6.96-6.90 (m, 1H), 6.88-6.80 (m, 2H), 5.23 (s, 2H), 3.67-3.57 (m, 
2H), 2.87 (t, J = 7.2 Hz, 2H). 13C-NMR (75 MHz, DMSO-d6) δ [ppm]: 162.88 (Cquat), 159.66 
(Cquat), 154.39 (Cquat), 142.70 (Cquat), 134.53 (+, Ar-CH), 134.26 (Cquat), 133.16 (Cquat), 129.06 
(+, Ar-CH), 128.95 (+, Ar-CH), 123.49 (+, Ar-CH), 120.36 (+, Ar-CH), 118.26 (+, Ar-CH), 
115.34 (+, Ar-CH), 115.06 (+, Ar-CH), 114.92 (+, Ar-CH), 107.61 (+, Ar-CH), 43.58 (-, CH2), 
42.45 (-, CH2), 26.83 (-, CH2). HRMS (EI-MS) m/z: calcd for C19H18FN5 [MH+] 336.1619, found 
336.1625.  
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N-[2-(1H-imidazol-4-yl)ethyl]-1-phenethyl-1H-benzo[d]imidazol-2-amine (4.19b).  
Synthesized from compound 4.12b (520 mg, 2 mmol) by analogy with the procedure for the 
preparation of 4.19a. White solid (370 mg, 1.12 mmol, 56%); mp 163 °C. 1H-NMR (600 MHz, 
CD3OD) δ [ppm]: 7.58 (d, J = 1.0 Hz, 1H), 7.27-7.25 (m, 1H), 7.20-7.12 (m, 3H), 7.07-7.03 (m, 
2H), 7.01-6.97 (m, 2H), 6.95-6.90 (m, 1H), 6.84 (s, 1H), 4.15 (t, J = 7.1 Hz, 2H), 3.54 (t, J = 
7.4 Hz, 2H), 2.93 (t, J = 7.1 Hz, 2H), 2.83 (t, J = 7.3 Hz, 2H). 13C-NMR (151 MHz, CD3OD) δ 
[ppm]: 154.28 (Cquat), 141.39 (Cquat), 138.11 (2Cquat), 134.57 (+, Ar-CH), 133.84 (Cquat), 128.64 
(+, 2Ar-CH), 128.16 (+, 2Ar-CH), 126.29 (+, 2Ar-CH), 120.66 (+, Ar-CH), 119.19 (+, Ar-CH), 
114.51 (+, Ar-CH), 107.35 (+, Ar-CH), 43.03 (-, CH2), 42.47 (-, CH2), 34.18 (-, CH2), 26.47 (-, 
CH2). HRMS (EI-MS) m/z: calcd for C20H21N5 [MH+] 332.1870, found 332.1870. 
 
1-(4-Fluorobenzyl)-N-[2-(4-methylpiperazin-1-yl)ethyl]-1H-benzo[d]imidazol-2-amine 
(4.20a).  
tert-Butyl [2-(4-methylpiperazin-1-yl)ethyl]carbamate (630 mg, 2.6 mmol) was dissolved in 
20 mL DCM, 20 mL of TFA was added dropwise, the mixture was stirred at rt for 2 h. 
Afterward, 10 mL DCM was added and the solvent was removed under reduced pressure to 
yield 4-methyl-1-piperazineethanamine tri(hydrotrifluoroacetate)50 (1.12 g, 2.6 mmol). 
4-methyl-1-piperazineethanamine tri(hydrotrifluoroacetate) (1.12 g, 2.6 mmol) and compound 
4.12c (512 mg, 2 mmol) was added to a mixture of NMP (10 mL), DIPEA (3.87 g, 30 mmol) in 
a 20-mL microwave tube. The microwave tube was sealed and subjected to irradiation 
(180 °C) for 2 h. The obtained suspension was poured into brine and extracted with DCM, the 
organic phase was dried over Na2SO4 and evaporated. Purification by column 
chromatography (DCM/MeOH/25% aqueous ammonia, 100/5/1), yielded a white solid (270 
mg, 0.7 mmol, 35%); mp 139 °C. 1H-NMR (300 MHz, CDCl3) δ [ppm]: 7.51 (d, J = 7.7 Hz, 1H), 
7.21-6.97 (m, 8H), 5.07 (s, 2H), 3.55-3.46 (m, 2H), 2.63-2.27 (m, 10H), 2.24 (s, 3H). 13C-NMR 
(75 MHz, CDCl3) δ [ppm]: 154.44 (Cquat), 142.29 (Cquat), 134.78 (Cquat), 131.60 (Cquat), 131.56 
(Cquat), 128.45 (+, Ar-CH), 128.34 (+, Ar-CH), 121.49 (+, Ar-CH), 119.84 (+, Ar-CH), 116.59 (+, 
Ar-CH), 116.31 (+, Ar-CH), 116.02 (+, Ar-CH), 107.00 (+, Ar-CH), 55.86 (-, CH2), 54.92 (-, 
2CH2), 52.45 (-, 2CH2), 45.95 (+, CH3), 45.06 (-, CH2), 39.26 (-, CH2). HRMS (EI-MS) m/z: 
calcd for C21H26FN5 [MH+] 368.2245, found 368.2251. 
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N-[2-(4-Methylpiperazin-1-yl)ethyl]-1-phenethyl-1H-benzo[d]imidazol-2-amine (4.20b). 
Synthesized from compound 4.12b (512 mg, 2 mmol) by analogy with the procedure for the 
preparation of 4.20a. White solid (130 mg, 0.36 mmol, 18.7%); mp 89 °C. 1H-NMR (400 MHz, 
CDCl3) δ [ppm]: 7.46 (d, J = 7.7 Hz, 1H), 7.32-7.20 (m, 3H), 7.16-7.07 (m, 3H), 7.03 (d, J = 
4.0 Hz, 2H), 4.10 (t, J = 7.3 Hz, 2H), 3.52-3.43 (m, 2H), 3.02 (t, J = 7.3 Hz, 2H), 2.66-2.35 (m, 
10H), 2.29 (s, 3H). 13C-NMR (101 MHz, CDCl3) δ [ppm]: 154.12 (Cquat), 141.92 (Cquat), 137.99 
(Cquat), 134.08 (Cquat), 128.89 (+, 4Ar-CH), 126.99 (+, Ar-CH), 121.29 (+, Ar-CH), 119.65 (+, 
Ar-CH), 116.21 (+, Ar-CH), 107.18 (+, Ar-CH), 56.47 (-, CH2), 55.12 (-, 2CH2), 52.65 (-, 2CH2), 
46.04 (+, CH3), 44.25 (-, CH2), 39.32 (-, CH2), 35.24 (-, CH2). HRMS (EI-MS) m/z: calcd for 
C22H30N5 [MH+] 364.2496, found 364.2500.  
 
1-(4-Fluorobenzyl)-2-(piperazin-1-yl)-1H-benzo[d]imidazole (4.21a).68  
Compound 4.12c (520 mg, 2 mmol) was added to NMP (3 mL), DIPEA (516 mg, 4 mmol) 
and piperazine (1.03 g, 12 mmol) in a 5-mL microwave tube. The microwave tube was sealed 
and subjected to irradiation (180 °C) for 1 h. The obtained suspension was poured into brine 
and extracted with EtOAc, the organic phase was dried over Na2SO4 and evaporated. 
Purification by column chromatography (DCM/MeOH/25% aqueous ammonia, 100/5/1) 
yielded a yellow oil (630 mg, 2 mmol, 100%). 1H-NMR (300 MHz, CDCl3) δ [ppm]: 7.66-7.60 
(m, 1H), 7.21-6.96 (m, 7H), 5.18 (s, 2H), 3.27-3.15 (m, 4H), 3.04-2.94 (m, 4H). 13C-NMR (75 
MHz, CDCl3) δ [ppm]: 158.18 (Cquat), 141.58 (Cquat), 135.24 (Cquat), 134.94 (Cquat), 127.84 
(+,Ar-CH), 127.73 (+, Ar-CH), 122.12 (+, Ar-CH), 121.61 (+, Ar-CH), 118.26 (+, Ar-CH), 
116.13 (+, Ar-CH), 115.85 (+, Ar-CH), 109.31 (+, Ar-CH), 51.81 (-, 4CH2), 47.02 (-, CH2), 
45.61 (-, 4CH2). 
 
1-Phenethyl-2-(piperazin-1-yl)-1H-benzo[d]imidazole (4.21b).70  
Synthesized from compound 4.3 (768 mg, 3 mmol) by analogy with the procedure for the 
preparation of 4.21a. Yellow oil (900 mg, 2.94 mmol, 98.0%). 1H-NMR (300 MHz, CDCl3) δ 
[ppm]: 7.70-7.56 (m, 1H), 7.38-7.12 (m, 6H), 7.09-6.92 (m, 2H), 4.28-4.17 (m, 2H), 3.13-2.87 
(m, 10H). 13C-NMR (75 MHz, CDCl3) δ [ppm]: 158.18 (Cquat), 141.69 (Cquat), 137.98 (Cquat), 
134.34 (Cquat), 128.76 (+, 2Ar-CH), 128.69 (+, 2Ar-CH), 126.83 (+, Ar-CH), 121.79 (+, Ar-CH), 
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121.48 (+, Ar-CH), 118.52 (+, Ar-CH), 109.25 (+, Ar-CH), 51.96 (-, 2CH2), 45.69 (-, 2CH2), 
45.56 (-, CH2), 35.13 (-, CH2). 
 
2-{4-[2-(1H-imidazol-4-yl)ethyl]piperazin-1-yl}-1-(4-fluorobenzyl)-1H-benzo[d]imidazole 
(4.22a).  
Compound 4.21a (310 mg, 1 mmol) was added to a mixture of NMP (10 mL), DIPEA (390 
mg, 3 mmol) and 4-(2-bromoethyl)-imidazole (230 mg, 1.2 mmol) in a 20-mL microwave tube. 
The microwave tube was sealed and subjected to irradiation (120 °C) for 50 min. The 
obtained suspension was poured into brine and extracted with EtOAc, the organic phase was 
dried over Na2SO4 and evaporated. Purification by column chromatography (DCM/MeOH/25% 
aqueous ammonia, 100/2.5/1), yielded a white solid (180 mg, 0.44 mmol, 44.6%); mp 59 °C. 
1H-NMR (300 MHz, CDCl3) δ [ppm]: 7.62 (d, J = 7.7 Hz, 1H), 7.23-7.09 (m, 4H), 7.05-6.95 (m, 
4H), 6.82 (s, 1H), 5.19 (s, 2H), 3.34-3.22 (m, 4H), 2.85-2.61 (m, 8H). 13C-NMR (75 MHz, 
CDCl3) δ [ppm]: 163.84 (Cquat), 160.58 (Cquat), 157.88 (Cquat), 141.42 (Cquat), 135.19 (Cquat), 
134.27 (+, Ar-CH), 131.85 (Cquat), 127.85 (+, Ar-CH), 127.74 (+, Ar-CH), 122.22 (+, Ar-CH), 
121.77 (+, Ar-CH), 119.34 (+, Ar-CH), 118.18 (+, Ar-CH), 116.18 (+, Ar-CH), 115.89 (+, 
Ar-CH), 109.38 (+, Ar-CH), 57.75 (-, CH2), 52.59 (-, 2CH2), 50.80 (-, 2CH2), 47.02 (-, CH2), 
23.06 (-, CH2). HRMS (EI-MS) m/z: calcd for C23H25FN6 [MH+] 405.2197, found 405.2206. 
 
2-{4-[2-(1H-imidazol-4-yl)ethyl]piperazin-1-yl}-1-phenethyl-1H-benzo[d]imidazole 
(4.22b). 
Synthesized from compound 4.21b (306 mg, 1 mmol) by analogy with the procedure for the 
preparation of 4.22a yielded a white solid (210 mg, 0.52 mmol, 52.5%); mp 130 °C. 1H-NMR 
(300 MHz, CDCl3) δ [ppm]: 7.65-7.54 (m, 2H), 7.33-7.20 (m, 6H), 7.02-6.96 (m, 2H), 6.83 (s, 
1H), 4.24 (t, J = 7.3 Hz, 2H), 3.16-3.03 (m, 6H), 2.88-2.66 (m, 4H), 2.65-2.55 (m, 4H). 
13C-NMR (75 MHz, CDCl3) δ [ppm]: 157.90 (Cquat), 141.47 (Cquat), 137.89 (Cquat), 134.26 
(2Cquat), 133.63 (+, Ar-CH), 128.77 (+, 2Ar-CH), 128.70 (+, 2Ar-CH), 126.87 (+, Ar-CH), 
121.93 (+, Ar-CH), 121.66 (+, Ar-CH), 119.58 (+, Ar-CH), 118.41 (+, Ar-CH), 109.37 (+, 
Ar-CH), 57.74 (-, CH2), 52.68 (-, 2CH2), 50.89 (-, 2CH2), 45.54 (-, CH2), 35.11 (-, CH2), 22.98 
(-, CH2). HRMS (EI-MS) m/z: calcd for C24H28N6 [MH+] 401.2448, found 401.2449.  
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2-(4-Methylpiperazin-1-yl)-1-phenethyl-1H-benzo[d]imidazole (4.23).67  
Compound 4.12b (260 mg, 1 mmol) was added to a mixture of NMP (3 mL), DIPEA (390 
mg, 3 mmol) and 1-methylpiperazine (600 mg, 6 mmol) in a 5-mL microwave tube. The 
microwave tube was sealed and subjected to irradiation (180 °C) for 1 h. The obtained 
suspension was poured into brine and extracted with EtOAc, the organic phase was dried 
over Na2SO4 and evaporated. Purification by column chromatography (DCM/MeOH, 10/1), 
yielded a yellow oil (310 mg, 0.96 mmol, 96.0%). 1H-NMR (300 MHz, CDCl3) δ [ppm]: 
7.67-7.59 (m, 1H), 7.31-7.16 (m, 6H), 7.06-7.00 (m, 2H), 4.31-4.11 (m, 2H), 3.18-3.12 (m, 4H), 
3.12-3.04 (m, 2H), 2.56-2.45 (m, 4H), 2.34 (s, 3H). 13C-NMR (75 MHz, CDCl3) δ [ppm]: 
157.96 (Cquat), 141.70 (Cquat), 137.95 (Cquat), 134.50 (Cquat), 128.75 (+, 2Ar-CH), 128.71 (+, 
2Ar-CH), 126.84 (+, Ar-CH), 121.77 (+, Ar-CH), 121.39 (+, Ar-CH), 118.44 (+, Ar-CH), 109.15 
(+, Ar-CH), 54.81 (-, CH2), 50.59 (-, CH2), 46.22 (+, CH3), 45.66 (-, CH2), 35.12 (-, CH2). 
HRMS (EI-MS) m/z: calcd for C20H24N4 [MH+] 321.2074, found 321.2089. 
 
4-(1H-benzo[d]imidazol-2-yl)phenol (4.24).71  
A solution of 1,2-phenylenediamine (2.16 g, 20 mmol) and 4-hydroxybenzaldehyde (2.44 g, 
20 mmol) in DMF (40 mL) was treated with Na2S2O5 (3.80 g, 20 mmol). After heating at 90 °C 
for 2 h, the reaction mixture was cooled to rt and subsequently diluted with ice water. The 
resulting suspension was stirred for 4 h, cooled to 0 °C and filtered through a glass fritted 
funnel. The solid was washed with cold water and dried in vacuum and used without further 
purification. White solid (4.17 g, 19.86 mmol, 99.3%); mp > 250 °C. 1H-NMR (300 MHz, 
DMSO-d6) δ [ppm]: 8.06-7.97 (m, 2H), 7.60-7.49 (m, 2H), 7.21-7.12 (m, 2H), 6.97-6.88 (m, 
2H). 13C-NMR (75 MHz, DMSO-d6) δ [ppm]: 159.07 (2Cquat), 151.63 (Cquat), 139.17 (Cquat), 
128.08 (+, 2Ar-CH), 121.57 (+, 2Ar-CH), 120.68 (Cquat), 115.59 (+, 2Ar-CH), 114.51 (+, 
2Ar-CH). HRMS (EI-MS) m/z: calcd for C13H10N2O [MH+] 211.0866, found 211.0872. 
 
tert-Butyl {3-[4-(1H-benzo[d]imidazol-2-yl)phenoxy]propyl}carbamate (4.25).  
To a solution of compound 4.24 (1.30 g, 6.17 mmol) in acetone, K2CO3 (851 mg, 6.17 mmol) 
was added. The mixture was stirred for 30 min, subsequently, tert-butyl 
(3-bromopropyl)carbamate (1.61 g, 6.79 mmol) was added, and the reaction mixture was 
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heated to reflux for 17 h. Purification by column chromatography (DCM/MeOH, 30/1). White 
solid (970 mg, 2.64 mmol, 42.8%); mp > 250 °C. 1H-NMR (300 MHz, DMSO-d6) δ [ppm]: 
8.17-8.06 (m, 2H), 7.65-7.50 (m, 2H), 7.21-7.13 (m, 2H), 7.12-7.06 (m, 2H), 4.06 (t, J = 6.2 Hz, 
2H), 3.11 (q, J = 6.7 Hz, 2H), 1.87 (quint, J = 6.5 Hz, 2H), 1.38 (s, 9H). 13C-NMR (75 MHz, 
DMSO-d6) δ [ppm]: 159.86 (2Cquat), 155.55 (Cquat), 151.23 (2Cquat), 127.87 (+, 4Ar-CH), 
122.48 (Cquat), 114.70 (+, 4Ar-CH), 114.51 (+, 2Ar-CH), 77.42 (Cquat), 65.33 (-, CH2), 36.79 (-, 
CH2), 29.05 (-, CH2), 28.14 (+, 3CH3). HRMS (EI-MS) m/z: calcd for C21H25N3O3 [MH+] 
368.1969, found 368,1977.  
 
3-{4-[1-(4-Fluorobenzyl)-1H-benzo[d]imidazol-2-yl]phenoxy}propan-1-amine (4.26).  
To a solution of compound 4.25 (670 mg, 1.82 mmol) in ACN (50 mL), 
1-(chloromethyl)-4-fluorobenzene (788 mg, 5.47 mmol) and NaOH (364 mg, 9.1 mmol) were 
added. The mixture was stirred at rt for 5 h, the obtained suspension was poured into brine 
and extracted with EtOAc. The organic phase was dried over Na2SO4 and evaporated, and 
the residue was dissolved in 10 mL of DCM, TFA (10 mL) was added dropwise, and the 
mixture was stirred at rt for 2 h. Purification by column chromatography (DCM/MeOH 25% 
aqueous ammonia, 100/5/1), yielded a pale oil (610 mg, 1.63 mmol, 89.3%). 1H-NMR (300 
MHz, CDCl3) δ [ppm]: 7.87-7.79 (m, 1H), 7.62-7.51 (m, 2H), 7.33-7.13 (m, 3H), 7.12-6.89 (m, 
6H), 5.38 (s, 2H), 4.09 (t, J = 6.1 Hz, 2H), 2.91 (t, J = 6.8 Hz, 2H), 1.94 (quint, J = 6.5 Hz, 2H). 
13C-NMR (75 MHz, CDCl3) δ [ppm]: 160.38 (Cquat), 154.12 (Cquat), 143.19 (Cquat), 135.94 
(Cquat), 132.25 (Cquat), 132.21 (Cquat), 130.63 (+, 2Ar-CH), 127.73 (+, Ar-CH), 127.62 (+, 
Ar-CH), 122.88 (+, Ar-CH), 122.68 (+, Ar-CH), 122.21 (Cquat), 119.84 (+, Ar-CH), 116.18 (+, 
Ar-CH), 115.89 (+, Ar-CH), 114.75 (+, 2Ar-CH), 110.22 (+, Ar-CH), 66.00 (-, CH2), 47.75 (-, 
CH2), 39.13 (-, CH2), 32.88 (-, CH2). HRMS (EI-MS) m/z: calcd for C23H22FN3O [MH+] 
376.1820, found 376.1823. 
 
N- [2- (1H- imidazol- 4- yl)ethyl]- 3- {4- [1- (4- fluorobenzyl)- 1H- benzo[d]imidazol- 2- 
yl]phenoxy}propan- 1- amine (4.27).  
Compound 4.27 was prepared by analogy with the procedure for the preparation of 
compound 4.16a, using compound 4.26 (480 mg, 0.67 mmol) and 
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4-(2-bromoethyl)-1-trityl-1H-imidazole (416 mg, 1.0 mmol) as educts. Purification by column 
chromatography (DCM/MeOH/25% aqueous ammonia, 100/5/1) yielded yellow-white crystals 
(80 mg, 0.17 mmol, 26.7%); mp 120 °C. 1H-NMR (300 MHz, CDCl3) δ [ppm]: 7.81 (d, J = 7.7 
Hz, 1H), 7.58-7.50 (m, 2H), 7.39 (s, 1H), 7.35-7.14 (m, 3H), 7.07-6.88 (m, 6H), 6.74 (s, 1H), 
5.37 (s, 2H), 4.05 (t, J = 6.0 Hz, 2H), 2.97-2.86 (m, 2H), 2.85-2.70 (m, 4H), 1.97 (quint, J = 6.4 
Hz, 2H). 13C-NMR (75 MHz, CDCl3) δ [ppm]: 160.60 (Cquat), 160.38 (Cquat), 154.12 (Cquat), 
142.94 (Cquat), 135.81 (Cquat), 134.66 (+, Ar-CH), 132.12 (Cquat), 132.08 (Cquat), 130.65 (+, 
2Ar-CH), 127.74 (+, Ar-CH), 127.64 (+, Ar-CH), 123.03 (+, Ar-CH), 122.81 (+, Ar-CH), 122.05 
(Cquat), 119.61 (+, 2Ar-CH), 116.20 (+, Ar-CH), 115.92 (+, Ar-CH), 114.83 (+, 2Ar-CH), 110.37 
(+, Ar-CH), 66.41 (-, CH2), 49.20 (-, CH2), 47.73 (-, CH2), 46.47 (-, CH2), 29.36 (-, CH2), 26.66. 
HRMS (EI-MS) m/z: calcd for C28H28FN5O [MH+] 470.2351, found 470.2354.  
 
4-{[1-(4-Fluorobenzyl)-1H-benzo[d]imidazol-2-yl]amino}phenol (4.28).  
Compound 4.12c (1.04 g, 4.00 mmol) and 4-aminophenol (2.18 g, 20.0 mmol) were 
dissolved in 20 mL EtOH, and 4 mL pf HCl in iso-propanol were added dropwise while stirring. 
The reaction mixture was stirred and refluxed for two days, subsequently concentrated and 
subjected to flash column chromatography (MeOH with 10% NH3/DCM, 5/95), yielding 
compound 4.28 as sticky oil (530 mg, 1.59 mmol, 40.0% yield). 1H-NMR (400 MHz, DMSO-d6) 
δ [ppm]: 7.70-7.56 (m, 2H), 7.33 (d, J = 7.8 Hz, 1H), 7.27-7.20 (m, 2H), 7.19-7.11 (m, 3H), 
7.05-6.91 (m, 2H), 6.80-6.68 (m, 2H), 5.47 (s, 2H). 13C-NMR (101 MHz, DMSO-d6) δ [ppm]: 
163.07 (Cquat), 160.65 (Cquat), 151.50 (Cquat), 142.69 (Cquat), 134.08 (Cquat), 133.75 (Cquat), 
132.88 (Cquat), 129.31 (+, Ar-CH), 129.23 (+, Ar-CH), 121.37 (+, Ar-CH), 120.80 (+, Ar-CH), 
120.70 (+, Ar-CH), 119.86 (+, Ar-CH), 116.33 (+, Ar-CH), 116.00 (+, Ar-CH), 115.79 (+, 
Ar-CH), 115.53 (+, Ar-CH), 115.48 (+, Ar-CH), 108.71 (+, Ar-CH), 44.47 (-, CH2). HRMS 
(EI-MS) m/z: calcd for C20H16FN3O [MH+] 334.1350, found 334.1356.  
 
tert- Butyl [3- (4- {[1- (4- fluorobenzyl)- 1H- benzo[d]imidazol- 2- yl] amino} phenoxy) 
propyl] carbamate (4.29).  
Compound 4.29 was prepared by analogy with the procedure for the preparation of 
compound 4.25, using compound 4.28 (530 mg, 1.59 mmol) as educt. Purification by flash 
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column chromatography (MeOH with 10% NH3 / DCM = 4/96) yielded a brown oil (290 mg, 
0.59 mmol, 37%). 1H-NMR (400 MHz, CDCl3) δ [ppm]: 7.50 (d, J = 7.8 Hz, 1H), 7.33-7.27 (m, 
2H), 7.17-7.06 (m, 5H), 7.03-6.95 (m, 2H), 6.77-6.73 (m, 2H), 5.16 (s, 2H), 3.91-3.84 (m, 2H), 
3.32-3.25 (m, 2H), 1.95-1.85 (m, 2H), 1.44 (s, 9H). 13C-NMR (101 MHz, CDCl3) δ [ppm]: 
163.66 (Cquat), 161.21 (Cquat), 156.09 (Cquat), 154.91 (Cquat), 151.02 (Cquat), 134.05 (Cquat), 
131.24 (Cquat), 131.20 (Cquat), 128.37 (+, Ar-CH), 128.29 (+, Ar-CH), 121.92 (+, Ar-CH), 
121.48 (+, Ar-CH), 120.71 (+, Ar-CH), 116.22 (+, Ar-CH), 116.01 (+, Ar-CH), 115.14 (+, 
2Ar-CH), 107.83 (+, Ar-CH), 79.23 (Cquat), 66.17 (-, CH2), 45.46 (-, CH2), 38.04 (-, CH2), 29.55 
(-, CH2), 28.46 (+, 3CH3). HRMS (EI-MS) m/z: calcd for C28H31FN4O3 [MH+] 491.2453, found 
491.2463.  
 
N-[4-(3-{[2-(1H-imidazol-4-yl)ethyl]amino}propoxy)phenyl]-1-(4-fluorobenzyl)-1H-benzo
[d]imidazol-2-amine (4.30).  
Compound 4.29 (280 mg, 0.57 mmol) was dissolved in 5 mL of DCM, TFA (5 mL) was 
added dropwise, and the mixture was stirred at rt for 3 h. After concentration and vacuum 
drying overnight, 4-(2-bromoethyl)-1-trityl-1H-imidazole (200 mg, 0.48 mmol) in ACN (25 mL), 
DIPEA (368 mg, 2.85 mmol) and NaI (80 mg, 0.53 mmol) were added. The mixture was 
heated at reflux for 48 h, the solvent was evaporated, the remaining mixture was poured into 
brine and extracted with DCM. The combined organic layers were dried over Na2SO4, and the 
solvent was removed under reduced pressure. The residue was dissolved by 2 mL of DCM, 
TFA (2 mL) was added dropwise, the mixture was stirred at rt for 3 h and dried by evaporation. 
Purification by column chromatography (DCM/MeOH/25% aqueous ammonia, 100/8/1) 
yielded a brown solid (16 mg, 0.03 mmol, 5.8%); mp 83 °C. 1H-NMR (400 MHz, CD3OD) δ 
[ppm]: 7.54 (s, 1H), 7.40-7.33 (m, 3H), 7.23-7.13 (m, 2H), 7.13-6.96 (m, 5H), 6.87-6.83 (m, 
3H), 5.36 (s, 2H), 3.99 (t, J = 5.5 Hz, 2H), 2.92 (t, J = 6.9 Hz, 2H), 2.87-2.77 (m, 4H) , 
2.04-1.90 (m, 2H). 13C-NMR (101 MHz, CD3OD) δ [ppm]: 163.43 (Cquat), 161.00 (Cquat), 
155.07 (Cquat), 152.04 (Cquat), 41.21 (Cquat), 134.86 (+, Ar-CH), 133.71 (Cquat), 133.39 (Cquat), 
132.38 (Cquat), 128.27 (+, Ar-CH), 128.19 (+, Ar-CH), 122.05 (+, Ar-CH), 121.37 (+, Ar-CH), 
120.13 (+, Ar-CH), 115.53 (+, Ar-CH), 115.22 (+, Ar-CH), 115.00 (+, Ar-CH), 114.56 (+, 
Ar-CH), 108.14 (+, Ar-CH), 66.40 (-, CH2), 48.56 (-, CH2), 46.31 (-, CH2), 44.38 (-, CH2), 28.45 
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(-, CH2), 26.02 (-, CH2). HRMS (EI-MS) m/z: calcd for C28H29FN6O [MH+] 485.2460, found 
485.2462.  
 
N1-[1-(4-Fluorobenzyl)-1H-benzo[d]imidazol-2-yl]ethane-1,2-diamine (4.31a).  
Compound 4.12c (2.51 g, 9.65 mmol) was added to a mixture of ethane-1,2-diamine (15 
mL) and DIPEA (2.49 g, 19.31 mmol) in a 20-mL microwave tube. The microwave tube was 
sealed and subjected to irradiation (160 °C) for 40 min. The obtained mixture was poured into 
brine and extracted with EtOAc, the organic layer was dried over Na2SO4 and evaporated. 
The product was used without further purification. White solid (2.64 g, 9.29 mmol, 96.3%); mp 
117 °C. 1H-NMR (300 MHz, CDCl3) δ [ppm]: 7.52-7.46 (m, 1H), 7.15-7.08 (m, 3H), 6.99 (m, 
4H), 5.06 (s, 2H), 3.54-3.45 (m, 2H), 2.95-2.88 (m, 2H). 13C-NMR (75 MHz, CDCl3) δ [ppm]: 
160.74 (Cquat), 154.46 (Cquat), 142.35 (Cquat), 134.67 (Cquat), 131.38 (Cquat), 128.34 (+, Ar-CH), 
128.23 (+, Ar-CH), 121.53 (+, Ar-CH), 119.79 (+, Ar-CH), 116.50 (+, Ar-CH), 116.17 (+, 
Ar-CH), 115.88 (+, Ar-CH), 107.25 (+, Ar-CH), 45.37 (-, CH2), 45.01 (-, CH2), 41.00 (-, CH2). 
HRMS (EI-MS) m/z: calcd for C16H17FN4 [MH+] 285.1510, found 285.1513. 
 
N1-[1-(4-Fluorobenzyl)-1H-benzo[d]imidazol-2-yl]propane-1, 3-diamine (4.31b).  
Synthesized from compound 4.12c (1.30 g, 5 mmol) and propane-1,3-diamine (15 mL) by 
analogy with the procedure for the preparation of 4.31a. Sticky colorless oil (1.33 g, 4.46 
mmol, 89.3%). 1H-NMR (300 MHz, CDCl3) δ [ppm]: 7.50-7.45 (m, 1H), 7.15-7.05 (m, 3H), 
7.04-6.93 (m, 4H), 5.03 (s, 2H), 3.61 (t, J = 6.2 Hz, 2H), 2.83 (t, J = 5.9 Hz, 2H), 1.76-1.66 (m, 
2H). 13C-NMR (75 MHz, CDCl3) δ [ppm]: 163.92 (Cquat), 160.65 (Cquat), 154.71 (Cquat), 142.57 
(Cquat), 134.66 (Cquat), 131.66 (Cquat), 128.31 (+, Ar-CH), 128.20 (+, Ar-CH), 121.36 (+, Ar-CH), 
119.49 (+, Ar-CH), 116.29 (+, Ar-CH), 115.99 (+, Ar-CH), 115.70 (+, Ar-CH), 107.06 (+, 
Ar-CH), 44.94 (-, CH2), 43.25 (-, CH2), 41.08 (-, CH2), 31.00 (-, CH2). HRMS (EI-MS) m/z: 
calcd for C17H19FN4 [MH+] 299.1667, found 299.1670. 
  
N1-[1-(4-Fluorobenzyl)-1H-benzo[d]imidazol-2-yl]hexane-1,6-diamine (4.31c).  
Synthesized from compound 4.12c (520 mg, 2 mmol) and hexane-1,6-diamine (1.39 g, 12 
mmol) by analogy with the procedure for the preparation of 4.31a. Sticky colorless oil (440 mg, 
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1.29 mmol, 64.7%). 1H-NMR (400 MHz, CDCl3) δ [ppm]: 7.50 (d, J = 7.8 Hz, 1H), 7.15-7.07 
(m, 3H), 7.05-6.97 (m, 4H), 5.04 (s, 2H), 3.50-3.42 (m, 2H), 2.63 (t, J = 6.9 Hz, 2H), 1.61-1.53 
(m, 2H), 1.42-1.34 (m, 2H), 1.33-1.21 (m, 4H). 13C-NMR (101 MHz, CDCl3) δ [ppm]: 161.21 
(Cquat), 154.30 (Cquat), 142.44 (Cquat), 134.69 (Cquat), 131.32 (Cquat), 128.23 (+, Ar-CH), 128.15 
(+, Ar-CH), 121.51 (+, Ar-CH), 119.74 (+, Ar-CH), 116.60 (+, Ar-CH), 116.24 (+, Ar-CH), 
116.03 (+, Ar-CH), 107.10 (+, Ar-CH), 45.01 (-, CH2), 43.34 (-, CH2), 42.05 (-, CH2), 33.54 (-, 
CH2), 29.68 (-, CH2), 26.60 (-, CH2), 26.52 (-, CH2). HRMS (EI-MS) m/z: calcd for C20H25FN4 
[MH+] 341.2136, found 341.2143.  
 
N1-[2-(1H-imidazol-4-yl)ethyl]-N2-[1-(4-fluorobenzyl)-1H-benzo[d]imidazol-2-yl]ethane-1,
2-diamine (4.32a).  
To a solution of compound 4.31a (330 mg, 1.16 mmol) in ACN (25 mL), 
4-(2-bromoethyl)-1-trityl-1H-imidazole (488 mg, 1.17 mmol), DIPEA (454 mg, 3.52 mmol) and 
NaI (175 mg, 1.17 mmol) were added. The reaction mixture was heated at reflux for 40 h, the 
solvent was evaporated, and the remaining mixture was poured into water. The aqueous 
layer was extracted with DCM, and the combined organic layers were dried over Na2SO4 and 
evaporated under reduced pressure. Subsequently, the residue was dissolved in 10 mL DCM, 
TFA (10 mL) was added dropwise, and the mixture was stirred at rt for 24 h. Purification by 
column chromatography (DCM/MeOH/25% aqueous ammonia, 100/10/1), yielded a white 
solid (80 mg, 0.21 mmol, 18.1%); mp 85 °C. 1H-NMR (300 MHz, CDCl3) δ [ppm]: 7.41 (d, J = 
7.6 Hz, 1H), 7.34 (s, 1H), 7.11-7.02 (m, 3H), 7.01-6.88 (m, 4H), 6.69 (s, 1H), 5.04 (s, 2H), 
3.50 (t, J = 5.6 Hz, 2H), 2.84-2.75 (m, 4H), 2.65 (t, J = 6.3 Hz, 2H). 13C-NMR (75 MHz, CDCl3) 
δ [ppm]: 163.89 (Cquat), 160.62 (Cquat), 154.62 (Cquat), 142.06 (Cquat), 134.74 (+, Ar-CH), 
134.54 (Cquat), 131.48 (Cquat), 128.38 (+, Ar-CH), 128.27 (+, Ar-CH), 121.57 (+, Ar-CH), 
119.88 (+, Ar-CH), 117.63 (+, Ar-CH), 116.02 (+, Ar-CH), 116.00 (+, Ar-CH), 115.74 (+, 
Ar-CH), 107.49 (+, Ar-CH), 48.69 (-, CH2), 48.16 (-, CH2), 44.93 (-, CH2), 42.60 (-, CH2), 26.68 
(-, CH2). HRMS (EI-MS) m/z: calcd for C21H23FN6 [MH+] 379.2041, found 379.2047. 
 
N1-(2-(1H-imidazol-4-yl)ethyl)-N3-(1-(4-fluorobenzyl)-1H-benzo[d]imidazol-2-yl)propane-
1,3-diamine (4.32b).  
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Synthesized from compound 4.31b (600 mg, 2 mmol) by analogy with the procedure for the 
preparation of compound 4.32a. White solid (130 mg, 0.33 mmol, 24.9%); mp 72 °C. 1H-NMR 
(300 MHz, CDCl3) δ [ppm]: 7.46 (s, 1H), 7.39 (d, J = 7.7 Hz, 1H), 7.11-6.88 (m, 7H), 6.72 (s, 
1H), 5.03 (s, 2H), 3.57 (t, J = 6.1 Hz, 2H), 2.81 (t, J = 6.3 Hz, 2H), 2.76-2.62 (m, 4H), 
1.82-1.70 (m, 2H). 13C-NMR (75 MHz, CDCl3) δ [ppm]: 160.60 (Cquat), 154.80 (Cquat), 142.22 
(Cquat), 135.46 (Cquat), 134.83 (+, Ar-CH), 134.48 (Cquat), 131.55 (Cquat), 128.19 (+, Ar-CH), 
128.08 (+, Ar-CH), 121.49 (+, Ar-CH), 119.68 (+, Ar-CH), 115.98 (+, Ar-CH), 115.81 (+, 
Ar-CH), 115.69 (+, Ar-CH), 107.37 (+, Ar-CH), 49.02 (-, CH2), 47.34 (-, CH2), 44.82 (-, CH2), 
42.39 (-, CH2), 28.28 (-, CH2), 26.20 (-, CH2). HRMS (EI-MS) m/z: calcd for C22H25FN6 [MH+] 
393.2197, found 393.2199.  
 
N- (2- {[1- (4- Fluorobenzyl)- 1H- benzo[d]imidazol- 2- yl]amino}ethyl)- 3- (1H- imidazol- 
4- yl)acrylamide (4.33a).  
To a solution of urocanic acid (690 mg, 5 mmol) in a mixture of anhydrous DMF (10 mL), 
HOBT (675 mg, 5 mmol), TBTU (3.21 g, 10 mmol) and DIPEA (645 mg, 5 mmol) were added. 
The reaction mixture was stirred at rt for 30 min, subsequently, compound 4.31a (1.42 g, 5 
mmol), dissolved in DMF (5 mL), was added dropwise, and the mixture was heated to 60 °C 
for 1.5 h. After completion of the reaction, the mixture was poured into cold water and the pH 
value was adjusted to 10 by addition of 25% aqueous ammonia. Precipitated compound 
4.33a was collected by filtration. White solid (1.7 g, 4.2 mmol, 84.2%); mp 141 °C. 1H-NMR 
(300 MHz, DMSO-d6) δ [ppm]: 8.29-8.21 (m, 1H), 7.72 (s, 1H), 7.33-7.05 (m, 8H), 6.98-6.81 
(m, 2H), 5.23 (s, 2H), 3.49-3.44 (m, 4H). 13C-NMR (75 MHz, DMSO-d6) δ [ppm]: 165.95 (Cquat), 
162.88 (Cquat), 159.65 (Cquat), 154.39 (Cquat), 142.54 (Cquat), 134.26 (Cquat), 133.14 (Cquat), 
129.09 (+, 2Ar-CH), 128.98 (+, 2Ar-CH), 120.43 (+, CH), 118.37 (+, Ar-CH), 118.19 (+, 
Ar-CH), 115.37 (+, 2Ar-CH), 115.09 (+, 2Ar-CH), 114.95 (+, CH), 107.69 (+, Ar-CH), 43.66 (-, 
CH2), 42.09 (-, CH2), 38.42 (-, CH2). HRMS (EI-MS) m/z: calcd for C22H21FN6O [MH+] 
405.1834, found 405.1839.  
 
N- [6- ({1- [4- Fluorobenzyl)- 1H- benzo[d]imidazol- 2- yl]amino}hexyl)- 3- (1H- imidazol- 
4- yl)acrylamide (4.33b).  
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Synthesized from compound 4.31c (400 mg, 1.18 mmol) and urocanic acid (163 mg, 1.18 
mmol) by analogy with the procedure for the preparation of 4.33a. Yellow oil (300 mg, 0.63 
mmol, 53.6%). 1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 8.00-7.93 (m, 1H), 7.70 (s, 1H), 
7.31-7.24 (m, 1H), 7.24-7.11 (m, 5H), 7.06 (d, J = 7.4 Hz, 1H), 6.95-6.89 (m, 1H), 6.87-6.77 
(m, 2H), 5.24 (s, 2H), 3.40-3.36 (m, 2H), 3.17-3.10 (m, 2H), 1.66-1.54 (m, 2H), 1.48-1.38 (m, 
2H), 1.36-1.26 (m, 4H). 13C-NMR (101 MHz, DMSO-d6) δ [ppm]: 163.04 (Cquat), 160.62 (Cquat), 
155.14 (Cquat), 143.29 (Cquat), 134.87 (Cquat), 133.83 (Cquat), 133.80 (Cquat), 129.43 (+, 2Ar-CH), 
129.35 (+, 2Ar-CH), 120.89 (+, CH), 119.03 (+, Ar-CH), 118.74 (+, 2Ar-CH), 115.89 (+, 
2Ar-CH), 115.67 (+, CH), 115.43 (+, Ar-CH), 108.11 (+, Ar-CH), 44.09 (-, CH2), 42.87 (-, CH2), 
39.01 (-, CH2), 29.75 (-, CH2), 29.58 (-, CH2), 26.75 (-, CH2), 26.61 (-, CH2). HRMS (EI-MS) 
m/z: calcd for C26H29FN6O [MH+] 461.2460, found 461.2465.  
 
N- (2- {[1- (4- Fluorobenzyl)- 1H- benzo[d]imidazol- 2- yl]amino}ethyl)- 3- (1H- imidazol- 
4- yl)propanamide (4.34).  
Compound 4.33a (1010 mg, 2.48 mmol) was hydrogenated over 500 mg of 5% 
Pd/C-catalyst in 30 mL of MeOH in an autoclave filled with H2 at 10 bar for 19 h. The catalyst 
was filtered off, the filtrate was concentrated, and the residue was purified by column 
chromatography (DCM/MeOH/25% aqueous ammonia, 100/5/1). White solid (1.17 g, 2.88 
mmol, 82.3%); mp 101 °C. 1H-NMR (300 MHz, CDCl3) δ [ppm]: 8.15-8.00 (m, 1H), 7.35-7.28 
(m, 2H), 7.08-6.92 (m, 6H), 6.59 (s, 1H), 5.00 (s, 2H), 3.54-3.27 (m, 4H), 2.75 (t, J = 6.4 Hz, 
2H), 2.38 (t, J = 6.5 Hz, 2H). 13C-NMR (75 MHz, CDCl3) δ 174.39 (Cquat), 163.81 (Cquat), 
160.54 (Cquat), 154.73 (Cquat), 141.81 (Cquat), 134.59 (Cquat), 134.48 (+, Ar-CH), 131.52 (Cquat), 
128.36 (+, Ar-CH), 128.25 (+, Ar-CH), 121.60 (+, Ar-CH), 119.90 (+, Ar-CH), 117.20 (+, 
Ar-CH), 115.85 (+, Ar-CH), 115.57 (+, 2Ar-CH), 107.68 (+, Ar-CH), 44.81 (-, CH2), 43.88 (-, 
CH2), 40.08 (-, CH2), 36.08 (-, CH2), 22.65 (-, CH2). HRMS (EI-MS) m/z: calcd for C22H23FN6O 
[MH+] 407.1990, found 407.1992.  
 
N1-[3-(1H-imidazol-4-yl)propyl]-N2-[1-(4-fluorobenzyl)-1H-benzo[d]imidazol-2-yl]ethane-
1,2-diamine (4.35a).  
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To LiAlH4 (57 mg, 1.5 mmol) in a 25 mL argon flushed flask, anhydrous THF (5 mL) was 
dropped slowly under ice cooling. Subsequently, a solution of compound 4.33a (200 mg, 0.5 
mmol) in THF (5 mL) was added dropwise. The mixture was stirred at rt for 21 h and 
afterwards at 70 °C for 3 h. To quench the reaction, 57 µL water, 57 µL aqueous solution of 
15% NaOH and 171 µL of water were dropped to the reaction mixture under ice cooling, and 
the mixture was stirred at rt for 30 min. A white precipitate was filtered off, and the filtrate was 
concentrated and subjected to column chromatography (DCM/MeOH/25% aqueous ammonia, 
100/7/1). White solid (90 mg, 0.23 mmol, 46%); mp 91 °C. 1H-NMR (300 MHz, CDCl3) δ [ppm]: 
7.43-7.35 (m, 2H), 7.10-6.93 (m, 5H), 6.92-6.83 (m, 2H), 6.65 (s, 1H), 5.06 (s, 2H), 3.52-3.45 
(m, 2H), 2.77 (t, J = 5.2 Hz, 2H), 2.57-2.45 (m, 4H), 1.66 (quint, J = 6.8 Hz, 2H). 13C-NMR (75 
MHz, CDCl3) δ [ppm]: 163.84 (Cquat), 160.57 (Cquat), 154.68 (Cquat), 142.09 (Cquat), 136.57 
(Cquat), 134.56 (+, Ar-CH), 131.57 (Cquat), 128.34 (+, Ar-CH), 128.23 (+, Ar-CH), 121.52 (+, 
Ar-CH), 119.82 (+, Ar-CH), 117.19 (+, Ar-CH), 115.94 (+, Ar-CH), 115.90 (+, Ar-CH), 115.66 
(+, Ar-CH), 107.49 (+, Ar-CH), 65.89 (-, CH2), 48.26 (-, CH2), 44.89 (-, CH2), 42.27 (-, CH2), 
29.41 (-, CH2), 24.32 (-, CH2). HRMS (EI-MS) m/z: calcd for C22H25FN6 [MH+] 393.2197, found 
393.2198.  
 
N1-[3-(1H-imidazol-4-yl)propyl]-N6-[1-(4-fluorobenzyl)-1H-benzo[d]imidazol-2-yl]hexane
-1,6-diamine (4.35b).  
Synthesized from compound 4.33b (270 mg, 0.57 mmol) by analogy with the procedure for 
the preparation of 35a. However, purification was performed by HPLC. Yield 4.35b 
tri(hydrotrifluoroacetate) as a colorless sticky solid (10 mg, 0.013 mmol, 2.2%). 1H-NMR (600 
MHz, CD3OD) δ [ppm]: 8.82 (s, 1H), 7.47-7.43 (m, 1H), 7.38-7.24 (m, 6H), 7.14-7.06 (m, 2H), 
5.41 (s, 2H), 3.51 (t, J = 7.2 Hz, 2H), 3.10-2.96 (m, 4H), 2.84 (t, J = 7.6 Hz, 2H), 2.12-2.02 (m, 
2H), 1.79-1.66 (m, 4H), 1.48-1.39 (m, 4H). 13C-NMR (151 MHz, CD3OD) δ [ppm]: 161.77 
(Cquat), 149.81 (Cquat), 133.67 (Cquat), 132.46 (Cquat), 130.72 (Cquat), 130.00 (+, Ar-CH), 129.06 
(Cquat), 128.48 (+, Ar-CH), 128.42 (+, Ar-CH), 123.99 (+, Ar-CH), 123.71 (+, Ar-CH), 115.76 (+, 
Ar-CH), 115.60 (+, Ar-CH), 115.45 (+, Ar-CH), 111.37 (+, Ar-CH), 110.04 (+, Ar-CH), 49.03 (-, 
CH2), 48.60 (-, CH2), 46.46 (-, CH2), 44.75 (-, CH2), 43.27 (-, CH2), 28.26 (-, CH2), 25.80 (-, 
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CH2), 25.77 (-, CH2), 24.71 (-, CH2), 21.01 (-, CH2). HRMS (EI-MS) m/z: calcd for C26H33FN6 
[MH+] 449.2823, found 449.2825.  
 
2- {4- [2- (1H- imidazol- 4- yl)ethyl]piperazin- 1- yl}- 6- chloro- N- (thiophen- 2- ylmethyl) 
quinazolin- 4- amine (4.40).  
A mixture of compound 3.12 (360 mg, 1 mmol), ACN (10 mL), DIPEA (387 mg, 3 mmol) 
and 4-(2-bromoethyl)-imidazole (225 mg, 1.2 mmol) in a 20-mL microwave tube was 
subjected to microwave irradiation (120 °C) for 30 min. The obtained suspension was poured 
into brine and extracted with EtOAc, the organic layer was dried over Na2SO4, and the 
solvent was removed. Purification by column chromatography (DCM/MeOH/25% aqueous 
ammonia, 100/3.3/1) yielded a white solid (140 mg, 0.31 mmol, 31.4%); mp 157 °C. 1H-NMR 
(400 MHz, CDCl3) δ [ppm]: 7.54 (d, J = 0.9 Hz, 1H), 7.51 (d, J = 2.0 Hz, 1H), 7.45-7.37 (m, 
2H), 7.23-7.19 (m, 1H), 7.06-7.02 (m, 1H), 6.98-6.93 (m, 1H), 6.82 (d, J = 0.6 Hz, 1H), 4.94 (d, 
J = 5.4 Hz, 2H), 4.03-3.96 (m, 4H), 2.85 (t, J = 6.7 Hz, 2H), 2.71 (t, J = 6.7 Hz, 2H), 2.65-2.56 
(m, 4H). 13C-NMR (101 MHz, CDCl3) δ [ppm]: 158.72 (Cquat), 158.70 (2Cquat), 150.92 (Cquat), 
141.27 (Cquat), 134.20 (+, Ar-CH), 133.18 (+, Ar-CH), 127.43 (+, Ar-CH), 126.71 (+, Ar-CH), 
126.22 (+, Ar-CH), 125.88 (2Cquat), 125.40 (+, Ar-CH), 120.54 (+, 2Ar-CH), 57.92 (-, CH2), 
53.17 (-, 2CH2), 44.06 (-, 2CH2), 39.93 (-, 2CH2). HRMS (EI-MS) m/z: calcd for C22H24ClN7S 
[MH+] 454.1575, found 454.1576.  
 
6-Chloro-N2-[2-(4-methylpiperazin-1-yl)ethyl]-N4-(thiophen-2-ylmethyl)quinazoline-2,4-
diamine (4.41).  
Compound 3.10 (69 mg, 0.3 mmol) was added to a mixture of EtOAc (5 mL) and DIPEA 
(77 mg, 0.6 mmol) in a 5-mL microwave tube. 2-Thienylmethylamine (34 mg, 0.3 mmol) was 
added, and the mixture was stirred at rt for 30 min. The solvent was removed by evaporation, 
and the residue dissolved in DMF. Subsequently, 4-methyl-1-piperazineethanamine 
tri(hydrotrifluoroacetate)50 (448 mg, 0.9 mmol) was added, the microwave tube was sealed 
and subjected to irradiation (160 °C) for 10 min. The obtained suspension was poured into 
brine and extracted with EtOAc, the organic layer was dried over Na2SO4, the solvent was 
removed and the residue subjected to HPLC, yielded 4.41 tri(hydrotrifluoroacetate) as a white 
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solid (31 mg, 0.04 mmol, 13.6%). 1H-NMR (300 MHz, CDCl3) δ [ppm]: 7.51 (d, J = 2.0 Hz, 1H), 
7.45-7.31 (m, 2H), 7.25-7.17 (m, 1H), 7.05-7.01 (m, 1H), 6.97-6.93 (m, 1H), 4.93 (d, J = 5.0 
Hz, 2H), 3.66-3.50 (m, 2H), 2.69-2.34 (m, 10H), 2.27 (s, 3H). 13C-NMR (75 MHz, CDCl3) δ 
[ppm]: 159.31(Cquat), 158.87 (Cquat), 150.50 (Cquat), 140.97 (2Cquat), 133.29 (+, Ar-CH), 126.78 
(+, 2Ar-CH), 126.38 (+, Ar-CH), 125.81 (Cquat), 125.48 (+, Ar-CH), 120.59 (+, Ar-CH), 57.01 (-, 
CH2), 55.09 (-, 2CH2), 52.86 (-, 2CH2), 46.03 (+, CH3), 39.84 (-, CH2), 38.10 (-, CH2). HRMS 
(EI-MS) m/z: calcd for C20H25ClN6S [MH+] 417.1623, found 417.1624.  
 
6-Chloro-N2-(1-methylpiperidin-4-yl)-N4-(thiophen-2-ylmethyl)quinazoline-2,4-diamine 
(4.42). 
Synthesized from compound 3.10 (230 mg, 1 mmol) and 1-methylpiperidin-4-amine (460 
mg, 4 mmol) by analogy with the procedure for the preparation of 4.41. Purification by column 
chromatography (DCM/MeOH/25% aqueous ammonia, 100/4/1) yielded a white solid (320 
mg, 0.83 mmol, 82.7%); mp 93 °C. 1H-NMR (300 MHz, CD3OD) δ [ppm]: 7.92-7.88 (m, 1H), 
7.48-7.40 (m, 1H), 7.34-7.18 (m, 2H), 7.05-7.00 (m, 1H), 6.94-6.88 (m, 1H), 4.90 (s, 2H), 
4.03-3.85 (m, 1H), 2.88-2.76 (m, 2H), 2.27 (s, 3H), 2.23-2.07(m, 2H), 2.05-1.90 (m, 2H), 
1.65-1.48 (m, 2H). 13C-NMR (75 MHz, CD3OD) δ [ppm]: 160.90 (Cquat), 160.69 (Cquat), 151.49 
(Cquat), 143.76 (Cquat), 134.19 (+, Ar-CH), 127.49 (+, Ar-CH), 126.92 (2Cquat), 126.64 (+, 
Ar-CH), 126.47 (+, Ar-CH), 125.58 (+, Ar-CH), 122.98 (+, Ar-CH), 76.73 (+, CH), 55.76 (-, 
2CH2), 46.30 (+, CH3), 40.38 (-, CH2), 33.09 (-, 2CH2). HRMS (EI-MS) m/z: calcd for 
C19H22ClN5S [MH+] 388.1357, found 388.1362.  
 
6-Chloro-N4-(thiophen-2-ylmethyl)-N2-[2-(1-trityl-1H-imidazol-4-yl)ethyl]quinazoline-2,4-
diamine (4.43).  
To a solution of N-[2-(1-Triphenylmethylimidazol-4-yl)ethyl]phthalimide (1.90 g, 3.93 mmol) 
in EtOH (50 mL), hydrazine hydrate (1.18 g, 23.6 mmol) was added and stirred at room 
temperature for 2 h. After reaction (control by TLC), a white precipitate formed was removed 
by filtration. The filtrate was evaporated to dryness yielded 
2-(1-trityl-imidazol-4-yl)ethan-1-amine as a yellow oil (1.37 g, 3.88 mmol, 98.8%).52 
Compound 4.43 was synthesized from compound 3.10 (573 mg, 2.48 mmol) and 
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2-(1-trityl-imidazol-4-yl)ethan-1-amine (865 mg, 2.45 mmol) by analogy with the procedure for 
the preparation of 4.41. Purification by column chromatography (MeOH/DCM, 1/20) yielded a 
brown oil (170 mg, 0.27 mmol, 10.9%). HRMS (EI-MS) m/z: calcd for C37H31ClN6S [MH+] 
627.2092, found 627.2096.  
 
N2- [2- (1H- imidazol- 4- yl)ethyl]- 6- chloro- N4- (thiophen- 2- ylmethyl)quinazoline- 2, 4- 
diamine (4.44).  
Compound 4.43 (130 mg, 0.21 mmol) was dissolved in 10 mL DCM, TFA (10 mL) was 
added dropwise, the mixture was stirred overnight at rt (control by TLC). The solvent was 
evaporated, and the remaining oil was subjected to HPLC, yielding 4.44 
tri(hydrotrifluoroacetate) as a white solid (60 mg, 0.08 mmol, 39.4%). 1H-NMR (300 MHz, 
DMSO-d6) δ [ppm]: 8.99 (s, 1H), 8.40 (d, J = 2.1 Hz, 1H), 7.87-7.81 (m, 1H), 7.54-7.36 (m, 
3H), 7.15 (d, J = 2.8 Hz, 1H), 7.00-6.96 (m, 1H), 4.98 (d, J = 5.4 Hz, 2H), 3.88-3.78 (m, 2H), 
2.99 (t, J = 6.3 Hz, 2H). 13C-NMR (75 MHz, DMSO-d6) δ [ppm]: 158.71 (Cquat), 153.00 (Cquat), 
139.60 (Cquat), 138.21 (Cquat), 135.21 (+, Ar-CH), 133.79 (+, Ar-CH), 130.42 (Cquat), 128.03 
(Cquat), 126.87 (+, Ar-CH), 126.67 (+, Ar-CH), 125.79 (+, Ar-CH), 123.44 (+, Ar-CH), 118.67 (+, 
Ar-CH), 116.42 (+, Ar-CH), 110.56 (Cquat), 39.63 (-, CH2), 39.44 (-, CH2), 24.10 (-, CH2). 
HRMS (EI-MS) m/z: calcd for C18H17ClN6S [MH+] 385.0997, found 385.1001.  
 
4.4.2. Pharmacological Methods 
Histamine dihydrochloride was from Alfa Aesar (Karlsruhe, Germany). Guanosine 
diphosphate (GDP) was from Sigma-Aldrich Chemie (Munich, Germany), unlabeled GTPγS 
was from Roche (Mannheim, Germany) and thioperamide was from R&D Systems 
(Wiesbaden, Germany) [3H]pyrilamine and [3H]histamine were from Hartmann Analytic 
(Braunschweig, Germany). [35S]GTPγS was from PerkinElmer Life Sciences (Boston, MA) or 
from Hartmann Analytic (Braunschweig, Germany). GF/C filters were from Whatman 
(Maidstone, UK). [3H]UR-PI29458 and [3H]UR-DE25757 were synthesized as described 
previously. 
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4.4.2.1. Preparation of compound stock solutions 
  See section 3.3.2.2. 
 
4.4.2.2. Competition binding experiments  
Competition binding experiments were performed on membrane preparations of Sf9 insect 
cells expressing the hH1R + RGS4, hH2R-GsαS, hH3R + Gαi2 + β1γ2 or the hH4R + Gαi2 + β1γ2. 
General procedures for the generation of recombinant baculoviruses, culture of Sf9 cells and 
membrane preparation are described elsewhere.72 The respective membranes were thawed 
and sedimented by centrifugation at 4 °C and 13000 rpm for 10 min. Membranes were 
re-suspended in binding buffer (12.5 mM MgCl2, 1 mM EDTA, and 75 mM Tris/HCl, pH 7.4). 
Each tube (total volume 100 μL) contained 30 μg (hH1R), 40 μg (hH2R), 60 μg (hH3R) or 100 
μg (hH4R) of membrane protein and increasing concentrations of unlabeled ligands. 
Radioligands: H1R: [3H]pyrilamine, specific activity 20.0 Ci/mmol, Kd = 4.5 nM,73 c = 5 nM, 
nonspecific binding determined in the presence of 10 μM of diphenhydramine; H2R: 
[3H]UR-DE257 (radioligand was diluted with unlabeled ligand due to economic reasons), 
specific activity 33.0 Ci/mmol, Kd = 12.1 nM,57 c = 20 nM, nonspecific binding determined in 
the presence of 10 μM of famotidine; H3R: [3H]UR-PI294, specific activity 41.8 Ci/mmol, Kd = 
3.3 nM, c = 3.5 nM, nonspecific binding determined in the presence of 10 μM of thioperamide; 
H4R: [3H]histamine, specific activity 25 Ci/mmol, Kd = 10 nM,56 c = 10 nM, nonspecific binding 
determined in the presence of 10 μM of histamine. Filtration through glass microfiber filters 
(for hH4R, glass microfiber filters was pretreated with 0.3% polyethylenimine, Whatman GF/B, 
Maidstone, UK) using a Brandel 96 sample harvester (Brandel, Gaithersburg, MD) separated 
unbound from membrane associated radioligand. After three washing steps with binding 
buffer, filter pieces for each well were punched out and transferred into 96-well sample plates 
1450-401 (Perkin Elmer, Rodgau Germany). Each well was supplemented with 200 μL of 
scintillation cocktail (Rotiscint Eco plus, Roth, Karlsruhe, Germany) and incubated in the dark. 
Radioactivity was measured with a Micro Beta2 1450 scintillation counter (Perkin Elmer, 
Rodgau, Germany). Protein concentration was determined by the method of Lowry using 
bovine serum albumin as standard.74 Data analysis of the resulting competition curves was 
accomplished by non-linear regression analysis using the algorithms in PRISM GraphPad 
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Software (GraphPad Prism 5.0 software, San Diego, CA). Ki values were calculated 
according to the Cheng-Prusoff equation.75 Values represent the mean ± SEM of 3 
independent experiments each performed in triplicate. 
 
4.4.2.3. [35S]GTPγS binding assay76, 77 
The Sf9 cell membranes used in [35S]GTPγS binding assay and their preparations were the 
same as described above. The respective membranes were thawed and sedimented by 10 
min centrifugation at 4 °C and 13000 rpm. Membranes were re-suspended in binding buffer 
(12.5 mM MgCl2, 1 mM EDTA, and 75 mM Tris/HCl, pH 7.4). Each assay tube contained Sf9 
membranes expressing the respective HxR subtype (10-20 μG-Protein/tube), 1 μM GDP, 0.05% 
(w/v) bovine serum albumin, 0.2 nM [35S]GTPγS and the investigated ligands (dissolved in 
Millipore water or in a mixture (v/v) of 50% Millipore water and 50% DMSO) at various 
concentrations in binding buffer (total volume 100 μL). In case of H1R assays the binding 
buffer additionally contained 150 mM of NaCl and 50 µg/mL of saponin, H4R assays were 
performed with buffer containing 100 mM of NaCl. For the determination of Kb values 
(antagonist mode of the [35S]GTPγS binding assay) histamine was added to the reaction 
mixtures (final concentrations: hH1/2R: 1 μM, hH3/4R: 100 nM). Incubation was performed at 
25 °C and shaking at 250 rpm for 90 min. Bound [35S]GTPγS was separated from free 
[35S]GTPγS by filtration through GF/C filters, followed by three washing steps with 2 mL of 
binding buffer (4 °C) using a Brandel Harvester. Filter-bound radioactivity was determined by 
liquid scintillation counting after an equilibration phase of at least 12 h. The experimental 
conditions chosen ensured that not more than 10% of the total amount of [35S]GTPγS added 
was bound to the filters. Nonspecific binding was determined in the presence of 10 μM 
unlabeled GTPγS. IC50 values were converted to Kb values using the Cheng-Prussoff 
equation.75 EC50 and Kb values from the functional GTPγS assays were analyzed by 
nonlinear regression and best fit to sigmoidal concentration-response curves (GraphPad 
Prism 5.0 software, San Diego, CA). 
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5. Summary 
 
G-protein coupled receptors are the most important class of biological targets for drug 
development. Among them, the histamine receptors may be considered as representative 
examples for aminergic GPCRs. The latest member of the histamine receptor family, the H4R, 
was reported to be involved in immunological processes and inflammatory diseases. 
However, the (patho)physiological role of the H4R is far from being fully understood. Thus, 
potent and selective pharmacological tools in various forms targeting H4R are required. 
Based on complementary and overlapping functions of hH1R and hH4R, it is presumed that 
combined H1R/H4R antagonism might be superior to monotherapy in the treatment of allergic 
diseases. 
 In the first part of this thesis, twenty-two novel homo-dimeric ligands based on the 
prominent H1R antagonists diphenhydramine (3.1), pyrilamine (3.2) and dual H1R/H4R 
antagonist quinazoline derivative (3.3), were synthesized to probe putative accessory binding 
sites on hH1R and hH4R. Furthermore, their binding affinities were determined at the hH1R 
and/or hH4R. Between the two types of spacers which were employed in this study, 
connecting chains comprising amide groups exhibited similar affinity compared to their 
monomeric counterparts. By contrast, alkyl chains without amides showed decreased affinity 
at the hH1R, suggesting that the lipophilicity of the compounds plays an important role in 
binding affinity, e.g., high lipophilicity may result a poor solubility and high non-specific 
binding of the compound in assays. Since the variation of the spacer length had no significant 
influence on binding affinities, it may be suggested that one pharmacophore of the 
homo-dimeric ligand was not binding to the hH1R, thus it did not contribute to receptor-ligand 
binding. At the hH4R, all bivalent quinazoline-type ligands showed no obvious activity. This 
may be interpreted that the quinazoline-type homo-dimeric ligands are not tolerated at the 
hH4R. In a word, the data of the present study were not sufficient to prove the existence of 
accessory binding sites on hH1R and hH4R. 
The second part of this thesis was focused on developing dual hH1R/hH4R antagonists. 
Thirty benzimidazole- and quinazoline-type compounds were synthesized and 
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pharmacologically characterized at the four human histamine receptor subtypes. The 
incorporation of an imidazole moiety, separated from the benzimidazole moiety by an 
appropriate linker, largely improved the binding affinities at the hH4R and resulted in a 
balanced dual hH1R/hH4R antagonist (compound 4.35b) with Ki values in the two-digit nM 
range. However, ligands comprising imidazolylalkyl moieties did not discriminate between 
hH3R and hH4R. 
In summary, although the dimeric approach may be an interesting and useful strategy in 
developing bitopic and dual target ligands targeting H1R and/or H4R, there are numerous 
problems associated with this approach. Due to the low homology between ligand binding 
sites of H1R and H4R, it appears extremely difficult to identify a common H1R/H4R 
pharmacophore at a high level of affinity. Moreover, as the H4R has a relatively high 
homology with the H3R, a poor discrimination between both receptor subtypes may result in 
more complex binding and functional properties of hybrid compounds targeting the H4R.     
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6. Appendix 
6.1. Abbreviations 
 
α intrinsic activity or selectivity factor 
A agonist 
abs absolute 
AC adenylyl cyclase 
aq aqueous 
atm atmosphere 
Boc tert-butoxycarbonyl 
Boc2O di-tert-butyl dicarbonate 
BSA bovine serum albumin 
[Ca2+]i intracellular calcium ion concentration 
calcd. calculated 
cAMP cyclic 3’, 5’-adenosine monophosphate 
CH2Cl2 dichloromethane 
CHCl3 chloroform 
CH3CN acetonitrile 
Ci curie 
CNS central nervous system 
COSY correlated spectroscopy 
cpm counts per minute 
d day(s) or doublet 
DAG diacylglycerol 
δ chemical shift 
DCC N,N’-dicyclohexylcarbodiimide 
DCM dichloromethane 
dd doublet of doublets 
DIPEA diisopropylethylamine 
DMAP 4-dimethylaminopyridine 
DMF dimethylformamide 
DMSO dimethylsulfoxide 
DMSO-d6 per-deuterated dimethylsulfoxide 
EC50 agonist concentration which induces 50 % of the 
maximum response 
EDC N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride 
eq equivalents 
EtOAc ethylacetate 
Et2O diethylether 
EtOH ethanol 
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FCS fetal bovine serum 
G G-Protein 
GDP guanosine diphosphate 
GTP guanosine triphosphate 
GPCR G-protein coupled receptor 
h hour(s) or human 
HCl hydrochloric acid 
HMBC heteronuclear multiple bond correlation 
HSQC heteronuclear single quantum correlation 
HOBt 1-Hydroxybenzotriazole hydrate 
HPLC high-performance liquid chromatography 
HRMS high resolution mass spectrometry 
Hz hertz 
IC50 radioligand binding assay: ligand concentration inhibiting 
the binding of a radioligand by 50 % 
IP3 inositol-1,4,5-trisphosphate 
J coupling constant 
k capacity factor 
Kb dissociation constant (functional assay) 
KBr potassium bromide 
K2CO3 potassium carbonate 
Kd dissociation constant (saturation binding) 
KHSO4 potassium bisulfate 
Ki dissociation constant (competition binding) 
L liter 
LiAlH4 Lithiumaluminiumhydrid 
m multiplet 
M molar (mol/L) 
MeCN acetonitrile 
MeOH methanol 
MeI methyl iodide 
mol mole (s) 
min minute(s) 
μ micro 
mp. melting point 
HR histamine receptor 
HxR histamine Hx receptor (x = 1,2,3,4) 
MS mass spectrometry 
n nano or amount of substance 
NaHCO3 sodium bicarbonate 
NaI sodium iodide 
Na2SO4 sodium sulfate 
NEt3 triethylamine 
NHS N-hydroxysuccinimide 
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NMR nuclear magnetic resonance 
PBS phoshpate buffered saline 
PE petroleum ether 
pEC50 negative decadic logarithm of the molar concentration of 
the agonist causing 50 % of the maximal response 
Ph phenyl 
Ph3P triphenylphosphine 
PIP2 Phosphatidylinositol-4,5-bisphosphate 
PKC protein kinase C 
pKb negative decadic logarithm of the dissociation constant 
(functional assay) 
pKi negative decadic logarithm of the dissociation constant 
(competition binding assay) 
ppm parts per million 
Py pyridyl or pyrylium 
q quartet 
ref reference 
Rf retardation factor 
RGS regulator of G-protein signaling 
RP reversed phase 
rpm revolutions per minute 
rt room temperature 
s singulet or second(s) 
sat. saturated 
SEM standard error of the mean 
t triplet 
t0 dead time 
TBDPS tert-butyldiphenysily 
TBTU 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethylaminium 
tetrafluoroborate 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
TLC thin layer chromatography  
TM transmembrane 
TM transmembrane 
TMS trimethylsilyl 
tR retention time 
UV ultraviolett 
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6.2. Purity determined by HPLC 
cpd. tR (min) k Purity (%) Method cpd. tR (min) k Purity (%) Method 
3.6a 9.12 2.18 97.34 b 4.16a 15.06 4.25 96.10 d 
3.6b 12.54 3.37 97.26 b 4.16b 15.12 4.27 96.85 d 
3.6c 14.43 4.03 98.53 b 4.17a 13.51 3.71 98.85 c 
3.6d 15.35 4.35 99.94 b 4.17b 11.57 3.03 100.00 c 
3.7a 11.15 2.89 96.80 a 4.17c 13.47 3.69 97.15 c 
3.7b 5.43 0.89 100.00 b 4.18a 9.71 2.38 97.84 c 
3.7c 16.24 4.66 98.60 a 4.18b 15.47 4.39 98.29 d 
3.7d 19.16 5.68 95.33 a 4.19a 9.76 2.40 100.00 c 
3.9a 18.53 5.46 97.02 c 4.19b 9.89 2.45 100.00 c 
3.9b 18.81 5.55 97.57 c 4.20a 8.73 2.04 98.46 c 
3.9c 19.87 5.92 96.66 c 4.20b 9.59 2.34 96.71 c 
3.9d 21.29 6.42 95.18 c 4.22a 15.08 4.25 97.68 d 
3.13a 12.35 3.30 100.00 a 4.22b 14.45 4.03 99.99 d 
3.13b 13.81 3.81 96.35 a 4.23 9.64 2.36 98.92 c 
3.15a 12.91 3.50 99.14 c 4.26 16.83 4.86 97.51 d 
3.15b 13.54 3.72 97.07 c 4.27 16.01 4.57 95.13 d 
3.15c 14.15 3.93 97.93 c 4.30 16.86 4.87 98.78 d 
3.15d 14.78 4.15 97.60 c 4.32a 15.05 4.24 95.53 d 
3.16a 13.33 3.64 97.58 c 4.32b 14.98 4.22 98.23 d 
3.16b 13.63 3.75 95.85 c 4.34 15.75 4.49 99.04 d 
3.16c 14.05 3.90 100.00 c 4.35a 15.09 4.26 98.11 d 
3.16d 14.81 4.16 99.99 c 4.35b 16.36 4.70 95.15 d 
4.14a 13.4 3.67 99.24 c 4.40 8.55 1.98 97.70 c 
4.14b 13.61 3.74 99.87 c 4.41 9.12 2.18 96.19 c 
4.14c 10.73 2.74 99.89 c 4.42 10.92 2.80 97.41 c 
4.15b 8.59 2.00 99.93 c 4.44 11.9 3.15 99.87 c 
t0 = 2.87 min; gradient mode: a) MeCN/0.1% TFA (aq.): 0 min: 30/70, 30 min: 90/10, 
31 min: 95/5, 40 min: 95/5, 41 min: 20/80, 50 min: 20/80; b) MeCN/0.1% TFA (aq.): 0 
min: 50/50, 30 min: 85/15, 32 min: 95/5, 40 min: 95/5, 41 min: 5/95, 50 min: 5/95; c) 
MeCN/0.1% TFA (aq.): 0 min: 20/80, 30 min: 90/10, 31 min: 95/5, 40 min: 95/5, 41 
min: 20/80, 50 min: 20/80; d) MeCN/0.1% TFA (aq.): 0 min: 5/95, 30 min: 85/15, 32 
min: 95/5, 40 min: 95/5, 41 min: 5/95, 50 min: 5/95. 
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6.3. Saturation binding at the hH3R with N1- [3- (1H- imidazol- 4- 
yl)propyl]-N2-propionylguanidine ([3H]UR-PI294) 
 
Representative N1-[3-(1H-imidazol-4-yl)propyl]-N2-propionylguanidine ([3H]UR-PI294) saturation 
binding experiment on Sf9 insect cell membranes expressing hH3R + Gαi2 + Gβ1γ2 (performed in 
triplicate). Membranes were incubated with increasing concentrations of 
N1-[3-(1H-imidazol-4-yl)propyl]-N2-propionylguanidine ([3H]UR-PI294). Nonspecific binding was 
determined in the presence of 10 μM thioperamide. Specific binding is the difference between the total 
and nonspecific binding of N1-[3-(1H-imidazol-4-yl)propyl]-N2-propionylguanidine ([3H]UR-PI294) at a 
given concentration. (Kd = 3.27 ± 0.38 nM from three independent experiments performed in triplicate, 
ref1: 1.1 nM) 
 
6.4. NMR spectra of selected compounds 
To verify the position of Cl at benzimidazole scaffold, 2D-NMR spectra of compounds 
4.13a and 4.13b were recorded. 
6.4.1. NMR spectra (COSY, HSQC, HMBC, NOESY) of 4.13a: 
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NMR spectra (COSY) of compound 4.13a. 
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NMR spectra (HSQC) of compound 4.13a. 
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NMR spectra (HMBC) of compound 4.13a. 
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NMR spectra (NOESY) of compound 4.13a. 
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6.4.2. NMR spectra (COSY, HSQC, HMBC, NOESY) of 4.13b: 
 
NMR spectra (COSY) of compound 4.13b. 
 
 
NMR spectra (HSQC) of compound 4.13b. 
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NMR spectra (HMBC) of compound 4.13b. 
 
 
NMR spectra (NOESY) of compound 4.13b. 
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To verify the alkylation reaction taking place at 4-position instead of imidazole ring of 
histamine, 2D-NMR spectra of compound 4.16a and 4.16b were recorded. 
 
6.4.3. NMR spectra (COSY, HSQC, HMBC, ROESY) of 4.16a: 
 
NMR spectra (COSY) of compound 4.16a. 
 
NMR spectra (HSQC) of compound 4.16a. 
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NMR spectra (HMBC) of compound 4.16a. 
 
NMR spectra (ROESY) of compound 4.16a. 
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6.4.4. NMR spectra (COSY, HSQC, HMBC) of 4.16b 
 
NMR spectra (COSY) of compound 4.16b. 
 
 
NMR spectra (HSQC) of compound 4.16b. 
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NMR spectra (HMBC) of compound 4.16b. 
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